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This paper presents two types of information from the Carcinogenic Potency Database (CPDB): (a) the sixth chronological plot of analyses of long-
term carcinogenesis bioassays, and (b) an index to chemicals in all six plots, including a summary compendium of positivity and potency for each
chemical (Appendix 14). The five earlier plots of the CPDB have appeared in this journal, beginning in 1984 (1-5). Including the plot in this paper, the
CPDB reports results of 5002 experiments on 1230 chemicals. This paper includes bioassay results published in the general literature between
January 1989 and December 1990, and in Technical Reports of the National Toxicology Program between January 1990 and June 1993. Analyses are
included on 17 chemicals tested in nonhuman primates by the Laboratory of Chemical Pharmacology, National Cancer Institute. This plot presents
results of 531 long-term, chronic experiments of 182 test compounds and includes the same information about each experiment in the same plot
format as the earlier papers: the species and strain of test animal, the route and duration of compound administration, dose level and other aspects
of experimental protocol, histopathology and tumor incidence, TD50 (carcinogenic potency) and its statistical significance, dose response, author's
opinion about carcinogenicity, and literature citation. We refer the reader to the 1984 publications (1,6,7) for a detailed guide to the plot of the data-
base, a complete description of the numerical index of carcinogenic potency, and a discussion of the sources of data, the rationale for the inclusion of
particular experiments and particular target sites, and the conventions adopted in summarizing the literature. The six plots of the CPDB are to be
used together since results of individual experiments that were published earlier are not repeated. Appendix 14 is designed to facilitate access to
results on all chemicals. References to the published papers that are the source of experimental data are reported in each of the published plots. For
readers using the CPDB extensively, a combined plot is available of all results from the six separate plot papers, ordered alphabetically by chemical;
the combined plot in printed form or on computer tape or diskette is available from the first author. A SAS database is also available. For further infor-
mation, ourWorld Wide Web URL is http://potency.berkeley.edu/cpdb.html - Environ Health Perspect 103(Suppl 81:3-123 (1995)
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Background
The Carcinogenic Potency Database
(CPDB) is a standardized resource of
results ofchronic, long-term carcinogenesis
bioassays (1-5). It provides an easily acces-
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sible resource with sufficient information
on each experiment to permit investigations
in many research areas of carcinogenesis.
Both qualitative and quantitative informa-
tion on positive and negative tests are
reported. All experiments in the CPDB
meet a specific set of inclusion criteria
designed to permit the estimation of car-
cinogenic potency; therefore, reasonable
consistency of experimental protocols is
assured. Bioassays are included in the data-
base only ifthe test agent was administered
alone, rather than in combination with
other substances; ifthe bioassay included a
control group; if the route of administra-
tion was diet, water, gavage, inhalation, iv
injection or ip injection; and if the length
ofexperiment was at least halfthe standard
lifespan for the species and the duration of
dosing one-fourth the standard lifespan.
Many cancer tests do not meet these rules
and are not included, e.g., if a rodent test
was shorter than 1 year or the duration of
dosing was shorter than 6 months, if dos-
ing was not chronic, or if the compound
was administered by skin painting or sc
injection.
The CPDB is exhaustive because it
includes all published tests that meet a set
of experimental criteria. There is great
diversity in the testing ofchemicals reported
in the database; while most chemicals have
been tested in rats or mice, some have been
tested in hamsters, dogs, prosimians, or
monkeys. Experiments with 107 different
mouse strains and 76 rat strains are
included. For a given chemical, the data-
base may have only a single experiment or
several experiments. For example, among
the 952 chemicals tested in rats, 26% have
only one rat test and 53% have two tests;
however, 18 chemicals have more than 10
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tests. Among the 1230 chemicals in the
CPDB, 52% have been tested in only a sin-
gle species, 45% in two species, and 3% in
more than two.
In the CPDB we do not ourselves eval-
uate whether the results in each experiment
provide evidence for carcinogenicity;
rather, we report the published opinions of
the investigators and the statistical
significance of the dose response. We have
corresponded with many researchers to
clarify their evaluations ofparticular target
sites as well as to obtain additional experi-
mental results; this is indicated in the plot
by "pers. comm." in the reference field.
The CPDB includes results ofall National
Cancer Institute/National Toxicology
Program (NCI/NTP) Technical Reports
published through June 1993, except for a
few bioassays of particulates or where the
compound was administered by skin paint-
ing. Thirty percent (370/1230) of the
chemicals included in the CPDB have been
tested in NCI/NTP bioassays.
A detailed guide to the plot ofthe data-
base was included in the first published
plot in 1984 (1). It described the contents,
field by field, and discussed the sources of
data, the criteria for the inclusion ofpartic-
ular experiments and particular target sites,
and the conventions adopted in summariz-
ing the literature. Therefore, readers who
are not familiar with the CPDB should
read the 1984 paper before using the plot
in this paper.
The TD50, our numerical index of car-
cinogenic potency, has been fully described
(1,6,7) and may be briefly defined as fol-
lows: for a given target site(s), ifthere are no
tumors in control animals, then TD50 is the
chronic dose rate in mg/kg bodyweight/day
that would induce tumors in half the test
animals at the end of a standard lifespan
for the species. Since the tumor(s) ofinter-
est often does occur in control animals,
TD50 is more precisely defined as the
chronic dose rate that will halve the proba-
bility of remaining tumor-free throughout
the standard lifespan. One reason for
choosing TD50 is that it is easy to under-
stand the concept, particularly because of
the analogy to LD50. Importantly, TD50 is
often within the range ofdoses tested; thus
the experimental results do not have to be
extrapolated far to estimate TD50. The
TD50 does not indicate anything about
carcinogenic effects at low doses, since car-
cinogenesis bioassays are generally con-
ducted at doses at or near the maximum
tolerated dose (MTD). In the CPDB,
TD50 values for NCI/NTP bioassays have
been estimated using lifetable data, whereas
summary analyses have been used for the
general literature. [See (8) for a compari-
son of methods.] The range of statistically
significant TD50 values for chemicals in the
CPDB that are carcinogenic in rodents is
more than 10 millionfold.
In each of the six plot papers,
Appendices 1 through 13 are in the same
format and provide information for the
data in that publication. Appendices 1
through 13 below apply only to the plot
presented here. Appendix 1 lists alphabeti-
cally the compounds included in the cur-
rent plot, their common synonyms, and
Chemical Abstracts Service (CAS) registry
numbers; Appendix 2 provides a list of
those same compounds ordered by CAS
number. The next several appendices pro-
vide codes and definitions required for
using the plot: strains of test animal
(Appendix 3); routes of administration
(Appendix 4); sites of tumor induction
(Appendix 5); histopathology of tumors
(Appendix 6); notes about the experiment,
e.g., survival problems (Appendix 7);
dose-response curve symbols (Appendix 8);
journal reference codes (Appendix 9);
species of test animal (Appendix 10); and
author's opinion codes (Appendix 11).
Appendices 12 and 13 give full biblio-
graphic information for experiments
reported in this plot: a bibliography for the
general literature (Appendix 12); and a list
of NTP Technical Reports (Appendix 13).
Appendix 14 provides an index to chemi-
cals in all six plots ofthe CPDB, and evalu-
ations of positivity and carcinogenic
potency in rats and mice for each chemical.
In the fifth plot paper ofthe CPDB (5)
we updated several analyses reported ear-
lier, in order to reflect data in the CPDB at
that time: i.e., the proportion ofchemicals
that are positive for several datasets, the
association between mutagenicity and car-
cinogenicity, prediction of positivity
between species, reproducibility of results
in "near-replicate" experiments, and car-
cinogen identification on the basis of two
vs four sex-species groups. When data
from this sixth plot are added, results in
each of these analyses are similar to those
reported in plot 5 (within two percentage
points); therefore, we have not presented
the updated tables in this paper.
We have used the CPDB to address
many issues relevant to chemical carcino-
genesis and interspecies extrapolation
(8-24). Papers published since the fifth
plot discuss: how tautological are inter-
species correlations of carcinogenic poten-
cies (25); three key factors in mutagenesis
and carcinogenesis: DNA lesions, inducible
DNA repair, and cell division (26); com-
parison of target organs of carcinogenicity
for mutagenic and nonmutagenic chemi-
cals (27); prediction of carcinogenicity
from two instead offour sex-species groups
(28); the importance of data on mecha-
nism of carcinogenesis in efforts to predict
low-dose human risk (29); comparison of
results for heterocyclic amines with other
chemicals in the CPDB (30); setting prior-
ities among possible carcinogenic hazards
in the workplace (31); causes and preven-
tion ofhuman cancer (32); and quick esti-
mation ofthe regulatory, virtually safe dose
based on the MTD (33).
Plot in this Supplement
This sixth plot of the CPDB includes
results of 531 long-term, chronic experi-
ments on 182 chemicals. It reports on 50
compounds published in Technical
Reports ofthe NTP between January 1990
and June 1993, and 139 compounds pub-
lished in the general literature between
January 1989 and December 1990.
Experiments are reported in rats, mice,
hamsters, prosimians, and monkeys.
Eighty-seven of the 182 chemicals in this
plot were also included in an earlier plot,
and we have flagged the chemical names on
the plot with a triple asterisk (***).
Whereas only a few experiments may be
reported here for a given chemical, several
experiments may have been reported in
earlier plots (e.g. 2-acetylaminofluorene,
BHT, formaldehyde, and lead acetate). By
using Appendix 14, the reader can identify
the earlier plot publications that include
data on each chemical as well as informa-
tion on whether the chemical was tested
and evaluated as carcinogenic in each sex of
rat and mouse; the most potent TD50 value
in rats and mice from all six plots is also
reported in Appendix 14.
Chemicals from a variety ofsources and
with a variety of uses are included in this
sixth plot: for example, industrial chemicals
(e.g. cadmium chloride, glycidol, rho-
damine 6G, and tetranitromethane); food
additives (e.g., sodium benzoate and
polysorbate 80); agricultural chemicals
(e.g., methyl bromide, ethylene thiourea,
mirex, and 1,1-dimethylhydrazine
[UDMH]); and pharmaceuticals (e.g.,
acetaminophen, doxefazepam, probenecid,
and sulfamethazine). Some are naturally
occurring substances in the human diet
that we have discussed and ranked in possi-
ble carcinogenic hazard and compared to
synthetic chemicals (24,30) (e.g., caffeic
acid, furfural, sesamol, IQ, PhIP.HC1 and
MeIQx). Some experiments reported in
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this plot have extensive dose-response data,
with more than four dose groups (e.g., 1,3-
butadiene, diethylstilbestrol, N-nitrosopy-
rrolidine, and sulfamethazine). The TD50
values for the compounds in this plot fall
within the 10 millionfold range reported
earlier (1).
For several recent bioassays in which
NTP suspected a potential for chemically
induced renal tubule neoplasms, multiple
additional sections were taken of the kid-
neys. This is the first CPDB plot to include
results on these step sections. For bioassays
with kidney step sections in which NTP
evaluated the evidence for carcinogenicity
as "clear" "some" or "equivocal," we have
estimated one TD50 value using data from
the standard protocol and one that includes
the step section data. On the plot the TD50
including step sections is indicated by the
words "with step." Whereas TD50 values
for NTP bioassays throughout the CPDB
are estimated with lifetable methods, only
summary data were available for the kidney
step sections. The confidence limits ofthe
summary TD50 value for the step sections
are therefore indicated on the plot by the
symbol "." (as for all summary values in the
CPDB). For example, see TD50 values for
kidney tubule adenoma in male mice for
tris(2-chloroethyl)phosphate.
Analyses of Bioassays in
Nonhuman Primates
A series oflifetime studies of30 chemicals
in cynomolgus and rhesus monkeys have
been conducted at the Laboratory of
Chemical Pathology, National Cancer
Institute (NCI) [SM Sieber and UP
Thorgeirsson, personal communication;
(34-36)]. Included in this plot of the
CPDB, are lifetable analyses of results on
17 completed studies, 16 of which are
rodent carcinogens. The duration ofexper-
iments is up to 27 years. We have relaxed
some ofour standard CPDB rules in order
to report these results, for example, because
there were often fewer than five animals
per sex-species, because controls are from a
colony rather than concurrent, and because
some positive experiments were shorter
than half the standard lifespan. We
describe our methods of analysis below,
and details of each experiment appear on
the plot including exposure and experi-
ment length, special notecodes, and tumor
incidence for each site. The first plot ofthe
CPDB included interim results for 7 of
these studies, using summary incidence
data to estimate TD50 (1). These 7 are
indicated with the notecode "j" in this plot.
The published authors evaluated 10 of
the test agents as carcinogenic in monkeys:
aflatoxin Bl, N-nitrosopiperidine, procar-
bazine.HC4 urethane, IQ, sterigmatocystin,
cycasin and methylazoxymethanol acetate,
N-methyl-N-nitrosourea, N-nitrosodi-
propylamine, and N-nitrosodiethylamine.






methylamine. We note that the protocol
for most of the negative studies differed
from that of all but one of the positive
studies in that exposure to the test agent
was stopped early in the experiment rather
than being administered to death or nearly
to death. Three other negative compounds
are not included here because they did not
meet the inclusion rules of the CPDB:
cigarette smoke condensate (a mixture
administered by implant); 2,4,9,10-diben-
zopyrene and copper chelate of N-OH-
acetylaminofluorene (administered sc).
Studies are ongoing at NCI for 10 addi-
tional compounds; many animals are still
alive, and few or no tumors have been
observed in those that have died. These
studies will be added to the CPDB when
completed: adriamycin, melphalan, aza-
thioprine, cyclophosphamide, cyclamate,
saccharin, MeIQx, PhIP, DDT, and 2,7-
acetylaminofluorene.
Special Considerations
(i) Generally, few animals of each sex of
either cynomolgus or rhesus monkeys were
on test for each chemical, and there was
usually only one dose group per experi-
ment. Even combining results for males
and females ofeach species, about halfthe
experiments had 10 or fewer dosed ani-
mals, and never more than 22 in a dose
group. Therefore, we have combined males
and females ofeach species in our analyses;
this results in having at least 5 dosed ani-
mals in all experiments but one (in which
all of the 4 dosed animals developed
tumors). (ii) Whereas experiments with
surgical intervention are excluded from the
CPDB, laparoscopic examination of the
liver was performed every 3 to 6 months,
followed by wedge or needle biopsies of
observed liver lesions. (iii) We have
included experiments that were shorter than
our rule of one-half the standard lifespan,
when tumors were induced in nearly all
animals (cycasin, N-nitrosodipropylamine,
IQO; these are indicated on the plot by the
symbol "(+)". (iv) A few experiments have
been included in which animals were put
on test as adults (4 years of age). (v)
Control monkeys for all analyses are from
the colony at NCI, which includes breed-
ers, offspring, and some feral monkeys. At
any given time, the age of colony control
animals ranged from neonate to greater
than 25 years. In our lifetable analyses,
control animals ofeach species are included
if they lived longer than 8 months of age,
the age of the first tumor in any group in
these experiments. [For one ongoing study,
IQ in cynomolgus, only summary data
were available and concurrent vehicle con-
trols were used in our analyses (37).] We
note that, compared to rodent bioassays,
the tumor incidence rate in control mon-
keys in this colony is low: for all tumor-
bearing animals, whether benign or
malignant, the tumor rate is 3% (3/99) in
dead cynomolgus controls, and 10%
(11/108) in rhesus.
EstimationofAverageDailyDoseLevel
In the CPDB for standard rodent bioassays
the dose rate used to estimate TD50 is the
daily dose rate for each group (in mg/kg
body weight); if dosing is less than the
experiment length, then the dose rate is
obtained by averaging over the duration of
the experiment. For this series of monkey
studies we use the same averaging over
experiment length; however, the dose rate
for the group is calculated based on the
average rate for individual animals. We
obtained from NCI the total cumulative
dose for each animal in mg/kg bodyweight.
Using the age at death, we calculate an
average daily dose rate for each animal, and
the dose rate for the group (mg/kg/day) is
the mean of these individual daily dose
rates. This value can be considerably lower
than the administered dose level reported
by Thorgeirsson et al. (35) because the
duration of dosing is often less than the
experiment length (sometimes less than
one-fourth the experiment length) and
because dosing schedules ranged from once
every 2 weeks to 5 times perweek.
ifetableAnalyses
Estimates of TD50 are based on lifetable
analysis, which adjusts for the differential
effects of toxicity among dose groups and
for differences between groups in the time
pattern oftumor incidence.
On the plot, a TD50 is reported for each
site at which a benign or malignant tumor
was diagnosed in dosed monkeys. The
denominators in each group, whether con-
trol or dosed, represent the number ofani-
mals alive at the age ofthe first death with
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the tumor of interest in any group. The
numerator on the plot for control animals
excludes tumors found at death in animals
that lived to be older than the last dosed
animal, and such cases are indicated by the
notecode "W' on the plot.
Since individual animal pathology
reports were made available to us, we were
able to calculate a TD50 for combined
tumors, just as we do in the CPDB for
lifetable analyses of the NCI/NTP rodent
bioassays; these are signified in the plot by
the code MXB for "Berkeley Mix". For
each experiment in monkeys, we estimated
a TD50 for "all tumor-bearing animals"
("tba" on the plot) for all benign tumors,
for all malignant tumors, and for any ani-
mal with either a benign or malignant
tumor. The denominators in the tumor
incidence fields of the plot for "all tumor-
bearing animals" represent the maximum
number of animals used in any TD50 in
the experiment, and indicate the number
alive at the first tumor in any group. As for
NCI/NTP bioassays, we also estimate a
composite TD50 value for all sites that were
evaluated as target sites by the published
authors (35) This composite value
(denoted on the plot by MXB MXB), is
reported for four chemicals that were eval-
uated as having more than one target site
in a monkey experiment.
Further analyses are in progress which
compare results in rodents and monkeys.
For example, the liver is the most frequent
target site in monkeys, just as it is in mice
and rats.
Addenda and Errata to Earlier Plots
A few changes have been made to earlier plots. In plot 1 the chem-
ical name "ethylene glycol" should have been "ethylene glycol,
cyclic sulfate."
Two code changes are necessary in previously reported results
due to typographical errors. The code "cca" (c-cell adenoma) in
the fifth plot was used with adrenal gland when the code should
have been "coa" (cortical-cell adenoma) for the following chemi-
cals: acetaldoxime, acrolein, acrolein diethylacetal, acrolein oxime,
allyl alcohol, cyclohexanone, N-methyldopamine, 0,0'-diisobuty-
royl ester.HCI and 3-nitro-4-hydroxyphenylarsonic acid. In the
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
FUROSEMIDE 10Ong..:.. .lug..: 10 : 1 *.100
1 R m f34 eat pta adn 24m24
a R m f34 eat kid MXA 24m24
b R m f34 eat brm mng 24m24
c R m f34 eat TBA MXB 24m24
d R m f34 eat liv MXB 24m24
2 R m f34 eat kid MXA 24m24 with step
first plot for N>N-dimethyl-4-aminoazobenzene, the tumor code
for liver cell carcinoma should have been "1cc" but was reported as
"cca". The author's opinion for urinary bladder papilloma in a test
of sodium saccharin in plot 4 (Hasegawa et al., Cancer Research
45:1469-1473, 1985) has been changed from + (positive) to blank
(none) following recent personal communication with the author.
Kidney step section data in the CPDB for NTP bioassays are
reported for the first time in this publication. Below we plot step
section results for furosemide and nitrofurantoin, which were
induded in an earlier plot without this data. The previously pub-
lished results are included for comparison.
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c R m f34 eat liv MXB 24m24 332.mg \ P<.2
4 R m f34 eat kid MXA 24m24 with step + 163.mg * P<.0005p


















































3 c55196 142.mg n.s.s. 0/50 51.3mg 5/50 98.1mg
a c55196 240.mg n.s.s. 0/50 51.3mg 1/50 98.1mg
b c55196 62.1mg n.s.s. 48/50 51.3mg 47/50 98.1mg
c c55196 90.0mg n.s.s. 1/50 51.3mg 4/50 (98.1mg
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1 M f b6c eat TBA MXB 24m24
a M f b6c eat liv MXB 24m24
b M f b6c eat lun MXB 24m24
2 M f b6c eat liv mix 31m31 e
a M f b6c eat lun mix 3lm3l e
b M f b6c eat tba tum 3lm3l e
3 M m b6c eat TBA MXB 24m24
a M m b6c eat liv MXB 24m24
b M m b6c eat lun MXB 24m24
4 M m b6c eat liv mix 31m31 e
a M m b6c eat lun mix 3lm3l e
b M m b6c eat tba tum 31m31 e
5 R f f34 eat --- mnl 24m24
a R f f34 eat TBA MXB 24m24
b R f f34 eat liv MXB 24m24
6 R m f34 eat zym car 24m24
a R m f34 eat TBA MXB 24m24
b R m f34 eat liv MXB 24m24
lbOng..:. . lug.... -10 ....:..100 ....:..mg ....:.-10 ..... -100 .... g......10


















2-ACETYLAMINOFLUORENE *** 1 O0ng. * lug ..10 .... 1 :100°. :._mg. :.-10 ... :. -100 : .-Ig . .... :.-10
7 P b rhe eat npl adc 5y26 w ± 33.Omg





















AFLATOXIN Bl*** lbOng..:...... lug . ...10. :100 . 1 :1mg. : 10. :100 . : 1g. :10
8 P b cym mix MXB MXBl7yl7 Wjmw + 9.25ug P<.0005
a P b cym mix bil mix l7yl7 Wjn
b P b cym mix gab adc l7y17 Wjn
c P b cym mix --- ost 17y17 Wjn
d P b cym mix liv hes l7yl7 Wjn
e P b cym mix k/p tcc l7yl7 Wjn
f P b cym mix liv clc 17y17 Wjn
g P b cym mix liv hpc l7yl7 Wjn
h P b cym mix pel fbs l7yl7 Wjn
i P b cym mix pnd adc 17y17 Wjn
j P b cym mix bil scc l7yl7 Wjn
k P b cym mix tba mall7yl7 Wjn
9 P b rhe mix MXB MXBl5yl5 Wjn
a P b rhe mix liv clc l5yl5 Wjn
b P b rhe mix bil mix l5yl5 Wjn
c P b rhe mix gab adc l5yl5 Wjn
d P b rhe mix liv hes 15y15 Wjn
e P b rhe mix pnd adc i5yl5 Wjn
f P b rhe mix liv hpc 15y15 Wjn
g P b rhe mix --- ost 15y15 Wjn
h P b rhe mix tba mal 15y15 Wjn
ALLYL GLYCIDYL ETHER
10 M f b6c inh hag ade 24m24
a M f b6c inh nre ade 24m24
b M f b6c inh TBA MXB 24m24
c M f b6c inh liv MXB 24m24
d M f b6c inh lun MXB 24m24
11 M m b6c inh nre ade 24m24
a M m b6c inh TBA MXB 24m24
b M m b6c inh liv MXB 24m24
c M m b6c inh lun MXB 24m24
12 R f osm inh TBA MXB 24m25
a R f osm inh liv MXB 24m25
13 R m osm inh MXA MXA 24m25 s
a R m osm inh TBA MXB 24m25 s
b R m osm inh liv MXB 24m25 s
1-ALLYL-1-NITROSOUREA
14 R f f34 gav for tum
a R f f34 gav mgl adc
b R f f34 gav ute mix
c R f f34 gav liv tum
d R f f34 gav lun mix
15 R m f34 gav for tum
a R m f34 gav lun mix
b R m f34 gav col tum











16 M f b6c eat TBA MXB 24m24
a M f b6c eat liv MXB 24m24









































O0ng.. -lug.... -10 ..... -100 ....:..mg ....:. -10 ..... -100 . lg. 10



































































lOOngs. .: * -lug ...: *_10 ....: *-100 ....:1*Img ...:* 10 ....:* 100 ....:I*-lg ....:..10












RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
ACETAMINOPHEN*** (Tylenol, paracetamol) 103-90-2
1 c55801 955.mg n.s.s.
a c55801 2.21gm n.s.s.
b c55801 1.83gm n.s.s.
2 1955 3.29gm n.s.'s.
a 1955 12.0gm n.s.s.
b 1955 1.12gm n.s.s.
3 c55801 717.mg n.s.s.
a c55801 2.27gm n.s.s.
b c55801 1.05gm n.s.s.
4 1955 4.85gm n.s.s.
a 1955 7.41gm n.s.s.
b 1955 1.99gm n.s.s.
5 c55801 220.mg n.s.s.
a c55801 154.mg n.s.s.
b c55801 n.s.s. n.s.s.
6 c55801 580.mg n.s.s.
a c55801 106.mg n.s.s.
























































7 2001 5.37mg n.s.s. 0/15 6.77mg 1/5
a 2001 9.47mg n.s.s. 5/76 6.77mg 1/10
AFLATOXIN B1*** 1162-65-8
8 2001 3.25ug 26.5ug 0/67
a 2001 6.34ug 68.3ug
b 2001 12.9ug .203mg
c 2001 12.Oug 1.98mg
d 2001 21.4ug .526mg
e 2001 7.26ug n.s.s.
f 2001 7.26ug n.s.s.
g 2001 7.26ug n.s.s.
h 2001 16.9ug n.s.s.
i 2001 55.7ug n.s.s.
2001 60.5ug n.s.s.
k 2001 3.08ug 20.3ug
9 2001 1.7lug 20.lug
a 2001 1.52ug .185mg
b 2001 2.llug 71.9ug
c 2001 2.24ug .130mg
d 2001 4.lOug .139mg
e 2001 6.39ug .171mg
f 2001 25.2ug 1.90mg
g 2001 25.9ug n.s.s.






























































Amo; jjhg, 40, 567-574; 1985
liv:hpa,hpc,nnd.
lun: a/a, a/c.
Amo; jjhg, 40, 567-574; 1985
liv: hpa, hpc, nnd.
liv: hpa, hpc, nnd.
Adamson;ossc, 129-156;
1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
Adamson;ossc, 129-156;
1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
ALLYL GLYCIDYL ETHER 106-92-3
10 c56666 46.Omg n.s.s. 0/50
a c56666 100.mg n.s.s. 0/50
b c56666 25.Omg n.s.s. 35/50
c c56666 84.8mg n.s.s. 6/50
d c56666 46.7mg n.s.s. 0/50
11 c56666 55.0mg n.s.s. 0/50
a c56666 9.02mg n.s.s. 32/50
b c56666 20.6mg n.s.s. 23/50
c c56666 27.8mg n.s.s. 7/50
12 c56666 1.78mg n.s.s. 43/50
a c56666 29.7mg n.s.s. 1/50
13 c56666 3.48mg n.s.s. 0/50
a c56666 .457mg n.s.s. 30/50
b c56666 n.s.s. n.s.s. 0/50
1-ALLYL-1-NITROSOUREA 760-56-5
14 1915 .197mg 1.66mg 0/12
a 1915 .238mg 2.70mg 0/12
b 1915 .399mg n.s.s. 2/12
c 1915 1.50mg n.s.s. 0/12
d 1915 1.50mg n.s.s. 1/12
15 1915 .113mg .812mg 0/12
a 1915 .167mg 1.89mg 0/12
b 1915 .201mg 4.34mg 0/12

























































16 c55710 3.80mg n.s.s. 40/50
a c55710 16.Omg n.s.s. 5/50
b c55710 6.80mg n.s.s. 8/50
2.56mg 27/50 (12.8mg 15/50)
2.56mg 1/50 (12.8mg 1/50)
2.56mg 6/50 (12.8mg 1/50)
liv:hpa,hpc,nnd.
lun: a/a, a/c.
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Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
17 M m b6c eat thy MXA 24m24
a M m b6c eat TBA MXB 24m24
b M m b6c eat liv MXB 24m24
c M m b6c eat lun MXB 24m24
18 R f f34 eat TBA MXB 24m24
a R f f34 eat liv MXB 24m24
19 R m f34 eat TBA MXB 24m24
a R m f34 eat liv MXB 24m24
1-ANYL-1-NITROSOUREA***
20 R f f34 gav for tum 12m24
a R f f34 gav lun mix 12m24
b R f f34 gav ute mix 12m24
c R f f34 gav mgl adc 12m24
d R f f34 gavliv tum 12m24
21 R m f34 gav for tum 12m24
a R m f34 gav lun mix 12m24
b R m f34 gav --- mso 12m24
c R m f34 gav liv tun 12m24
trans-ANETHOLE
22 R f cdr eat liv hpc
a R f cdr eat liv hpa
b R f cdr eat liv cho
23 R m cdr eat lmr rts
a R m cdr eat tes ict
b R m cdr eat liv hpa
c R m cdr eat liv cho
d R m cdr eat liv hpc
























































ARSENATE, SODIUMn ....... ........... :.._mg ..... ........ :*- g ..... :10g 10g10
24 P b cym eat kcx ade l4yl9 Ww ± 50.3ug P<.08
a P b cym eat tba ben l4yl9 Ww 87.5ug P<.5
ATRAZINE***
25 R f f31 eat ute mal 28m29 ae
a R f f31 eat --- mix 28m29 ae
b R f f31 eat --- leu 28m29 ae
c R f f3l eat --- lym 28m29 ae
d R f f31 eat tba mal 28m29 ae
26 R m f31 eat --- mix 29m29 ae
a R m f31 eat --- leu 29m29 ae
b R m f31 eat mgl mix 29m29 ae
c R m f31 eat mgl ben 29m29 ae
d R m f31 eat --- lym 29m29 ae
e R m f31 eat mgl mal 29m29 ae
f R m f31 eat liv hpc 29m29 ae
g R m f3l eat tba mal 29m29 ae
AZATHIOPRINE***
27 M f b6c eat liv tum 86w86 k
a M f b6c eat lun tum 86w86 k
28 M f b6c eat lun tum 94w94 k
a M f b6c eat --- lsl 94w94 k
b M f b6c eat liv tum 94w94 k
29 M f b6c eat ute hae 23m23
a M f b6c eat --- lsl 23m23
b M f b6c eat liv hpa 23m23
c M f b6c eat lun tum 23m23
d M f b6c eat liv hem 23m23
30 M m b6c eat liv tum 86w86 k
a M m b6c eat lun tum 86w86 k
31 M m b6c eat lun ade 94w94 k
a M m b6c eat liv hpa 94w94 k
b M m b6c eat --- lsl 94w94 k
32 M m b6c eat --- lsl 23m23
a M m b6c eat liv hpc 23m23
b M m b6c eat lun car 23m23
c M m b6c eat liv hpa 23m23
d M m b6c eat lun ade 23m23
AZIDE, SODIUM***
33 R f f34 gav TBA MXB 24m24
a R f f34 gavliv MXB 24m24
34 R m f34 gav tes MXA 24m24
a R m f34 gav TBA MXB 24m24
b R m f34 gav liv MXB 24m24
O0ng..:..lug.... -10 ....:* 100.- - -: ..mg.. :* 10 ..... :* 100...g. :10
± 197.mg * P<.09 +




+ 68.2mg * P<.06
109.mg * P<.l
262.mg * P<.02 +




























































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
2.37mg 1/50 11.9mg 3/50
2.37mg 25/50 (11.9mg 18/50)
2.37mg 12/50 (11.9mg 2/50)
2.37mg 3/50 11.9mg 4/50
.985mg 42/50 (4.93mg 30/50)
.985mg 0/50 4.93mg 0/50
.790mg 45/50 (3.95mg 37/50)







20 1915 .199mg 1.33mg 0/12 1.25mg
a 1915 .420mg 21.2mg 1/12 1.25mg
b 1915 .353mg n.s.s. 2/12 1.25mg
c 1915 .894mg n.s.s. 0/12 1.25mg
d 1915 1.15mg n.s.s. 0/12 1.25mg
21 1915 n.s.s. .422mg 0/12 .875mg
a 1915 .232mg 1.67mg 0/12 .875mg
b 1915 .343mg 3.88mg 0/12 .875mg











22 1843 2.97gm 82.2gm 1/104 125.mg 0/78 250.mg
a 1843 2.66gm n.s.s. 2/104 125.mg 2/78 250.mg
b 1843 9.49gm n.s.s. 4/104 125.mg 1/78 250.mg
23 1843 1.07gm n.s.s. 2/104 100.mg 2/78 200.mg
a 1843 1.94gm n.s.s. 0/104 100.mg 3/78 200.mg
b 1843 2.72gm n.s.s. 3/104 100.mg 3/78 200.mg
c 1843 4.29gm n.s.s. 0/104 100.mg 1/78 200.mg
d 1843 3.31gm n.s.s. 2/104 100.mg 1/78 200.mg
e 1843 6.06gm n.s.s. 0/104 100.mg 1/78 200.mg
ARSENATE, SODIUM-** 7631-89-2
24 2001 12.4ug n.s.s. 0/13






























27 1935m .366mg n.s.s.
a 1935m .366mg n.s.s.
28 1935n 1.68mg n.s.s.
a 1935n 2.20mg n.s.s.
b 1935n 1.22mg n.s.s.
29 1935o 3.85mg 30.8mg
a 1935o 4.89mg n.s.s.
b 1935o 11.0mg n.s.s.
c 1935o 3.04mg n.s.s.
d 1935o 3.04mg n.s.s.
30 1935m .338mg n.s.s.
a 1935m .338mg n.s.s.
31 1935n 3.18mg n.s.s.
a 1935n 5.97mg n.s.s.
b 1935n 5.97mg n.s.s.
32 1935o 3.65mg n.s.s.
a 1935o 9.10mg n.s.s.
b 1935o 9.10mg n.s.s.
c 1935o 2.69mg n.s.s.






























































































































































33 c06462 3.58mg n.s.s. 53/60
a c06462 64.7mg n.s.s. 1/60
34 c06462 1.68mg n.s.s. 52/60
a c06462 2.23mg n.s.s. 56/60
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35 R m f34 eat ubl turn 56w56 a
36 R m f34 eat ktu tumn 52w52 kr
37 R m f34 eat k/p tpp 72w72 ar
a R m f34 eat ktu tla 72w72 ar
BENZALDEHYDE
38 N f b6c gay for sop 24m24
a M fb6c gavTBA MXB 24r24
b Mfb6c gav liv MXB24m24
c N f b6c gay lun MXB 24m24
39 N m b6c gay for sojp 24m25
a M m b6c gay TBA MXB 24m25
b M m b6c gay liv MXB 24m25
c M mb6c gav lunMXB 24m25
40 R f f34 gay TBA MXB 24m24
a R f f34 gay liv MXB 24m24
41 R m f34 gay tes NXA 24m24
a R m f34 gay pit ade 24m24
b R mf34 gavamndRXA 24m24
c R m f34 gay msnl 24m24
d R mf34 gav thyNRXA24m24
a R m f34 gay thy cca 24m24
f R m f34 gay pan ade 24m24
g R m f34 gay ski ker 24m24
h R mf34 gavarndphms24m24
i R mf34 gavpre MRA24m24
j R m f34 gay msm 24m24
k R m f34 gay ski pam 24m24
1 R m f34 gay TBA MRB 24m24
m R m f34 gay liv I4XB 24m24
bOOng..:..lug...:.10 ...:.100...1m.g... .10 ....100...l.g....10































42 N f swa wat lun turn 31m31
a N f swa wet liv turn 31m31
43 M m swa wat liv hpt 26m26
a MNmswawat luntum 26m26





BENZYL ACETATE** b1Ong. .: ug...:-10 ....:100 ...:.mg.....10 100 .ig ....:,10
44 R m f34 eat pan cic 24m24 er. 2.67gm P<.03
a R m f34 eat pan ade 24m24 er 27.0gm P<l.
BIS (2 -HYDROXYPROPYL) AMINE
45 R m wis eat liv hpc 94w94
a R mwiseat luntum 94w94
b R m wis eat nas turn 94w94




BIS(TRI-N-BUTYLTIN)OXIDE, TECHNICAL GRADE ..lug.....10 ...:. 100 1..mg.....10 100 l..g 10
46 R f wis eat amnd phe 25m25 + 1.79mg
a R f wis eat pta turn 25m25 3.73mg
47 R m wis eat amd pha 25m25 + 1.93mg *








C.I. DIRECT BLUE 15
48 R ff34 watNMXBMXB96w97
bOOng..:..bug .I ...:.100 :mg.....10 ...:.100 ...l..g ....10
+ 21.3mg *P<.0005
a R f f34 wat cli NRA 96w97
b R f f34 wat mul mnl 96w97
c R f f34 watMRA MRA 96w97
d R ff34 wat cli MRA96w97
R f f34 wat zym NRA 96w97
f R f f34 wat cliNMXA96w97
g R ff34 watuteaMXA 96w97
h R f f34 wet uta asp 96w97
i R ff34 watRXAsojp 96w97
j R f f34 wat zym car 96w97
k R f f34 wat pal sqp 96w97
1 R ff34 wat ski MRA96w97
m R f f34 wat ski sqp 96w97
n R f f34 watNMXA sqc 96w97
R ff34 wat ton MXA96w97
p R f f34 wet zym ada 96w97
q R f f34 wet ton sqc 96w97
r R f f34 wet liv NRA 96w97
s R f f34 wet liv nod 96w97
t R f f34 wet pal sqc 96w97
u R ff34watNRXA adp96w97
v R ff34 watuteaMXA 96w97



























































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
BARBITAL, SODIUM 144-02-5
35 1942 35.9mg n.s.s. 0/15
36 1993m 41.2mg n.s.s. 0/5
37 1993n 52.4mg 266.mg 0/24
a 1993n 118.mg n.s.s. 0/24
BENZALDEHYDE 100-52-7
38 c56133 653.mg 20.8gm
a c56133 528.mg n.s.s.
b c56133 881.mg n.s.s.
c c56133 2.33gm n.s.s.
39 c56133 617.mg n a.s.
a c56133 198.mg n.s.s.
b c56133 380.mg n.s.s.
c c56133 867.mg n.s.s.
40 c56133 51.9mg 491.mg
a c56133 1.81gm n.s.s.
41 c56133 39.6mg 181.mg
a c56133 91.3mg 882.mg
b c56133 117.mg 456.mg
c c56133 141.mg 668.mg
d c56133 240.mg 1.65gm
e c56133 260.mg 1.18gm
f c56133 354.mg 2.36gm
g c56133 632.mg 55.Ogm
h c56133 382.mg n.s.s.
i c56133 390.mg n.s.s.
j c56133 458.mg n.s.s.
k c56133 735.mg n.s.s.
1 c56133 67.Omg 241.mg


























42 1996 18.3gm n.s.s. 21/100
a 1996 68.4gm n.s.s. 0/100
43 1996 21.7gm n.s.s. 0/100
a 1996 17.5gm n.s.s. 23/100































































































liv: hpa, hpc, nnd.





44 1988 807.mg n.s.s. 0/49 320.mg 3/38
a 1988 660.mg n.s.s. 10/49 320.mg 8/38
BIS(2-HYDROXYPROPYL)AMINE 110-97-4
45 1914 1.35gm n.s.s. 0/20 400.mg 0/20
a 1914 1.35gm n.s.s. 0/20 400.mg 0/20
b 1914 1.35gm n.s.s. 0/20 400.mg 0/20
Longnecker; fctx, 28, 665-668; 1990/pers. comm.
Yamamoto;carc,10,1607-1611; 1989
BIS (TRI-N-BUTYLTIN) OXIDE, TECHNICAL GRADE
46 1975 1.15mg 3.04mg 3/50 25.Oug
a 1975 1.53mg n.s.s. 22/50 25.Oug
47 1975 1.06mg 5.03mg 16/50 20.Oug
a 1975 .774mg n.s.s. 34/50 20.Oug
56-35-9
3/50 .250mg 3/50 2.50mg 34/50
32/50 .250mg 22/50 2.50mg 35/50
13/50 .200mg 14/50 2.00mg 33/50
39/50 .200mg 29/50 2.00mg 43/50
Wester; fctx, 28,179-196; 1990/pers comm.
C.I. DIRECT BLUE 15 2429-74-5
48 c61290 15.1mg 32.5mg 16/50 35.5mg 24/35 70.3mg 59/65 141.mg 45/50 asc:adp; cli:ade,anb,car,cnb; col:adp; dsc:adp;
duo:muc; jej:adc,muc; liv:hpc,nnd; mul:mnl; pal:sqc,sqp; ski:sqc,sqp; ton:sqc,sqp; ute:adc,ade; zym:
ade,car. C
a c61290 30.2mg 80.1mg
b c61290 31.1mg 101.mg
c c61290 49.7mg 151.mg
d c61290 50.Omg 226.mg
e c61290 63.4mg 178.mg
f c61290 62.4mg 229.mg
g c61290 56.8mg 1.06gm
h c61290 59.3mg 3.45gm
i c61290 71.2mg 344.mg
j c61290 85.9mg 278.mg
k c61290 86.9mg 317.mg
1 c61290 79.8mg 377.mg
m c61290 85.6mg 442.mg
n c61290 105.mg 484.mg
o c61290 103.mg 1.38gm
p c61290 135.mg 1.48gm
q c61290 151.mg 2.35gm
r c61290 154.mg 1.43gm
a c61290 159.mg 1.92gm
t c61290 186.mg 2.33gm
u c61290 164.mg n.s.s.
v c61290 162.mg n.s.s.


































































































































































13Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
x R f f34 wat jej MXA 96w97
y R f f34 wat TBA MXB 96w97
z R f f34 wat liv MXB 96w97
49 R m f34 wat MXB MXB 97w97
a R m f34 wat tes MXA 97w97
b R m f34 wat ski MXA 97w97
c R m f34 wat ski MXA 97w97
d R m f34 wat ski bca 97w97
e R m f34 wat mul mnl 97w97
f R m f34 wat amd MXA 97w97
g R m f34 wat MXA MXA 97w97
h R m f34 wat amd MXA 97w97
i R m f34 wat MXA sqp 97w97
j R m f34 wat pal sqp 97w97
k R m f34 wat thy fca 97w97
1 R m f34 wat ski MXA 97w97
m R m f34 wat liv MXA 97w97
n R m f34 wat pre MXA 97w97
o R m f34 wat liv nnd 97w97
p R m f34 wat pre MXA 97w97
q R m f34 wat zym MXA 97w97
r R m f34 wat ski sqc 97w97
s R m f34 wat ski sqp 97w97
t R m f34 wat ski bcc 97w97
u R m f34 wat thy MXA 97w97
v R m f34 wat ski sea 97w97
w R m f34 wat sub MXA 97w97
x R m f34 wat zym car 97w97
y R m f34 wat sub fib 97w97
z R m f34 wat ski ker 97w97
A R m f34 wat MXA MXA 97w97
B R m f34 wat zym ade 97w97
C R m f34 wat MXA adp 97w97
D R m f34 wat col adc 97w97
E R m f34 wat liv hpc 97w97
F R m f34 wat thy MXA 97w97
G R m f34 wat thy MXA 97w97
H R m f34 wat pre MXA 97w97
I R m f34 wat thy fcc 97w97
J R m f34 wat MXA sqc 97w97
K R m f34 wat ton MXA 97w97
L R m f34 wat phr sqc 97w97
M R m f34 wat MXA asl 97w97
N R m f34 wat jej MXA 97w97
0 R m f34 wat TBA MXB 97w97
P R m f34 wat liv MXB 97w97
FD & C BLUE NO. 1***
50 M f cdl eat lun adc 24m24 e
a M f cdl eat lun alc 24m24 e
b M f cdl eat lun bcd 24m24 e
c M f cdl eat lun ala 24m24 e
d M f cdl eat liv hem 24m24 e
e M f cdl eat lun bde 24m24 e
51 M m cdl eat lun bcd 24m24 e
a M m cdl eat lun adc 24m24 e
b M m cdl eat lun bde 24m24 e
c M m cdl eat liv hpc 24m24 e
d M m cdl eat lun agc 24m24 e
e M m cdl eat lun alc 24m24 e
f M m cdl eat lun ala 24m24 e











































600.mg * P<.03 e
1.63gm * P<.2 c
12.Omg * P<.0005
55.2mg * P<.0005





























1,3-BUTADIENE** * Ong .. ..-lug - :*.10. -:*100. °* --:..-mg....0.......0.. . ........ :g.-g..... :*-10
52 M f b6c inh MXB MXB 19m24 a +: 6.79mg Z P<.0005
a M f b6c inh lun MXA 19m24 a
b M f b6c inh lun a/a 19m24 a
c M f b6c inh liv MXA l9m24 a
d M f b6c inh lun MXA 19m24 a
e M f b6c inh hag MXA l9m24 a
f M f b6c inh hag MXA l9m24 a








h M f b6c inh liv hpa l9m24 a
i M f b6c inh --- MXA19m24 a







RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
x c61290 340.mg n.s.s.
y c61290 13.5mg 36.2mg
z c61290 154.mg 1.43gm
49 c61290 8.18mg 18.Omg
a c61290 8.38mg 23.1mg
b c61290 12.2mg 28.2mg
c c61290 13.1mg 30.8mg
d c61290 14.Omg 35.3mg
e c61290 13.7mg 46.5mg
f c61290 20.7mg 84.2mg
g c61290 24.9mg 65.4mg
h c61290 22.1mg 95.2mg
i c61290 27.Omg 71.6mg
j c61290 29.Omg 77.1mg
k c61290 15.1mg 310.mg
1 c61290 29.3mg 97.2mg
m c61290 31.4mg 102.mg
n c61290 29.8mg 148.mg
o c61290 34.9mg 133.mg
p c61290 36.9mg 267.mg
q c61290 51.3mg 166.mg
r c61290 45.3mg 178.mg
s c61290 42.9mg 293.mg
t c61290 50.5mg 213.mg
u c61290 41.8mg 464.mg
v c61290 50.7mg 279.mg
w c61290 53.4mg 994.mg
x c61290 73.7mg 267.mg
y c61290 57.Omg 2.72gm
z c61290 60.6mg 2.32gm
A c61290 84.3mg 359.mg
B c61290 88.4mg 1.09gm
C c61290 131.mg 1.16gm
D c61290 144.mg 1.66gm
E c61290 129.mg 1.87gm
F c61290 44.4mg n.s.s.
G c61290 52.4mg n.s.s.
H c61290 79.1mg n.s.s.
I c61290 85.4mg n.s.s.
J c61290 117.mg n.s.s.
K c61290 108.mg n.s.s.
L c61290 130.mg n.s.s.
M c61290 188.mg n.s.s.
N c61290 484.mg n.s.s.
0 c61290 8.00mg 20.Omg
P c61290 31.4mg 102.mg
0/50 35.5mg 0/35 70.3mg 0/65 141.mg 3/50 jej:adc,muc. S
43/50 35.5mg 33/35 70.3mg 64/65 141.mg 49/50
0/50 35.5mg 0/35 70.3mg 2/65 141.mg 5/50 liv:hpa,hpc,nnd.
14/50 31.5mg 27/35 61.7mg 59/65 124.mg 45/50 asc:adp; col:adc,adp; dsc:adp; jej:adc,adp,muc;









































































































































































FD & C BLUE NO. 1*** (brilliant blue FCF) 3844-45-9
50 1976 60.6gm n.s.s. 0/120 650.mg 0/60 1.95gm
a 1976 64.1gm n.s.s. 1/120 650.mg 0/60 1.95gm
b 1976 58.1gm n.s.s. 1/120 650.mg 1/60 1.95gm
c 1976 93.1gm n.s.s. 5/120 650.mg 1/60 1.95gm
d 1976 73.5gm n.s.s. 1/120 650.mg 1/60 1.95gm
e 1976 5.61gm n.s.s. 2/120 650.mg 0/60 1.95gm
51 1976 29.4gm n.s.s. 0/120 600.mg 1/60 1.80gm
a 1976 43.6gm n.s.s. 0/120 600.mg 1/60 1.80gm
b 1976 55.9gm n.s.s. 0/120 600.mg 0/60 1.80gm
c 1976 47.9gm n.s.s. 8/120 600.mg 2/60 1.80gm
d 1976 5.18gm n.s.s. 1/120 600.mg 0/60 1.80gm
e 1976 5.18gm n.s.s. 1/120 600.mg 0/60 1.80gm
f 1976 53.3gm n.s.s. 4/120 600.mg 0/60 1.80gm







































































































































































52 c50602 4.92mg 9.63mg 28/50 4.26mg 36/50 13.7mg 39/50 42.8mg 45/50 139.mg 48/50 435.mg 71/80 --:hcs,mlm,mlp,
mlu,mly; for:sqc,sqp; hag:adc,ade,anb; hea:hes; liv:hpa,hpc; lun:a/a,a/c,adc; mgl:adc,ado,mtm; ova:
ade,gcb,gcm,mtb. C
a c50602 8.55mg 19.5mg 4/50 4.26mg 15/50 13.7mg 19/50 42.8mg 24/50 139.mg 25/50 435.mg 22/80
b c50602 12.9mg 35.5mg 4/50 4.26mg 11/50 13.7mg 12/50 42.8mg 17/50 139.mg 14/50 435.mg 17/80
c c50602 13.7mg 44.6mg 15/50 4.26mg 14/50 13.7mg 15/50 42.8mg 19/50 139.mg 16/50 435.mg 2/80
d c50602 15.3mg 39.1mg 0/50 4.26mg 5/50 13.7mg 11/50 42.8mg 9/50 139.mg 19/50 435.mg 8/80
e c50602 16.1mg 47.3mg 8/50 4.26mg 10/50 13.7mg 6/50 42.8mg 15/50 139.mg 20/50 435.mg 9/80
f c50602 16.1mg 47.2mg 8/50 4.26mg 10/50 13.7mg 7/50 42.8mg 15/50 139.mg 20/50 435.mg 9/80





hag: adc, ade, anb.
--:hcs,mlm,mlp,
mlu,mly. S
h c50602 16.3mg 61.6mg 11/50 4.26mg 10/50 13.7mg 9/50 42.8mg 14/50 139.mg 12/50 (435.mg 1/80) S
i c50602 21.6mg 59.1mg 5/50 4.26mg 3/50 13.7mg 3/50 42.8mg 9/50 139.mg 24/50 435.mg 27/80 --:hem,hes. S
j c50602 19.6mg 74.7mg 6/50 4.26mg 12/50 13.7mg 11/50 42.8mg 7/50 139.mg 9/50 435.mg 32/80 --:mlm,mlp,mlu,
Volume 103, Supplement8, November 1995
Brkly Code
15Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
k M f b6c inh --- hes l9m24 a
1 M f b6c inh mgl MXAl9m24 a
mM f b6c inh liv hpc l9m24 a
n M f b6c inh ova MXA l9m24 a
o M f b6c inh --- mlp l9m24 a
p M f b6c inh ova MXA l9m24 a
q M f b6c inh for MXA l9m24 a
r M f b6c inh mgl ado l9m24 a
s M f b6c inh mgl adc l9m24 a
t M f b6c inh ova MXA 19m24 a
u M f b6c inh hea hes l9m24 a
v M f b6c inh --- hcs l9m24 a
w M f b6c inh for sqp l9m24 a
x M f b6c inh sub MXA l9m24 a
y M f b6c inh sub sar l9m24 a
z M f b6c inh ova gcm l9m24 a
A M f b6c inh ova mtb l9m24 a
B M f b6c inh for sqc l9m24 a
C M f b6c inh kid rua l9m24 a
D M f b6c inh mgl mtm l9m24 a
E M f b6c inh zym MXA l9m24 a
F M f b6c inh ova ade l9m24 a
G M f b6c inh TBA MXB l9m24 a
H M f b6c inh liv MXB l9m24 a
I M f b6c inh lun MXB l9m24 a



















1.06gm * P<.O1 e
2.71gm * P<.0005






a M m b6c inh lun MXA 19m24 a
b M m b6c inh liv MXA l9m24 a
c M m b6c inh hag MXA l9m24 a
d M m b6c inh hag MXA l9m24 a
e M m b6c inh lun MXA l9m24 a
f M m b6c inh lun a/a 19m24 a
g M m b6c inh liv hpa 19m24 a
h M m b6c inh liv hpc l9m24 a
i M m b6c inh --- MXA 19m24 a
j M m b6c inh --- hes l9m24 a












1 M m b6c inh hea hes l9m24 a
m M m b6c inh --- MXA 19m24 a
64.8mg Z P<.0005c
99.8mg Z P<.0005c
n M m b6c inh --- mlp l9m24 a
o M m b6c inh --- hcs l9m24 a
p M m b6c inh for MXA l9m24 a
q M m b6c inh hag adc 19m24 a
r M m b6c inh for sqp l9m24 a
s M m b6c inh pre car l9m24 a
t M m b6c inh kid rua 19m24 a
u M m b6c inh jej car 19m24 a
v M m b6c inh sub hes l9m24 a
w M m b6c inh bra onm l9m24a
x M m b6c inh bra ogm l9m24 a
y M m b6c inh TBA MXB 19m24 a
z M m b6c inh liv MXB l9m24 a
A M m b6c inh lun MXB l9m24 a
54 M m b6c inh MXB MXB 12m24
a M m b6c inh lun MXA 12m24
b M m b6c inh lun a/a 12m24
c M m b6c inh --- MXA 12m24
d M m b6c inh --- hes 12m24
e M m b6c inh lun MXA 12m24
f M m b6c inh hag MXA 12m24
g M m b6c inh liv MXA 12m24
h M m b6c inh hea hes 12m24
i M m b6c inh liv MXA 12m24
j M m b6c inh hag MXA 12m24
k M mb6c inh liv hpa 12m24
1 M m b6c inh pre MXA 12m24
m M mb6c inh --- MXA 12m24
n M m b6c inh liv MXA 12m24
o M m b6c inh for MXA 12m24
p M m b6c inh --- MXA 12m24
q M m b6c inh liv hpc 12m24
r M m b6c inh --- MXA 12m24
s M m b6c inh for sqp 12m24
t M m b6c inh hag MXA 12m24







268.mg * P<.02 c











































































































































































23/50 11.4mg 19/50 35.6mg
23/50 11.4mg 30/50 35.6mg
7/50 11.4mg 9/50 35.6mg
7/50 11.4mg 8/50 35.6mg
6/50 11.4mg 11/50 35.6mg
20/50 11.4mg 10/50 35.6mg
13/50 11.4mg 19/50 35.6mg
16/50 11.4mg 16/50 35.6mg
5/50 11.4mg 3/50 35.6mg
4/50 11.4mg 3/50 35.6mg
























































































































































hea:hes; kid:rua; liv:hpa,hpc; lun:a/a,a/c,adc; pre:car. C
31/50 114.mg 35/50 362.mg 3/73 lun:a/a,a/c,adc.
25/50 114.mg 33/50 362.mg 5/73 liv:hpa,hpc.
20/50 114.mg 31/50 362.mg 6/73 hag:adc,ade,anb.
19/50 114.mg 30/50 362.mg 6/73 hag:ade,anb. S
12/50 114.mg 22/50 362.mg 3/73 lun:a/c,adc. S
25/50 114.mg 21/50 362.mg 3/73 S
16/50 114.mg 24/50 362.mg 5/73 S
17/50 114.mg 26/50 362.mg 1/73 S
11/50 114.mg 24/50 362.mg 4/73 --:hem,hes. S
7/50 114.mg 24/50 362.mg 4/73 S
11/50 114.mg 9/50 362.mg 55/73 --:hcs,mlh,mlm,
mlp,mlu,mly. S
1 c50602 38.8mg 114.mg 0/50 3.55mg 0/50 11.4mg 1/50 35.6mg 5/50 114.mg 20/50 362.mg 4/73
































































































11.4mg 2/50 35.6mg 4/50 114.mg 2/50 362.mg 49/73
11.4mg 4/50 35.6mg 5/50 114.mg 7/50 362.mg 4/73
11.4mg 0/50 35.6mg 1/50 114.mg 8/50 362.mg 4/73 for:sqc,sqp.
11.4mg 1/50 35.6mg 3/50 114.mg 2/50 362.mg 0/73 S
11.4mg 0/50 35.6mg 1/50 114.mg 7/50 362.mg 2/73 S
11.4mg 0/50 35.6mg 0/50 114.mg 5/50 362.mg 0/73
11.4mg 0/50 35.6mg 3/50 114.mg 1/50 362.mg 0/73
11.4mg 1/50 35.6mg 1/50 114.mg 2/50 362.mg 0/73
11.4mg 1/50 35.6mg 0/50 114.mg 3/50 362.mg 0/73 S
11.4mg 0/50 35.6mg 0/50 114.mg 0/50 362.mg 0/73
11.4mg 0/50 35.6mg 0/50 114.mg 0/50 362.mg 0/73
11.4mg 45/50 35.6mg 48/50 114.mg 49/50 362.mg 62/73
11.4mg 30/50 35.6mg 25/50 114.mg 33/50 362.mg 5/73 liv:hpa,hpc,nnd.
11.4mg 18/50 35.6mg 30/50 114.mg 35/50 362.mg 3/73 lun:a/a,a/c.
--:hcs,mlm,mlp,mly; for:sqc,sqp; hag:adc,ade,adi,anb; hea:hes; kid:ade,rua;


































































































































































Spa Strain Site Xpo+Xpt TD50 2Tailpvl
Sex Route Hist Notes DR AuOp
v M m b6c inh for sqc 12m24 154.mg P<.0005
w M mb6c inh kid MXAl2m24 190.mg P<.003 c
x M m b6c inh-- mlp 12m24 129.mg P<.03 c
y M mb6c inh bra ogm 12m24 no dre P=1.
z M mb6c inh braonml12m24 no dre P=1.
A N m b6c inh --hem 12m24 no dre P=1.
B M mb6c inh zymadel12m24 no dre P=1.
C M mb6c inh zymcarl12m24 no dre P=1.
D M mb6c inh TBA MXBl2m24 5.84mg P<.0005
E M mb6c inh liv MXBl2m24 14.6mg P<.0005
F M mb6c inh lun MXBl2m24 7.25mg P<.0005
55 M mb6c inh MXB MXB 9m24 + 10.9mg P'z.0005
a N m b6c inh lun MXA 9m24 11.0mg P<.0005c
b M mb6c inh luna/c 9m24 16.3mg P<.0005
c N m b6c inh liv MXA 9m24 16.8mg Ps.0005
d M mb6c inh ---MXA 9m24 17.3mg P<.0005
e N m b6c inh hag MXA 9m24 17.5mg P<.0005c
f M mb6c inh hag MXA 9m24 18.0mg P<.0005
g M mb6c inh liv hpa 9m24 18.0mg P<.0005c
h M mb6c inh lun a/a 9m24 18.1mg P<.0005
i M mb6c inh ---hes 9m24 20.8mg P<.0005
j M mb6c inh hea hes 9m24 21.9mg P<.0005c
k M m b6c inh --MXA 9m24 57.1mg P<.002
1 M mb6c inh ---hcs 9m24 128.mg P<.002 c
m M mb6c inh kid rue 9m24 161.mg P<.005 c
n M mb6c inh liv hpc 9m24 62.0mg P<.02
o M mb6c inh --- hem 9m24 95.2mg P<.02
p M mb6c inh --- MXA 9m24 108.mg P<.03 c
q M mb6c inh --- mlp 9m24 142.mg P<.04 c
r M mb6c inh for sqp 9m24 171.mg P<.06
S M m b6c inh for MXA 9m24 171.mg P<.06 c
t M m b6c inh pre MXA 9m24 351.mg P<.l
u M m b6c inh pre MXA 9m24 351.mg P<.l c
v M mb6c inh hag adc 9m24 531.mg P<.07
w N m b6c inh --MXA 9m24 487.mg P<.5
x M mb6c inh zym car 9m24 625.mg P<.2
y M m b6c inh zym MXA 9m24 647.mg P<.5
z M mb6c inh bra ogm 9m24 no are 2=1.
A M mb6c inh braornm 9m24 no are P=1.
B N m b6c mnh TBA MXB 9m24 10.8mg P<.0005
C N m b6c inh liv M4XB 9m24 16.8mg P<.0005
D N m b6c inh lun MXB 9m24 11.0mg P<.0005
56 N m b6c inh MXB MXB 6m24 + 12.6mg P<.0005
a N m b6c mbh lun MXA 6m24 13.4mg P<.0005c
b M mb6c inh lun a/a 6m24 17.3mg PaQ0005
c M mb6c inhb--- hes 6m24 17.7mg Ps 0005
d M m b6c inh-- MXA 6m24 17.7mg PsO0005
e M mb6c inhblun a/c 6m24 17.8mg PsO0005
f M mb6c inhbhea hes 6m24 18.5mg P<.0005c
g N m b6c inh hag MXA 6m24 22.7mg P<.0005
h M m b6c inh hag MXA 6m24 22.7mg P<.0005c
i M mb6c inhbliv MXA 6m24 23.8mg PsO0005
j M m b6c inh liv MXA 6m24 23.8mg PsO0005
k M m b6c inh pre MXA 6m24 27.1mg P<.0005
1 M mb6c inhbpre MXA 6m24 27.1mg P<.0005c
m M mb6c inhbliv hpa 6m24 27.8mg P<.0005c
n M m b6c inh --MXA 6m24 28.8mg PsO0005
o M m b6c mbh-- MXA 6m24 31.3mg P<.0005c
p M m b6c inh-- mlp 6m24 46.0mg P<.0005c
q M mb6c inhliv hpc 6m24 60.0mg P<.004
r M mb6c inh liv MXA 6m24 60.0mg P<.004
s M mb6c inhfor MXA 6m24 91.4mg P<.0005c
t M m b6c inh --MXA 6m24 111.mg P<.002
u M m b6c inh zym MXA 6m24 135.mg PsO005
v M mb6c inhzym car 6m24 135.mg Ps 005 e
w M mb6c inhfor sqc 6m24 136.mg P<.0005
x M mb6c inh for sp 6m24 284.mg Ps.002
y M mb6c inhb--- hcs 6m24 396.mg Ps.02 c
z M mb6c inhbbra ogm 6m24 403.mg P<.05 c
A M mb6c inhbkid rua 6m24 961.mg P<.l c
B N m b6c inh-- hem 6m24 no dre P=1.
C M mb6c inhbbra onm 6m24 no are P=1.
D M m b6c mb TBA MX 6m2 12.5mg1
1 P__sOQOSnn
E M m b6c inh liv MXB 6m24 23.8mg P<.0005
F M m b6c inh lun MXB 6m24 13.4mg P<.0005
57 M m b6c inh MXB MXB 3m24 : (+) : 7.00mg P<.0005
a M m b6c inh lun MXA 3m24 8.59mg P<.0005c
EnvironmentalHealth Perspectives 18CARCINOGENIC POTENCYDATABASE


























--:hcs,mlm,mlp,mly; bra:ogm; for:sqc,sqp; hag:adc,ade,adi,anb; hea:hes; kid:







hag: adc, ade, adi, anb.
liv:hpa,hpc. S














--:hcs,mlm,mlp,mly; bra:ogm,onm; for:sqc,sqp; hag:adc,ade,adi,anb; hea:hes;
kid:rua; liv:hpa; lun:a/a,a/c,adc; pre:car,cnb. C
lun:a/a, a/c, adc.


































































































































































































































































































































































































19Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
b M m b6c inh hag MXA
c M m b6c inh lun MXA
d M m b6c inh hag MXA
e M m b6c inh liv MXA
f M m b6c inh liv MXA
g M m b6c inh --- MXA
h M m b6c inh lun a/a
i M m b6c inh liv hpa
j M m b6c inh --- hes
k M m b6c inh liv MXA
1 M m b6c inh liv hpc
m M m b6c inh --- MXA
n M m b6c inh hea hes
o M m b6c inh --- MXA
p M m b6c inh for sqc
q M m b6c inh for MXA
r M m b6c inh --- hem
s M m b6c inh hag MXA
t M m b6c inh --- mlp
u M m b6c inh --- hcs
v M m b6c inh pre MXA
w M m b6c inh pre MXA
x M m b6c inh --- MXA
y M m b6c inh for sqp
z M m b6c inh kid rua
A M m b6c inh bra ogm
S M m b6c inh zym car
C M m b6c inh bra onm
D M m b6c inh zym MXA
E M m b6c inh TBA MXB
F M m b6c inh liv MXB

































































































N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE*.: -lug.... :..10.... :.-100....:..:mg. :..10.... :.-100 .... I :.-g... 10 :* 1°
58 R f f34 eat ubl car 24m24 es <+ noTD50 P<.0005+
a R f f34 eat liv hpc 24m24 es no dre P=1.
59 R m f34 eat ubl car 24m24 es + .549mg * P<.0005+
a R m f34 eat liv hpc 24m24 es 185.mg * P<.4
N-N-BUTYL-N-NITROSOUREA***
60 R f f34 gav for tum 9m24
a R f f34 gav lun mix 9m24
b R f f34 gav ute mix 9m24
c R f f34 gav mgl adc 9m24
d R f f34 gav col tum 9m24
e R f f34 gav col tum 9m24
f R f f34 gav liv tum 9m24
61 R m f34 gav lun mix 9m24
a R m f34 gav for tum 9m24
b R m f34 gav col tum 9m24
c R m f34 gav liv tum 9m24
BUTYLATED HYDROXYANISOLE***
62 H m syg eat for sqc 48w72 r
a H m syg eat for pam 48w72 r
63 H m syg eat for pam 72w72 r
a H m syg eat for sqc 72w72 r
64 M m b6c eat for tum 64w64 ek
65 M m b6c eat for tum 72w72 ek
66 M m b6c eat for pam 80w80 ek
67 M m b6c eat for pam 88w88 ek
a M m b6c eat for sqc 88w88 ek
68 M m b6c eat for pam 96w96 ek
a M m b6c eat for sqc 96w96 ek
69 M m b6c eat for pam 24m24 er
a M m b6c eat for sqc 24m24 er
70 R m f34 eat ssq sqp 26m26 e
a R m f34 eat liv hpa 26m26 e
71 R m f3d eat for mix 51w52 er
a R m f3d eat for pam 51w52 er
b R m f3d eat for sqc 51w52 er
c R m f3d eat stg tum 51w52 er
BUTYLATED HYDROXYTOLUENE***
72 R m f34 eat liv hpa 26m26 e
a R m f34 eat ssq tum 26m26 e




























:r .> no dre P=1.
;r .> no dre P=1.
:r + 1.02gm * P<.03
r .> 3.75gm * P<.3
r +hist 3.75gm * P<.3 +
'r + 1.53gm * P<.02
:r +hist 10.5gm * P<.3 +
.> 13.1gm * P<.4
no dre P=1.





no dre P=1. -




73 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
lbOng..: lug .... -10 ..... -100 ....:..mg....:.-10 ..... -100 .... -lg ....:..10






RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
b e50602 5.73mg 27.Omg
c e50602 6.87mg 35.Omg
d e50602 7.17mg 36.3mg
e e50602 7.17mg 45.5mg
f e50602 7.17mg 45.5mg
g e50602 7.78mg 44.7mg
h e50602 7.56mg 68.5mg
i e50602 7.86mg 58.2mg
i e50602 9.92mg 58.7mg
k e50602 9.57mg 99.0mg
1 e50602 9.57mg 99.Omg
m e50602 12.4mg 61.8mg
n e50602 12.4mg 108.mg
o e50602 16.2mg 86.4mg
p e50602 13.4mg 264.mg
q e50602 14.6mg 226.mg
r e50602 13.7mg 449.mg
e50602 19.2mg 358.mg
t e50602 33.3mg 175.mg
u e50602 21.1mg 2.84gm
v e50602 43.9mg 550.mg
w e50602 56.7mg 1.32gm
x e50602 21.6mg n.s.s.
y e50602 27.3mg n.s.s.
z e50602 32.8mg n.s.s.
A e50602 51.Omg n.s.s.
B e50602 79.6mg n.s.s.
C e50602 93.4mg n.s.s.
D e50602 34.2mg n.s.s.
E e50602 3.87mg 15.Omg
F e50602 7.17mg 45.5mg







































































































N-BUTYL-N- (4-HYDROXYBUTYL)NITROSAMINE-** (butyl-butanol-nitrosamine) 3817-11-6
58 1954 n.s.s. .471mg
a 1954 4.01mg n.s.s.
59 1954 .347mg .873mg
a 1954 22.7mg n.s.s.
0/118 1.50mg 24/24 3.00mg 23/23 6.00mg 24/24
0/120 1.50mg 0/23 3.00mg 0/24 6.00mg 0/22
1/118 1.20mg 21/24 2.40mg 23/24 4.80mg 23/24


















60 1915 98.3ug .753mg
a 1915 99.5ug .880mg
b 1915 .216mg 4.51mg
c 1915 .314mg 2.64mg
d 1915 .693mg n.s.s.
e 1915 .693mg n.s.s.
f 1915 2.40mg n.s.s.
61 1915 68.8ug .527mg
a 1915 .108mg .721mg
b 1915 .485mg n.s.s.

























62 1997m 884.mg n.s.s.
a 1997m 1.70gm n.s.s.
63 1997n 270.mg 4.82gm
a 1997n 1.64gm n.s.s.
64 1901m 312.mg n.s.s.
65 1901n 395.mg n.s.s.
66 1901o 413.mg n.s.s.
67 1901r 920.mg n.s.s.
a 1901r 920.mg n.s.s.
68 1901s 620.mg n.s.s.
a 1901s 1.71gm n.s.s.
69 1901u 3.21gm n.s.s.
a 1901u 1.76gm n.s.s.
70 1973 424.mg 2.67gm
a 1973 1.14gm n.s.s.
71 1921 148.mg n.s.s.
a 1921 148.mg n.s.s.
b 1921 148.mg n.s.s.
c 1921 283.mg n.s.s.





0/10 600.mg 0/10 1.20gm 0/10
0/10 600.mg 0/10 1.20gm 0/10
0/10 600.mg 3/10 1.20gm 3/10
0/10 600.mg 1/7 1.20gm 1/10
0/10 600.mg 1/7 1.20gm 1/10
0/13 600.mg 3/9 1.20gm 3/11
0/13 600.mg 0/9 1.20gm 1/11
0/16 600.mg 1/21 1.20gm 1/22








Masui; gann, 77,1083-1090; 1986/pers comm.
Williams; fctx, 28, 799-806; 1990
Hirose;carc, 10, 2223-2226; 1989
BUTYLATED HYDROXYTOLUENE*** (BHT, 2, 6-DI-tert-butyl-p-cresol) 128-37-0
72 1973 1.49gm n.s.s. 9/25 480.mg 3/23
a 1973 2.55gm n.s.s. 0/25 480.mg 0/23
Williams; fctx, 28,799-806;1990
gamma-BUTYROLACTONE 96-48-0
73 c55878 307.mg n.s.s. 33/50 185.mg 31/50 370.mg 35/50
a c55878 1.95gm n.s.s. 8/50 185.mg 2/50 370.mg 4/50 liv:hpa,hpc,nnd.
Volume 103, Supplement 8, November 1995
Brkly Code
21Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
b M f b6c gav lun MXB 24m24
74 M m b6c gav amd MXA 24m24 s
a M m b6c gav TBA MXB 24m24 s
b M m b6c gav liv MXB 24m24 s
c M m b6c gav lun MXB 24m24 s
75 R f f34 gav TBA MXB 24m24
a R f f34 gav liv MXB 24m24
76 R m f34 gav amd phm 24m24
a R m f34 gav --- msm 24m24
b R m f34 gav TBA MXB 24m24
c R m f34 gavliv MXB 24m24
CADMIUM CHLORIDE***
77 H f syg inh lun tum 60w76 or
78 H f syg inh lun tum 64w76 or
79 H m syg inh lun tum 14m24 or
80 H m syg inh lun tum 15m26 or
81 M f nmr inh lun mix 42w82 eo:
a M f nmr inh lun ade 42w82 eo:
b M f nmr inh lun adc 42w82 eo:
82 M f nmr inh lun ade 69w89 eo:
a M f nmr inh lun mix 69w89 eo:
b M f nmr inh lun adc 69w89 eo:
83 R f wis inh lun mix 6m29 eo.
a R f wis inh lun sqa 6m29 eo:
b R f wis inh lun adc 6m29 eo:
84 R f wis inh lun mix 18m31 eo:
a R f wis inh lun adc 18m3l eo:
b R f wis inh lun a/a 18m31 eo.
c R f wis inh lun adq 18m3l eo:
85 R m wis inh lun mix 6m3O eo:
a R m wis inh lun adc 6m3O eo:
b R m wis inh lun a/a 6m3O eo:
c R m wis inh lun sqa 6m3O eo:
86 R m wis inh lun mix 18m30 eo:
a R m wis inh lun adc 18m30 eo:
b R m wis inh lun a/a 18m3O eo:
c R m wis inh lun adq 18m30 eo:

















r .> no dre
r no dre
r no dre













































a R m wis eat pro ade 77w77 e
b R m wis eat --- lle 77w77 e
56.9mg * P<.3 +
no dre P=1. +
CADMIUM SULPHATE (1:1) b0Ong..: .lug.... :.-10.... :. -100.... :1. -:mg.... : .1 ° :.-100 .... :g. - l .... :.-10
88 H f syg inh lun tum 61w76 or .> no dre
89 H f syg inh lun tum 64w77 or .> no dre
90 H m syg inh lun tum 14m24 or .> no dre
91 H m syg inh lun tum 15m26 or .> no dre
92 M f nmr inh lun adc 42w96 eor .> .829mg
a M f nmr inh lun ade 42w96 eor no dre
b M f nmr inh lun mix 42w96 eor no dre
93 M f nmr inh lun mix 69w94 eor .> no dre
a M f nmr inh lun ade 69w94 eor no dre
b M f nmr inh lun adc 69w94 eor no dre
94 R f wis inh lun mix 18m29 eor + 17.4ug
a R f wis inh lun adc 18m29 eor .112mg
b R f wis inh lun adq 18m29 eor .112mg
c R f wis inh lun a/a 18m29 eor .180mg
d R f wis inh lun sqa 18m29 eor .381mg
95 R m wis inh lun mix 14m3l eor + 28. 9ug
a R m wis inh lun adc 14m31 eor 53.7ug
b R m wis inh lun a/a 14m31 eor .219mg
c R m wis inh lun adq 14m31 eor .219mg
CAFFEIC ACID bOng..:. l ug.... :.-10.... :.-100 . . . .g :._mg.. :..1° :..1 ° ° .....:*10
96 M f b6c eat kid tla 96w96 e + 4.70gm
a M f b6c eat for sqc 96w96 e 43.3gm
b M f b6c eat liv hes 96w96 e 43.3gm
c M f b6c eat liv hpc 96w96 e no dre
d M f b6c eat lun ala 96w96 e no dre
e M f b6c eat tba tum 96w96 e 1.90gm
97 M m b6c eat for mix 96w96 e + 5.27gm
a M m b6c eat lun mix 96w96 e 5.12gm
b M m b6c eat lun ala 96w96 e 6.11gm
c M m b6c eat for pam 96w96 e 9.79gm
d M m b6c eat for sqc 96w96 e 13.3gm
e M m b6c eat lun alc 96w96 e 41.3gm
f M m b6c eat liv hem 96w96 e no dre
g M m b6c eat liv hes 96w96 e no dre






































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
b c55878 1.56gm n.s.s.
74 c55878 535.mg n.s.s.
a c55878 170.mg n.s.s.
b c55878 690.mg n.s.s.
c c55878 408.mg n.s.s.
75 c55878 226.mg n.s.s.
a c55878 n.s.s. n.s.s.
76 c55878 357.mg n.s.s.
a c55878 428.mg n.s.s.
b c55878 142.mg n.s.s.

























































































































a 2027 15.3mg n.s.s. 0/28





















































Heinrich; expl, 37,253-258; 1989/pers comm.
Oldiges;txec,19,217-222;1989/Glaser 1990
3.26mg 1/25 6.52mg 1/24 13.Omg 6/27
1.63mg 1/26 3.26mg 2/22 6.52mg 1/23 13.Omg 2/26
1.63mg 4/27 3.26mg 5/24 6.52mg 5/24 13.Omg 1/27
Waalkes; faat, 19, 512-520;
1992/pers .comm.
































































































CAFFEIC ACID (3,4-dihydroxy-cinnamic acid) 331-39-5
96 1932 2.12gm 15.4gm 0/29 2.60gm 8/29
a 1932 7.04gm n.s.s. 0/29 2.60gm 1/29
b 1932 7.04gm n.s.s. 0/29 2.60gm 1/29
c 1932 13.2gm n.s.s. 1/29 2.60gm 0/29
d 1932 6.00gm n.s.s. 4/29 2.60gm 3/29
e 1932 877.mg 16.6gm 9/29 2.60gm 20/29
97 1932 2.27gm 22.6gm 0/28 2.40gm 7/30
a 1932 2.13gm n.s.s. 1/28 2.40gm 8/30
b 1932 2.38gm n.s.s. 1/28 2.40gm 7/30
c 1932 3.38gm n.s.s. 0/28 2.40gm 4/30
d 1932 4.02gm n.s.s. 0/28 2.40gm 3/30
e 1932 6.73gm n.s.s. 0/28 2.40gm 1/30
f 1932 12.6gm n.s.s. 3/28 2.40gm 0/30
g 1932 12.6gm n.s.s. 1/28 2.40gm 0/30
h 1932 7.12gm n.s.s. 7/28 2.40gm 3/30
Heinrich; expl,37,253-258; 1989/pers. comm.
Oldiges;txec,19,217-222;1989/Glaser 1990
Hagiwara; canr, 51,5655-5660; 1991/pers comm.
Volume 103, Supplement 8, November 1995
Brkly Code
23Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
i M m b6c eat liv hnd 96w96 e
j M m b6c eat tba tum 96w96 e
98 R f f3d eat for mix 24m24 e
a R f f3d eat for pam 24m24 e
b R f f3d eat for sqc 24m24 e
c R f f3d eat liv hnd 24m24 e
d R f f3d eat tba tum 24m24 e
99 R m f3d eat for mix 24m24 e
a R m f3d eat for pam 24m24 e
b R m f3d eat for sqc 24m24 e
c R m f3d eat kid tla 24m24 e
d R m f3d eat liv hnd 24m24 e
e R m f3d eat liv hpc 24m24 e





























CAPTAFOL*** b1Ong..:, lug.0.. :1 . m 10. :100.. g : :..10
100 R f f34 eat kid mix 24m24 aers .> no dre P=1.
101 R m f34 eat kid mix 24m24 aers + 504.mg * P<.0005+
a R m f34 eat kid tuc 24m24 aers 570.mg * P<.0005
b R m f34 eat kid tua 24m24 aers 5.01gm * P<.6
102 R f f3d eat liv hnd 24m26 e + 64.4mg * P<.0005+
a R f f3d eat kid rca 24m26 e 276.mg * P<.004 +
b R f f3d eat thy cca 24m26 e 353.mg * P<.002
c R f f3d eat liv hpc 24m26 e 1.01gm * P<.02 +
103 R m f3d eat kid rca 24m26 e .+ 30.3mg * P<.0005+
a R m f3d eat liv hnd 24m26 e 104.mg * P<.0005+
b R m f3d eat kid rcc 24m26 e 345.mg * P<.002 +
c R m f3d eat liv hpc 24m26 e no dre P=1.
D-CARVONE
104 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
105 M m b6c gav TBA MXB 24m24
a M m b6c gav liv MXB 24m24
b M m b6c gav lun MXB 24m24
CATECHOL***
106 M f b6c eat stg ade 96w96 e
a M f b6c eat liv hnd 96w96 e
b M f b6c eat for pam 96w96 e
c M f b6c eat lun ade 96w96 e
d M f b6c eat liv hpc 96w96 e
107 M m b6c eat stg ade 96w96 e
a M m b6c eat --- lkm 96w96 e
b M m b6c eat lun ade 96w96 e
c M m b6c eat for pam 96w96 e
d M m b6c eat liv hnd 96w96 e
e M m b6c eat liv hpc 96w96 e
108 R f f3d eat stg ade 24m24 e
a R f f3d eat stg adc 24m24 e
b R f f3d eat liv hnd 24m24 e
109 R m f3d eat stg ade 24m24 e
a R m f3d eat stg adc 24m24 e
b R m f3d eat for pam 24m24 e
c R m f3d eat liv hnd 24m24 e
CELIPROLOL
110 M f cdl eat lun mix 24m24 e
111 M m cdl eat lun mix 24m24 e
CHLORAMINATED WATER
112 M f b6c wat TBA MXB 24m24
a M f b6c wat liv MXB 24m24
b M f b6c wat lun MXB 24m24
113 M m b6c wat mul MXA 24m24
a M m b6c wat TBA MXB 24m24
b M m b6c wat liv MXB 24m24
c M m b6c wat lun MXB 24m24
114 R f f34 wat pni MXA 24m24
a R f f34 wat mul mnl 24m24
b R f f34 wat TBA MXB 24m24
c R f f34 wat liv MXB 24m24
115 R m f34 wat sub fib 24m24
a R m f34 wat TBA MXB 24m24
b R m f34 wat liv MXB 24m24




:> no dre P=1.
63.8gm * P<l.
no dre P=l.





































1O0ng. : lug. :..10 . :.*100 ... :1mg * .... *10*... 100 .... : lg. 10 :..lo
.> 8.02gm * P<.3
.> 4.71gm * P<.2
bO0ng..:.:1ug :.-10.... :.-100 ...:.._ ...:.*10. :.100. lg :
10
: > no dre P=l.
no dre P=1.
no dre P=1.




+ 11.7mg Z P<.008
23.7mg * P<.04 e
26.9mg * P<.6
116.mg * P<.4
± + #23.3mg * P<.04 -
85.1mg * P<.9
no dre P=l.
CHLORDANE, TECHNICAL GRADE ** Ong..:.-lug.... : 10.......100.. :.mg. : 10. :100 . :.*lg * - - :*.10
116 M f icm eat liv mix 25m25 e + 13.4mg * P<.07






RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
i 1932 4.63gm n.s.s.
j 1932 977.mg n.s.s.
98 1932 162.mg 560.mg
a 1932 244.mg 795.mg
b 1932 534.mg 2.11gm
c 1932 4.14gm n.s.s.
d 1932 105.mg 3.07gm
99 1932 152.mg 507.mg
a 1932 217.mg 707.mg
b 1932 364.mg 1.34gm
c 1932 1.32gm n.s.s.
d 1932 3.31gm n.s.s.
e 1932 4.95gm n.s.s.
f 1932 138.mg n.s.s.
CAPTAFOL*** 2425-06-1
100 1953 191.mg n.s.s.
101 1953 290.mg 1.05gm
a 1953 318.mg 1.24gm
b 1953 1.23gm n.s.s.
102 1941 43.4mg 106.mg
a 1941 149.mg 1.48gm
b 1941 177.mg 1.14gm
c 1941 349.mg n.s.s.
103 1941 21.8mg 43.3mg
a 1941 63.3mg 220.mg
b 1941 163.mg 1.16gm





















































lOO.mg 0/50 250.mg 0/49
80.Omg 5/49 200.mg 12/49
80.Omg 3/49 200.mg 12/49









Nyska; isjm, 25,428-432; 1989
Tamano;gann, 81,1222-1231; 1990
D-CARVONE 2244-16-8
104 c55867 951.mg n.s.s.
a c55867 2.73gm n.s.s.
b c55867 1.34gm n.s.s.
105 c55867 1.40gm n.s.s.
a c55867 1.27gm n.s.s.








106 1971 268.mg 906.mg 0/29
a 1971 2.82gm n.s.s. 0/29
b 1971 2.82gm n.s.s. 0/29
c 1971 5.30gm n.s.s. 1/29
d 1971 3.22gm n.s.s. 1/27
107 1971 72.8mg 335.mg 0/28
a 1971 955.mg n.s.s. 1/27
b 1971 2.69gm n.s.s. 0/27
c 1971 2.69gm n.s.s. 0/27
d 1971 2.25gm n.s.s. 6/27
e 1971 2.02gm n.s.s. 7/27
108 1971 n.s.s. 125.mg 0/30
a 1971 249.mg 1.15gm 0/30
b 1971 2.31gm n.s.s. 1/30
109 1971 n.s.s. 100.mg 0/30
a 1971 154.mg 612.mg 0/30
b 1971 727.mg n.s.s. 0/30






































110 1968 2.40gm n.s.s.
111 1968 1.61gm n.s.s.
CHLORAMINATED WATER --
112 c56382 18.1mg n.s.s.
a c56382 97.9mg n.s.s.
b c56382 207.mg n.s.s.
113 c56382 13.8mg 466.mg
a c56382 2.95mg n.s.s.
b c56382 3.85mg n.s.s.
c c56382 27.9mg n.s.s.
114 c56382 4.42mg 226.mg
a c56382 10.1mg n.s.s.
b c56382 5.25mg n.s.s.
c c56382 26.Omg n.s.s.
115 c56382 11.3mg n.s.s.
a c56382 4.22mg n.s.s.
b c56382 33.6mg n.s.s.
13/100 100.mg 8/49 300.mg 9/50 900.mg 20/100















9.86mg 40/50 19.7mg 35/50 (39.4mg 31/50)
9.86mg 21/50 19.7mg 24/50 39.4mg 15/50
9.86mg 5/50 19.7mg 3/50 39.4mg 3/50
8.21mg 5/50 (16.4mg 3/50 32.8mg 2/51)
8.21mg 49/50 (16.4mg 41/50 32.8mg 37/51)
8.21mg 39/50 (16.4mg 33/50 32.8mg 25/51)
8.21mg 19/50 16.4mg 17/50 (32.8mg 7/51)
2.81mg 5/50 (5.63mg 1/50 11.3mg 0/50)
2.81mg 11/50 5.63mg 15/50 11.3mg 16/50
2.81mg 45/50 5.63mg 44/50 11.3mg 47/50
2.81mg 3/50 5.63mg 1/50 11.3mg 3/50
2.47mg 4/50 4.94mg 2/51 9.87mg 5/50
2.47mg 50/50 4.94mg 50/51 9.87mg 48/50
2.47mg 4/50 4.94mg 2/51 9.87mg 0/50
CHLORDANE, TECHNICAL GRADE* .. 57-74-9
116 1948 4.19mg n.s.s. 0/33 .130mg 2/43 .650mg 1/42 1.62mg 4/37
a 1948 4.86mg n.s.s. 0/33 .130mg 2/43 .650mg 1/42 1.62mg 3/37
Markiewicz;phrm, 38,421-434; 1989









Khasawinah; rtxp, 10,244-254;1989/pers. comm.




Spe Strain Site Xpo+Xpt
Sex Route Hist Nc
b M f icm eat liv hpc 25m25 e
c M f icm eat --- hem 25m25 e
117 M m icm eat liv mix 25m25 e
a M m icm eat liv hpa 25m25 e
b M m icm eat --- hem 25m25 e
c M m icm eat liv hpc 25m25 e
118 R f f34 eat mgl fba 30m30 e
a R f f34 eat liv hpa 30m30 e
119 R m f34 eat liv hpa 3Om30 e
CHLORINATED WATER
120 M f b6c wat ute esp 24m24
a M f b6c wat TBA MXB 24m24
b M f b6c wat liv MXB 24m24
c M f b6c wat lun MXB 24m24
121 M m b6c wat mul MXA 24m24
a M m b6c wat TBA MXB 24m24
b M m b6c wat liv MXB 24m24
c M m b6c wat lun MXB 24m24
122 R f f34 wat pni MXA 24m24
a R f f34 wat mul mnl 24m24
b R f f34 wat pni ade 24m24
c R f f34 wat TBA MXB 24m24
d R f f34 wat liv MXB 24m24
123 R m f34 wat tes MXA 24m24
a R m f34 wat MXA MXA 24m24
b R m f34 wat TBA MXB 24m24
c R m f34 wat liv MXB 24m24
2-CHLOROACETOPHENONE
124 M f b6c inh TBA MXB 24m24
a M f b6c inh liv MXB 24m24
b M f b6c inh lun MXB 24m24
125 M m b6c inh TBA MXB 24m25
a M m b6c inh liv MXB 24m25
b M m b6c inh lun MXB 24m25
126 R f f34 inh mgl fba 24m24
a R f f34 inh TBA MXB 24m24
b R f f34 inh liv MXB 24m24
127 R m f34 inh TBA MXB 24m24









































1-CHLOROETHYLNITROSO-3-(2-HYDROXYPROPYL)UREA ....... 10. :100 .. :.mg. : 10. :100 . : lg. :10
128 R f f34 wat liv tum 7m24 e .> no dre
129 R m f34 wat lun abt 7m24 e + . .124mg


































130 M m cen eat liv mix 52w52 r
a M m cen eat liv hpa 52w52 r
b M m cen eat liv hpc 52w52 r
c M m cen eat lun mix 52w52 r





CIMETIDINE 1O0ng.....-ug :. -10 : .-100 - lmg _10 .-100 :1. -lg
131 M f cb6 wat liv mix 29m29 g .> 52.2gm * P<1.
a M f cb6 wat lun tum 29m29 g no dre P=1.
CIPROFIBRATE*** lbOng....:-ug :u. -10 :..-100 :1. -mg :.-10 :. -100 :. -lg 10
132 R f f34 eat stg cnd 24m24 er .> 531.mg * P<.2 +
133 R m f34 eat stg cnd 24m24 er + 103.mg * P<.002 +
COMPOUND LY171883
134 M f b6c eat liv hpc 24m24 v
a M f b6c eat liv hpa 24m24 v
135 M m b6c eat liv hpc 24m24 v
a M m b6c eat liv hpa 24m24 v
00ng. lug......Io. : 1° . ..... :..:mg :..10 :..100 *g-lg :.-10
+ 112.mg Z P<. 0005+
369.mg * P<.002
+ 426.mg * P< .06
2.74gm * P<.6
CS2 (94% o-CHLOROBENZALMALONONITRILE, 5% Cab-O-Sil COLLOIDAL SILICA, 1% HEXAMETHYLDISILIZANE).100 ................10
136 M f b6c inh TBA MXB 24m25 :> no dre P=1.
a M f b6c inh liv MXB 24m25 no dre P=1.
b M f b6c inh lun MXB 24m25 no dre P=1.
137 M m b6c inh TBA MXB 24m25 :> no dre P=1.
a M m b6c inh liv MXB 24m25 no dre P=1.
b M m b6c inh lun MXB 24m25 no dre P=1.
138 R f f34 inh TBA MXB 24m25 :> no dre P=1.
a Rf f34 inh liv MXB 24m25 no dre P=1.
139 R m f34 inh thy MXA 24m25 + : #6.49ug Z P<.004
a R m f34 inh thy cca 24m25 7.34ug Z P<.008
b R m f34 inh TBA MXB 24m25 no dre P=l.










RefNum LoConf UpConf Cntrl iDose lInc 2Dose 2Inc Citation or Pathology
b 1948 9.77mg n.s.s.
c 1948 6.88mg n.s.s.
117 1948 1.02mg 4.10mg
a 1948 1.57mg 12.Omg
b 1948 2.18mg 13.3mg
c 1948 3.11mg n.s.s.
118 1949 .142mg 21.5mg
a 1949 27.8mg n.s.s.
119 1949 4.90mg n.s.s.
CHLORINATED WATER --
120 c56382 225.mg n.s.s.
a c56382 40.7mg n.s.s.
b c56382 48.8mg n.s.s.
c c56382 163.mg n.s.s.
121 c56382 90.5mg n.s.s.
a c56382 25.1mg n.s.s.
b c56382 42.5mg n.s.s.
c c56382 57.5mg n.s.s.
122 c56382 5.27mg n.s.s.
a c56382 9.89mg n.s.s.
b c56382 7.45mg n.s.s.
c c56382 8.52mg n.s.s.
d c56382 99.6mg n.s.s.
123 c56382 .545mg n.s.s.
a c56382 36.4mg n.s.s.
b c56382 .684mg n.s.s.



























.130mg 0/32 .650mg 0/37 1.62mg 1/35
.130mg 10/64 .650mg 8/68 1.62mg 8/68
.120mg 15/58 .600mg 21/61 1.50mg 37/60
.120mg 12/58 .600mg 13/61 1.50mg 28/60
.120mg 4/64 .600mg 11/65 1.50mg 20/66
.120mg 3/54 .600mg 8/59 1.50mg 9/55
50.Oug 12/62 (.250mg 6/63 1.25mg 6/64)
50.Oug 1/62 .250mg 0/63 1.25mg 0/64
40.Oug 4/64 .200mg 2/64 1.00mg 7/64
13.8mg 0/51 27.5mg 1/50 54.1mg 3/50
13.8mg 43/51 27.5mg 37/50 54.1mg 39/50
13.8mg 22/51 27.5mg 23/50 54.1mg 24/50
13.8mg 10/51 27.5mg 7/50 54.1mg 4/50
11.5mg 3/50 22.9mg 3/50 45.1mg 4/51
11.5mg 45/50 22.9mg 44/50 45.1mg 47/51
11.5mg 38/50 22.9mg 33/50 45.1mg 34/51
11.5mg 12/50 22.9mg 21/50 45.1mg 19/51
3.95mg 0/50 7.89mg 3/51 15.5mg 3/50
3.95mg 7/50 7.89mg 19/51 15.5mg 16/50
3.95mg 0/50 7.89mg 2/51 15.5mg 3/50
3.95mg 46/50 7.89mg 46/51 15.5mg 43/50
3.95mg 1/50 7.89mg 2/51 15.5mg 0/50
3.46mg 41/51 (6.91mg 42/50 13.3mg 38/51)
3.46mg 0/51 6.91mg 0/50 13.3mg 3/51
3.46mg 48/51 (6.91mg 48/50 13.3mg 46/51)
3.46mg 2/51 6.91mg 4/50 13.3mg 3/51











gnv:sqc; pal:ssqp; ton:sqp. S
liv: hpa, hpc, nnd.
2-CHLOROACETOPHENONE 532-27-4
124 c55107 .692mg n.s.s. 42/50
a c55107 2.74mg n.s.s. 12/50
b c55107 3.13mg n.s.s. 6/50
125 c55107 .668mg n.s.s. 33/50
a c55107 1.23mg n.s.s. 16/50
b c55107 1.58mg n.s.s. 11/50
126 c55107 85.6ug n.s.s. 12/50
a c55107 68.Oug n.s.s. 45/50
b c55107 n.s.s. n.s.s. 0/50
127 c55107 53.4ug n.s.s. 46/50























1-CHLOROETHYLNITROSO-3 - (2-HYDROXYPROPYL) UREA --
128 2010 .346mg n.s.s. 0/12 .140mg 0/12
129 2010 46.3ug .997mg 0/12 97.8ug 5/12
a 2010 90.Oug n.s.s. 0/12 97.8ug 2/12
CHOLINE CHLORIDE*** 67-48-1
130 1992 569.mg n.s.s. 2/30 1.20gm 4/30
a 1992 695.mg n.s.s. 2/30 1.20gm 3/30
b 1992 987.mg n.s.s. 0/30 1.20gm 1/30
c 1992 897.mg n.s.s. 2/30 1.20gm 2/30
CIMETIDINE 51481-61-9
131 1925 541.mg n.s.s. 3/20 22.6mg 1/15 226.mg 2/16
a 1925 627.mg n.s.s. 1/20 22.6mg 2/15 226.mg 1/16







Fullerton;carc, 11, 1301-1305; 1990
Anderson;canr, 45, 3561-3566; 1985
CIPROFIBRATE*** 52214-84-3
132 1952 86.5mg n.s.s. 0/60 .500mg 0/60
133 1952 39.3mg 461.mg 0/60 .500mg 0/60
2.50mg 0/60 10.Omg 1/60
2.50mg 0/60 10.Omg 5/60
Spencer; txpy, 17,7-15;1989/pers. comm.
COMPOUND LY171883 (1-(2-hydroxy-3-propyl-4-(4-(lH-tetrazol-5-yl)-butoxy)phenyl)ethanone) 88107-10-2
134 1969 57.7mg 267.mg 0/60 8.81mg 1/60 26.4mg 11/60 (88.1mg 11/60)
a 1969 194.mg 1.77gm 0/60 8.81mg 2/60 26.4mg 3/60 88.1mg 8/60
135 1969 159.mg n.s.s. 10/60 8.13mg 8/60 24.4mg 4/60 81.3mg 16/60
a 1969 372.mg n.s.s. 1/60 8.13mg 1/60 24.4mg 4/60 81.3mg 2/60
Bendele; faat, 15, 676-682; 1990
CS2 (94% o-CHLOROBENZALMALONONITRILE, 5% Cab-O-Sil COLLOIDAL SILICA, 1% HEXAMETHYLDISILIZANE) (CAS# 2698-41-1, 7631-86-9, and 999-97-3) --
136 c55118 1.28mg n.s.s. 46/50 .230mg 27/50 .464mg 27/50
a c55118 1.73mg n.s.s. 11/50 .230mg 4/50 .464mg 9/50 liv:hpa,hpc,nnd.
b c55118 2.71mg n.s.s. 5/50 .230mg 2/50 .464mg 3/50 lun:a/a,a/c.
137 c55118 .515mg n.s.s. 31/50 .191mg 24/50 .386mg 30/50
a c55118 1.06mg n.s.s. 18/50 .191mg 14/50 .386mg 13/50 liv:hpa,hpc,nnd.
b c55118 1.22mg n.s.s. 14/50 .191mg 8/50 .386mg 10/50 lun:a/a,a/c.
138 c55118 37.8ug n.s.s. 47/50 5.48ug 47/50 18.1ug 47/50 54.9ug 50/50
a c55118 .516mg n.s.s. 3/50 5.48ug 1/50 18.1ug 0/50 54.9ug 0/50 liv:hpa,hpc,nnd.
139 c55118 2.85ug 54.5ug 2/50 3.83ug 10/50 (12.7ug 9/50 38.4ug 6/50) thy:cca,ccr. S
a c55118 3.08ug .178mg 2/50 3.83ug 9/50 (12.7ug 7/50 38.4ug 6/50) S
b c55118 28.8ug n.s.s. 48/50 3.83ug 49/50 12.7ug 47/50 38.4ug 48/50
c c55118 .176mg n.s.s. 4/50 3.83ug 3/50 12.7ug 0/50 38.4ug 2/50 liv:hpa,hpc,nnd.
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Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
CYCASIN AND METHYLAZOXYMETHANOL ACETATE***. lug .... -10 ..... -100 ....:..._mg ....:...10 *..100 ....i:.-g....:..10
140 P b cym eat liv hpc 18y24 jmw : _ 19.4mg P<.03 +
a P b cym eat tba mal 18y24 jmw
141 P b rhe ipj liv hpc 8y8 Wjw
a P b rhe ipj MXBMXB 8y8 Wjw
b P b rhe ipj eso sqc 8y8 Wjw
c P b rhe ipj kid rcc 8y8 Wjw
d P b rhe ipj smi adc 8y8 Wjw
e P b rhe ipj tba mal 8y8 Wjw
142 P b rhe eat asc adc 18y24 jmw
a P b rhe eat bil ppa 18y24 jmw
b P b rhe eat pan adc 18y24 jmw
c P b rhe eat MXB MXB 18y24 jmw
d P b rhe eat liv hpc 18y24 jmw
e P b rhe eat kid rcc 18y24 jmw
f P b rhe eat bil adc 18y24 jmw
g P b rhe eat tba mal 18y24 jmw
h P b rhe eat tba mix 18y24 jmw





































143 M f ofl eat
a M f ofl eat
b M f ofl eat
c M f ofl eat
d M f ofl eat
144 M m ofl eat
a M m ofl eat
b M m ofl eat
c M m ofl eat
d M m ofl eat
145 R f ofs eat
a R f ofs eat
b R f ofs eat
c R f ofs eat
146 R m ofs eat
a R m ofs eat
lbOng..:. .lug... 10. -1° ..... -100 ....:.._mg....:.-10 ..... -100. lg .... :..10
--- lcl 78w78 es + 16.8mg * P<.01l
liv hpc 78w78 es 402.mg * P<.2
lun adc 78w78 es no dre P=l.
lun ade 78w78 es no dre P=l.
tba tum 78w78 es 38.2mg * P<.7
liv hpc 78w78 e .> 111.mg * P<.6
lun adc 78w78 e 334.mg Z P<.8
liv hpa 78w78 e no dre P=l.
lun ade 78w78 e no dre P=l.
tba tum 78w78 e 11.6mg * P<.2
liv cho 24m24 e .> no dre P=l.
liv hpc 24m24 e no dre P=l.
liv hpa 24m24 e no dre P=l.
tba tum 24m24 e no dre P=l.
liv hpc 96w96 es .> no dre P=l.
tba tum 96w96 es no dre P=l.
DELTAMETHRIN
147 M f cb6 gav --- lym 24m26
a M f cb6 gav liv hpt 24m26
b M f cb6 gav lun ade 24m26
c M f cb6 gav tba tum 24m26
148 M m cb6 gav lun ade 24m26
a M m cb6 gav liv hpt 24m26
b M m cb6 gav tba tum 24m26
149 R f bdf gav thy ade 24m26
a R f bdf gav liv hpt 24m26
b R fbdf gav tba tum 24m26
150 R m bdf gav thy ade 24m26
a R m bdf gav liv hpt 24m26
b R m bdf gav tba tum 24m26



























4,4'-DIAMINO-2,2'-STILBENEDISULFONIC ACID, DISODIUM SALT.. :.-100......mg. . -100.... :.._lg. :*10
151 M f b6c eat TBA MXB 24m24 :> no dre P=l.
a M f b6c eat liv MXB 24m24 no dre P=l.
b M f b6c eat lun MXB 24m24 no dre P=l.
152 M m b6c eat liv hpa 24m24 + #2.57gm \ P<.03
a M m b6c eat TBA MXB 24m24 12.9gm P<.8
b M m b6c eat liv MXB 24m24 9.72gm P<.4
c M m b6c eat lun MXB 24m24 no dre P=l.
153 R f f34 eat TBA MXB 24m24 :> 17.6gm P<1.
a R f f34 eat liv MXB 24m24 no dre P=l.
154 R m f34 eat TBA MXB 24m24 :> 5.81gm * P<.9
a R m f34 eat liv MXB 24m24 5.02gm * P<.2
2, 4-DIAMINOPHENOL. 2HC
155 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
156 M m b6c gav kid rua 24m24
a M m b6c gav TBA MXB 24m24
b M m b6c gav liv MXB 24m24
c M m b6c gav lun MXB 24m24
157 M m b6c gav kid rua 24m24
158 R f f34 gav TBA MXB 24m24
a R f f34 gav liv MXB 24m24
159 R m f34 gav TBA MXB 24m24
a R m f34 gav liv MXB 24m24
















RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
CYCASIN AND METHYLAZOXYMETHANOL ACETATE** (CAS# 592-62-1 and 14901-08-7) mixture











































0/8 7. 27mg 1/2










1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
CYCLOSPORIN A 59865-13-3
143 1927 7.50mg 2.10gm
a 1927 65.4mg n.s.s.
b 1927 67.6mg n.s.s.
c 1927 28.5mg n.s.s.
d 1927 4.51mg n.s.s.
144 1927 18.6mg n.s.s.
a 1927 33.6mg n.s.s.
b 1927 33.1mg n.s.s.
c 1927 24.5mg n.s.s.
d 1927 3.47mg n.s.s.
145 1927 4.00mg n.s.s.
a 1927 63.Omg n.s.s.
b 1927 89.6mg n.s.s.
c 1927 13.4mg n.s.s.
146 1927 74.6mg n.s.s.


















































































147 1965 13.7mg n.s.s.
a 1965 53.4mg n.s.s.
b 1965 53.4mg n.s.s.
c 1965 13.0mg n.s.s.
148 1965 29.6mg n.s.s.
a 1965 32.Omg n.s.s.
b 1965 28.3mg n.s.s.
149 1965 7.94mg 1.16gm
a 1965 16.1mg n.s.s.
b 1965 4.68mg n.s.s.
150 1965 2.25mg 28.9mg
a 1965 16.1mg n.s.s.















































Cabral; clet, 49,147-152; 1990/pers comm.
4,4 '-DIAMINO-2, 2' -STILBENEDISULFONIC ACID, DISODIUM SALT
151 c60162 3.18gm n.s.s. 34/50 803.mg 17/50 1.61gm
a c60162 12.0gm n.s.s. 5/50 803.mg 0/50 1.61gm
b c60162 8.73gm n.s.s. 13/50 803.mg 3/50 1.61gm
152 c60162 1.03gm n.s.s. 2/50 741.mg 9/50 (1.48gm
a c60162 1.57gm n.s.s. 23/50 741.mg 24/50 1.48gm
b c60162 2.47gm n.s.s. 5/50 741.mg 11/50 1.48gm
c c60162 5.18gm n.s.s. 15/50 741.mg 4/50 1.48gm
153 c60162 706.mg n.s.s. 45/50 615.mg 44/50 1.23gm
a c60162 9.09gm n.s.s. 3/50 615.mg 0/50 1.23gm
154 c60162 499.mg n.s.s. 44/50 492.mg 46/50 984.mg




















155 c60026 29.6mg n.s.s. 24/50
a c60026 60.1mg n.s.s. 4/50
b c60026 53.3mg n.s.s. 2/50
156 c60026 97.Omg n.s.s. 0/50
a c60026 30.8mg n.s.s. 30/50
b c60026 15.5mg n.s.s. 15/50
c c60026 53.0mg n.s.s. 3/50
157 c60026 58.3mg 892.mg 0/50
158 c60026 9.06mg n.s.s. 40/50
a c60026 n.s.s. n.s.s. 0/50
159 c60026 9.45mg n.s.s. 44/51
a c60026 n.s.s. n.s.s. 0/51
13.4mg 29/50 26.8mg 17/50
13.4mg 7/50 26.8mg 3/50
13.4mg 5/50 26.8mg 3/50
13.3mg 0/50 26.7mg 3/50
13.3mg 27/50 26.7mg 31/50
13.3mg 18/50 (26.7mg 8/50)
13.3mg 4/50 26.7mg 7/50
26.7mg 6/50
8.78mg 41/50 17.6mg 47/50
8.78mg 0/50 17.6mg 0/50
8.80mg 34/50 17.6mg 36/50
8.80mg 0/50 17.6mg 0/50
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Sex Route Hist Notes DR AuOp
1,2-DICHLOROETHANE*** 1 Ong....:ug.. . . :. 10..... :.-100.... :._mg.. :.-10 :.-100 . . .. :1.0-g : 10
160 R f cdr inh liv hpc 24m24 e .> 594.mg P<.3 -
a R f cdr inh liv nnd 24m24 e no dre P=1. -
b R f cdr inh tba tum 24m24 e no dre P=1. -
161 R m cdr inh liv nnd 24m24 e 206.mg P<.1 -
a R m cdr inh liv hpc 24m24 e no dre P=1. -
b R m cdr inh tba tum 24m24 e 17.9mg P<.4 -
DIETHYLACETYLUREA 1 O0ng....:lug. : 10. :100°. : 1mg. 10 : 100 ig. :.:10
162 R m f34 eat kid tla 71w71 e _ 30.4mg P<.09
a R m f34 eat liv hpt 71w71 e no dre P=1.
DIETHYLMALEATE 1O0ng....:-u u-g10.... :..-100 .... :1..a.mg.... : 0 . -100 .° :.-lg . : 10
163 R m f3d eat for tum 51w52 er .> no dre P=1. -
a R m f3d eat stg tum 51w52 er no dre P=1. -
DIETHYLSTILBESTROL*** 1b00ng*.:.- ug - g 10 * :..100 .... :._mg. :.-10 .... :.-100 .... lg :. 10
164 M f b62 eat pit ade 33m36 aes .+. 45.6ug * P<.0005+
a M f b62 eat thy fca 33m36 aes .186mg Z P<.003 +
b M f b62 eat cvx sqc 33m36 aes 1.03mg * P<.0005+
c M f b62 eat ute mso 33m36 aes 1.72mg * P<.0005+
d M f b62 eat ova gct 33m36 aes 1.74mg * P<.03
e M f b62 eat pit adc 33m36 aes 17.Omg * P<.8
165 M m b62 eat tes ict 34m37 aes .+. 66.lug Z P<.0005+
a M m b62 eat pit ade 34m37 aes 79.4ug * P<.0005+
b M m b62 eat pit adc 34m37 aes 4.36mg * P<.4
166 M f bcn eat ova gct 31m31 ae + .166mg Z P<.0005+
a M f bcn eat pit ade 31m31 ae .200mg Z P<.0005+
b M f bcn eat cvx sqc 31m31 ae .311mg * P<.0005+
c M f bcn eat mgl adb 31m31 ae .476mg * P<.0005+
d M f bcn eat cvx ado 31m31 ae 1.28mg * P<.0005+
e M f bcn eat vag sqc 31m31 ae 1.31mg * P<.003
f M f bcn eat mgl ado 31m31 ae 1.88mg * P<.004 +
g M f bcn eat pit adc 31m31 ae 5.10mg * P<.2
h M f bcn eat ute adc 31m31 ae 5.32mg * P<.3
167 M m bcn eat tes ict 28m29 aes .+. 21.5ug Z P<.0005+
a M m bcn eat pit ade 28m29 aes .171mg Z P<.0005+
168 M f c7b eat pit ade 34m37 aes .+ 38.7ug * P<.0005+
a M f c7b eat cvx sqc 34m37 aes 1.98mg * P<.0005+
b M f c7b eat pit adc 34m37 aes 2.01mg * P<.03
c M f c7b eat mgl adb 34m37 aes no dre P=1. +
d M f c7b eat thy fca 34m37 aes no dre P=l.
169 M m c7b eat tes ict 35m39 aes .+. 40.8ug Z P<.0005+
a M m c7b eat pit ade 35m39 aes 72.2ug Z P<.0005+
b M m c7b eat pit adc 35m39 aes no dre P=1.
170 M f cb6 eat pit ade 27m33 aes +. 25.9ug * P<.0005+
a M f cb6 eat pit adc 27m33 aes no dre P=1.
b M f cb6 eat thy fct 27m33 aes no dre P=1. +
171 M m cb6 eat pit ade 29m36 aes .+. 17.6ug Z P<.0005+
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RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
1,2-DICHLOROETHANE*** (ethylene dichloride, EDC) 107-06-2
160 1962 96.7mg n.s.s. 0/50 17.5mg 1/50
a 1962 110.mg n.s.s.
b 1962 5.32mg n.s.s.
161 1962 50.6mg n.s.s.
a 1962 76.8mg n.s.s.
b 1962 4.15mg n.s.s.







162 1951 7.47mg n.s.s.
a 1951 19.7mg n.s.s.
DIETHYLMALEATE 141-05-9
163 1921 60.6mg n.s.s.
a 1921 60.6mg n.s.s.
DIETHYLSTILBESTROL** (DES)
164 1936r 34.6ug 62.2ug
a 1936r 82.4ug 1.49mg
b 1936r .567mg 2.19mg
c 1936r .810mg 4.69mg
d 1936r .839mg n.s.s.
e 1936r 1.24mg n.s.s.
165 1936r 52.3ug 84.8ug
a 1936r 61.2ug .107mg
b 1936r 1.01mg n.s.s.
166 1936n .104mg .291mg
a 1936n .137mg .307mg
b 1936n .205mg .512mg
c 1936n .259mg 1.29mg
d 1936n .605mg 3.50mg
e 1936n .550mg 10.6mg
f 1936n .718mg 19.3mg
g 1936n 1.26mg n.s.s.
h 1936n 1.19mg n.s.s.
167 1936n 17.Oug 27.2ug
a 1936n 95.3ug .373mg
168 19360 29.6ug 51.9ug
a 1936o .933mg 5.40mg
b 1936o .765mg n.s.s.
c 19360 .647mg n.s.s.
d 1936o 1.26mg n.s.s.
169 1936o 32.4ug 51.9ug
a 1936o 53.5ug .101mg
b 1936o 1.04mg n.s.s.
170 1936m 17.9ug 39.3ug 2
a 1936m 1.65mg n.s.s.
b 1936m .504mg n.s.s. 1















































































































































0/52 600.ng 0/49 1.20ug 0/58
38.4ug 0/64 76.8ug 0/57
21/57 650.ng 22/60 1.30ug 21/65
41.6ug 59/62 83.2ug 58/62
1/57 650.ng 1/60 1.30ug 4/65
41.6ug 0/62 83.2ug 2/62
13/64 650.ng 11/56 1.30ug 10/51
41.6ug 4/60 (83.2ug 0/50)
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Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
a M m cb6 eat thy fct 29m36 aes 50.Oug Z P<.0005+
.257mg Z P<.0005+ b M m cb6 eat tes ict 29m36 aes
c M m cb6 eat pit adc 29m36 aes 1.42mg * P<.0005
3,3'-DIMETHOXYBENZIDINE.2HC1 lOOng. .:. lug. :* 10. : 100 . :._mg . * -10. : 100 ....-:.ig . - : 10
172 M f bcn wat hag ade 78w78 kr .> no dre P=1.
a M f bcn wat hag car 78w78 kr no dre P=1.
173 M f bcn wat hag ade 26m26 r no dre P=1.
174 M m bcn wat hag ade 78w78 kr 3.56gm * P<.9
175 M m bcn wat hag ade 26m26 r > no dre P=1.
176 R f f34 wat MXB MXB 91w93 1.19mg * P<.0005
a R f f34 wat cli MXA 91w93
b R f f34 wat cli MXA 91w93
c R f f34 wat mgl MXA 91w93
d R f f34 wat cli MXA 91w93
e R f f34 wat mgl MXA 9lw93
f R f f34 wat --- mnl 91w93
g R f f34 wat zym MXA 9lw93
h R f f34 wat mgl fba 91w93
i R f f34 wat mgl adc 91w93
j R f f34 wat zym MXA 91w93
k R f f34 wat MXA ade 91w93
1 R f f34 wat MXA MXA 91w93
m R f f34 wat ski MXA 91w93
n R f f34 wat ute esp 91w93
o R f f34 wat ski bca 91w93
p R f f34 wat MXA MXA 91w93
q R f f34 wat MXA MXA 91w93
r R f f34 wat MXA MXA 91w93
s R f f34 wat MXA sqp 91w93
t R f f34 wat ton MXA 9lw93
u R f f34 wat zym ade 91w93
v R f f34 wat liv MXA 91w93
w R f f34 wat MXA MXA 91w93
x R f f34 wat MXA sqc 9lw93
y R f f34 wat pal MXA 9lw93
z R f f34 wat pal sqp 91w93
A R f f34 wat TBA MXB 9lw93
B R f f34 wat liv MXB 91w93
177 R m f34 wat tes MXA 88w92 a






















33.3mg Z P<.002 c








b R m f34 wat ski MXA 88w92 a
c R m f34 wat ski MXA 88w92 a
d R m f34 wat ski MXA 88w92 a
e R m f34 wat ski bca 88w92 a
f R m f34 wat pre MXA 88w92 a
g R m f34 wat ski MXA 88w92 a
h R m f34 wat amd MXA 88w92 a
i R m f34 wat amd MXA 88w92 a
j R m f34 wat ski sqc 88w92 a
k R m f34 wat --- mnl 88w92 a
1 R m f34 wat zym MXA 88w92 a
m R m f34 wat pre MXA 88w92 a
n R m f34 wat MXA MXA 88w92 a
0 R m f34 wat MXA sqp 88w92 a
p R m f34 wat pre MXA 88w92 a
q R m f34 wat thy MXA 88w92 a
r R m f34 wat sub MXA 88w92 a
s R m f34 wat zym MXA 88w92 a
t R m f34 wat sub MXA 88w92 a
u R m f34 wat ski MXA 88w92 a
v R m f34 wat ski bcc 88w92 a
w R m f34 wat ski sqp 88w92 a
x R m f34 wat zym MXA 88w92 a
y R m f34 wat thy cca 88w92 a
z R m f34 wat liv MXA 88w92 a






























RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
a 1936m 32.7ug 84.lug
b 1936m .155mg .489mg
c 1936m .592mg 6.74mg
(38.4ug 39/62 76.8ug 22/43)
2/48 600.ng 0/51 1.20ug 1/47 2.40ug
(38.4ug 3/58 76.8ug 0/43)
0/70 600.ng 1/71 1.20ug 0/66 2.40ug
38.4ug 17/61 (76.8ug 3/52)
0/52 600.ng 0/57 1.20ug 1/57 2.40ug
38.4ug 2/62 76.8ug 5/43
3/48 4.80ug 6/51 19.2ug 27/54
0/69 4.80ug 1/69 19.2ug 3/64
0/59 4.80ug 1/59 19.2ug 0/64
3,3'-DIMETHOXYBENZIDINE.2HC1 20325-40-0
172 1919m 243.mg n.s.s.
a 1919m 551.mg n.s.s.
173 1919n 352.mg n.s.s.
174 1919m 151.mg n.s.s.
175 1919n 615.mg n.s.s.

















































































































4/24 4.00mg 3/21 8.00mg 1/19 16.Omg 6/24 32.Omg 0/20 63.Omg 2/21
126.mg 2/22 Schieferstein;jact,9,71-77;1990/pers. comm.
0/24 4.00mg 1/21 8.00mg 0/19 16.Omg 0/24 32.Omg 0/20 63.Omg 0/21
126.mg 0/22
1/25 4.00mg 3/27 8.00mg 3/26 16.Omg 3/22 32.Omg 6/28 63.Omg 3/24
126.mg 2/26
2/20 3.33mg 3/22 6.67mg 2/21 13.3mg 3/19 26.7mg 0/23 52.5mg 1/20
105.mg 3/20
2/26 3.33mg 4/25 6.67mg 4/25 13.3mg 3/27 26.7mg 4/26 52.5mg 4/30
105.mg 0/28
9/60 4.57mg 37/45 9.71mg 67/75 18.9mg 53/60 cli:ade,anb,car,cnb; cvu:car,ppa; dsc:adc,adp;



















































































































































































--:msb,msm; asc:adp; cec:muc; col:adc; dsc:adc,
duo:adc,muc; ilm:adc; jej:adc,muc; liv:hpc,nnd; pal:sqc; phr:ssqp; pre:ade,anb,car,cnb; rec:adc,
adp; ski:bca,bcc,sbr,sea,sqc,sqp; ton:sqc,sqp; zym:ade,anb,car,cnb. C
4.00mg 33/45 8.50mg 56/75 16.5mg 41/60 ski:bca,bcc,sbr,sea.
4.00mg 32/45 8.50mg 54/75 16.5mg 40/60 ski:bca,bcc. S
4.00mg 32/45 8.50mg 49/75 16.5mg 35/60 ski:bca,sea. S
4.00mg 31/45 8.50mg 47/75 16.5mg 35/60 S
4.00mg 12/45 8.50mg 33/75 16.5mg 29/60 pre:ade,anb,car,cnb.
4.00mg 13/45 8.50mg 28/75 16.5mg 22/60 ski:sqc,sqp.
4.00mg 17/45 8.50mg 23/75 16.5mg 9/60 amd:pbb,pob. S
4.00mg 18/45 8.50mg 23/75 16.5mg 9/60 amd:pbb,phm,pob. S
4.00mg 9/45 8.50mg 24/75 16.5mg 21/60 S
4.00mg 17/45 8.50mg 17/75 16.5mg 4/60 S
4.00mg 10/45 8.50mg 25/75 16.5mg 30/60 zym:ade,anb,car,cnb.
4.00mg 6/45 8.50mg 19/75 16.5mg 12/60 pre:ade,anb. S
4.00mg 8/45 8.50mg 10/75 16.5mg 11/60 pal:sqc; phr:sqp; ton:sqc,sqp.
4.00mg 7/45 8.50mg 10/75 16.5mg 9/60 phr:sqp; ton:sqp. S
4.00mg 6/45 8.50mg 15/75 16.5mg 19/60 pre:car,cnb. S
4.00mg 7/45 8.50mg 7/75 16.5mg 2/60 thy:cca,ccr. S
4.00mg 6/45 8.50mg 6/75 16.5mg 4/60 sub:fib,nfm. S
4.00mg 4/45 8.50mg 11/75 16.5mg 9/60 zym:ade,anb. S
4.00mg 6/45 8.50mg 6/75 16.5mg 5/60 sub:fbs,fib,nfm,sar. S
4.00mg 4/45 8.50mg 18/75 16.5mg 18/60 ski:bcc,sbr. S
4.00mg 4/45 8.50mg 18/75 16.5mg 17/60 S
4.00mg 5/45 8.50mg 7/75 16.5mg 5/60 S
4.00mg 7/45 8.50mg 14/75 16.5mg 21/60 zym:car,cnb. S
4.00mg 6/45 8.50mg 5/75 16.5mg 1/60 S
4.00mg 4/45 8.50mg 7/75 16.5mg 8/60 liv:hpc,nnd.


























































Volume 103, Supplement 8, November 1995
Brkly Code
33Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
B R m f34 wat ton MXA 88w92 a
C R m f34 wat pal sqp 88w92 a
D R m f34 wat MXA MXA 88w92 a
E R m f34 wat ski ker 88w92 a
F R m f34 wat ton sqp 88w92 a
G R m f34 wat MXA MXA 88w92 a
H R m f34 wat MXA asl 88w92 a
I R m f34 wat liv nnd 88w92 a
J R m f34 wat MXA adp 88w92 a
K R m f34 wat sub MXA 88w92 a
L R m f34 wat sub fib 88w92 a
M R m f34 wat ski MXA 88w92 a
N R m f34 wat --- MXA 88w92 a
0 R m f34 wat MXANXA 88w92 a
P R m f34 wat TBA MXB 88w92 a

















N,N-DIMETHYL-4-AMINOAZOBENZENE*** lO0ng..:. -lug. :.-10 .. 0 .:1 :._mg..:. -10. :.-100 .* :1.-g . 10
178 P b rhe eat lun a/c 5y2O Ww 4.84mg P<.02
a P b rhe eat tba mal 5y2O Ww 17.Omg P<.2
4-DIMETHYLAMINOANTIPYRINE
179 M f b6c wat liv hpa 23m24 e
a M f b6c wat lun a/c 23m24 e
b M f b6c wat liv hpc 23m24 e
c M f b6c wat lun a/a 23m24 e
d M f b6c wat tba tum 23m24 e
180 M m b6c wat lun a/a 23m24 e
a M m b6c wat liv hpa 23m24 e
b M m b6c wat liv hpc 23m24 e
c M m b6c wat lun a/c 23m24 e
d M m b6c wat tba tum 23m24 e











3,3'-DIMETHYLBENZIDINE.2HC1 1 O0ng.. :. lug.... :.-10..... :..100 .... mg... --10 . * -100. ig.
181 M f bcn wat lun mix 52w52 ekr .> 28.1mg * P<.2
a M f bcn wat lun adc 52w52 ekr 147.mg * P<.2
182 M f bcn wat lun adc 78w78 ekr 168.mg * P<.2
a M f bcn wat lun mix 78w78 ekr 295.mg * P<.8
no dre P=1. 183 M f bcn wat lun mix 26m26 er
a M f bcn wat lun adc 26m26 er no dre P=1.
184 M m bcn wat lun adc 52w52 ekr 123.mg * P<.3
684.mg * P<1. a M m bcn wat lun mix 52w52 ekr
185 M m bcn wat lun mix 78w78 ekr 423.mg * P<1.
a M m bcn wat lun adc 78w78 ekr no dre P=1.
186 M m bcn wat lun mix 26m26 er 28.6mg * P<.002 +
50.1mg * P<.002 + a M m bcn wat lun adc 26m26 er
187 R f f34 wat MXB MXB 6Ow6O .418mg * P<.0005
a R f f34 wat cli MXA 6Ow6O
b R f f34 wat zym MXA 6Ow6O
c R f f34 wat cli MXA 6Ow6O
d R f f34 wat zym MXA 6Ow6O
e R f f34 wat cli MXA 6Ow6O
f R f f34 wat zym MXA 60w60
g R f f34 wat ski MXA 6Ow6O
h R f f34 wat MXA MXA 6Ow6O
i R f f34 wat ski MXA 6Ow6O
j R f f34 wat MXA sqp 6Ow6O
k R f f34 wat ski sqc 60w60
1 R f f34 wat mgl MXA 6Ow6O
m R f f34 wat ski bca 60w60
n R f f34 wat --- mnl 60w60
o R f f34 wat MXA MXA 6Ow6O
p R f f34 wat liv MXA 60w60





















RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
B c99989 3.39mg 23.6mg
C c99989 3.06mg 27.2mg
D c99989 3.04mg 27.Omg
E c99989 3.33mg 42.4mg
F c99989 3.57mg 28.6mg
G c99989 3.90mg 23.1mg
H c99989 3.35mg 57.4mg
I c99989 4.43mg 30.2mg
J c99989 4.44mg 42.8mg
K c99989 4.44mg 50.4mg
L c99989 4.46mg 57.2mg
M c99989 5.01mg 1.67gm
N c99989 7.62mg 165.mg
0 c99989 10.5mg 194.mg
P c99989 .386mg .868mg

































































N,N-DIMETHYL-4-AMINOAZOBENZENE*** (Butter Yellow) 60-11-7
178 2001 .788mg n.s.s. 0/23 14.3mg 1/1
a 2001 1.95mg n.s.s. 4/76 14.3mg 1/3
4-DIMETHYLAMINOANTIPYRINE (aminopyrine) 58-15-1
179 1991 874.mg n.s.s. 1/45 76.9mg 0/41 154.mg
a 1991 1.06gm n.s.s. 0/45 76.9mg 0/41 154.mg
b 1991 437.mg n.s.s. 1/45 76.9mg 0/41 154.mg
c 1991 932.mg n.s.s. 2/45 76.9mg 2/41 154.mg
d 1991 196.mg n.s.s. 22/45 76.9mg 21/41 154.mg
180 1991 478.mg n.s.s. 1/46 64.1mg 0/44 128.mg
a 1991 213.mg n.s.s. 10/46 64.1mg 6/44 128.mg
b 1991 406.mg n.s.s. 6/46 64.1mg 4/44 128.mg
c 1991 902.mg n.s.s. 1/46 64.1mg 1/44 128.mg



















5/60 duo:adc,muc; ilm:adc; jej:adc,muc.
1/60 S
7/60 S












bra:asl; clb:asl; crb:asl; crl:asl.
S





cec:muc; col:adc; dsc:adc; rec:adc. S
liv: hpa, hpc, nnd.
Adamson;ossc, 129-156;
1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.








































































0/16 1.00mg 1/15 1.80mg
28.Omg 4/16
0/16 1.00mg 0/15 1.80mg
28.Omg 1/16
0/21 1.00mg 0/23 1.80mg
28.Omg 2/18
4/21 1.00mg 1/23 1.80mg
28.Omg 5/18
8/26 1.00mg 6/25 1.80mg
28.Omg 7/29
5/26 1.00mg 3/25 1.80mg
28.Omg 3/29
0/15 .833mg 0/16 1.50mg
23.3mg 0/16
1/15 .833mg 3/16 1.50mg
23.3mg 2/16
11/23 .833mg 4/20 1.50mg
23.3mg 8/20
0/23 .833mg 0/20 1.50mg
23.3mg 0/20
8/26 .833mg 12/26 1.50mg
23.3mg 17/27
3/26 .833mg 5/26 1.50mg
23.3mg 11/27











2/16 3.60mg 1/13 7.00mg
0/16 3.60mg 0/13 7.00mg
1/20 3.60mg 1/21 7.00mg






7/28 3.60mg 8/25 7.00mg 10/28 14.Omg 9/25
3/28 3.60mg 4/25 7.00mg 5/28 14.0mg 2/25
0/14 3.00mg 0/14 5.83mg 0/15 11.7mg 1/16
1/14 3.00mg 5/14 5.83mg 2/15 11.7mg 4/16
8/18 3.00mg 8/23 5.83mg 5/18 11.7mg 7/21
0/18 3.00mg 2/23 5.83mg 0/18 11.7mg 0/21
5/29 3.00mg 11/28 5.83mg 10/32 11.7mg 15/27
2/29 3.00mg 2/28 5.83mg 7/32 11.7mg 6/27
70/75 8.57mg 58/60 cli:ade,anb,car,cnb; col:adc,adp; duo:adc; ilm:
adp,mua; jej:adc,adp,muc; liv:hpc,nnd; lun:a/a,a/c; mgl:adc; phr:sqc,sqp; rec:adc,adp; ski:bca,bcc,
sqc,sqp; ton:sqc,sqp; zym:ade,anb,car,cnb. C
/60 1.71mg 14/45 4.00mg 42/75 8.57mg 32/60 cli:ade,anb,car,cnb.
/60 1.71mg 6/45 4.00mg 32/75 8.57mg 42/60 zym:ade,anb,car,cnb.
/60 1.71mg 9/45 4.00mg 32/75 8.57mg 17/60 cli:ade,anb. S
/60 1.71mg 2/45 4.00mg 22/75 8.57mg 35/60 zym:car,cnb. S
/60 1.71mg 5/45 4.00mg 11/75 8.57mg 18/60 cli:car,cnb. S
/60 1.71mg 4/45 4.00mg 11/75 8.57mg 12/60 zym:ade,anb. S
/60 1.71mg 3/45 4.00mg 9/75 8.57mg 12/60 ski:sqc,sqp.
/60 1.71mg 3/45 4.00mg 9/75 8.57mg 13/60 phr:sqc,sqp; ton:sqc,sqp.
/60 1.71mg 3/45 4.00mg 10/75 8.57mg 9/60 ski:bca,bcc.
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Brkly Code
35Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
r R f f34 wat MXA adp 6Ow6O
s R f f34 wat liv nnd 60w60
t R f f34 wat mgl adc 60w60
u R f f34 wat MXA MXA 6Ow6O
v R f f34 wat ski bcc 60w60
w R f f34 wat MXA sqc 60w60
x R f f34 wat lun MXA 6Ow6O
y R f f34 wat MXA MXA 6Ow6O
z R f f34 wat lun a/a 60w60
A R f f34 wat bra MXA 6Ow6O
B R f f34 wat TBA MXB 6Ow6O
C R f f34 wat liv MXB 60w60







11.9mg * P<.006 c
15.4mg * P<.0005
13.6mg * P<.02




a R m f34 wat ski MXA 58w6O a
b R m f34 wat ski bca 58w60 a
c R m f34 wat liv MXA 58w60 a
d R m f34 wat zym MXA 58w6O a
e R m f34 wat liv nnd 58w60 a
f R m f34 wat ski MXA 58w6O a
g R m f34 wat zym MXA 58w6O a
h R m f34 wat zym MXA 58w6O a
i R m f34 wat liv hpc 58w60 a
j R m f34 wat ski sqc 58w60 a
k R m f34 wat ski sqp 58w60 a
1 R m f34 wat MXA MXA 58w6O a
m R m f34 wat pre MXA 58w6O a
n R m f34 wat ski ker 58w60 a
o R m f34 wat MXA adp 58w6O a
p R m f34 wat lun MXA 58w6O a
q R m f34 wat pre ade 58w60 a
r R m f34 wat lun a/a 58w60 a
s R m f34 wat ski sea 58w60 a
t R m f34 wat MXA MXA 58w6O a
u R m f34 wat MXA MXA 58w6O a
v R m f34 wat MXA MXA 58w6O a
w R m f34 wat ski bcc 58w60 a
x R m f34 wat mul msm 58w60 a
y R m f34 wat amd pob 58w60 a
z R m f34 wat MXA MXA 58w6O a
A R m f34 wat MXA sqc 58w6O a
B R m f34 wat bra MXA 58w6O a
C R m f34 wat TBA MXB 58w6O a




























26.1mg * P<.02 e
.334mg Z P<.0005
.898mg Z P<.0005
1,1-DIMETHYLHYDRAZINE*** lOOng..:..lug . :°10 . :- 1mg. :.10 1... 1g lg
189 M f cdl wat lun a/a 52w52 ek
a M f cdl wat liv tum 52w52 ek
b M f cdl wat --- vsc 52w52 ek
190 M f cdl wat lun mix 24m24 e +
a M f cdl wat lun a/a 24m24 e
b M f cdl wat lun a/c 24m24 e
c M f cdl wat liv hes 24m24 e
d M f cdl wat liv vsc 24m24 e
e M f cdl wat liv mix 24m24 e
f M f cdl wat liv hpa 24m24 e
g M f cdl wat --- hes 24m24 e
h M f cdl wat liv hpc 24m24 e
i M f cdl wat liv hem 24m24 e
j M f cdl wat --- vsc 24m24 e
k M f cdl wat --- hem 24m24 e
191 M f cdl wat lun mix 52w52 eks +
a M f cdl wat lun a/a 52w52 eks
b M f cdl wat --- vsc 52w52 eks
c M f cdl wat liv vsc 52w52 eks
d M f cdl wat liv hem 52w52 eks
e M f cdl wat --- hem 52w52 eks
f M f cdl wat --- hes 52w52 eks
g M f cdl wat liv hes 52w52 eks
h M f cdl wat lun a/c 52w52 eks
192 M f cdl wat --- vsc 24m24 es +
a M f cdl wat --- hes 24m24 es
b M f cdl wat liv vsc 24m24 es
c M f cdl wat liv hes 24m24 es
d M f cdl wat lun mix 24m24 es
e M f cdl wat lun a/a 24m24 es
f M f cdl wat liv hpa 24m24 es
g M f cdl wat lun a/c 24m24 es

















3.68mg * P<.006 +
3.93mg * P<.007 +
26.0mg * P<.04 +










27.0mg * P<.03 +



















































0/60 1.71mg 1/45 4.00mg 6/75 8.57mg
0/60 1.71mg 0/45 4.00mg 7/75 8.57mg
0/60 1.71mg 1/45 4.00mg 3/75 8.57mg
0/60 1.71mg 1/45 4.00mg 3/75 8.57mg
0/60 1.71mg 0/45 4.00mg 5/75 8.57mg
0/60 1.71mg 1/45 4.00mg 2/75 8.57mg
1/60 1.71mg 1/45 4.00mg 3/75 8.57mg
0/60 1.71mg 0/45 4.00mg 2/75 8.57mg
1/60 1.71mg 1/45 4.00mg 3/75 8.57mg
0/60 1.71mg 2/45 4.00mg 2/75 8.57mg
18/60 1.71mg 33/45 4.00mg 71/75 8.57mg
0/60 1.71mg 0/45 4.00mg 7/75 8.57mg
5/60 1.48mg 19/45 3.45mg 73/75 7.50mg
jej:muc; lgi:adc; liv:hpc,nnd; lun:a/a,a/c;
0/60 1.48mg 11/45 3.45mg 54/75 7.50mg
0/60 1.48mg 10/45 3.45mg 52/75 7.50mg
0/60 1.48mg 0/45 3.45mg 35/75 7.50mg
1/60 1.48mg 3/45 3.45mg 32/75 7.50mg
0/60 1.48mg 0/45 3.45mg 29/75 7.50mg
0/60 1.48mg 2/45 3.45mg 17/75 7.50mg
0/60 1.48mg 2/45 3.45mg 21/75 7.50mg
1/60 1.48mg 1/45 3.45mg 13/75 7.50mg
0/60 1.48mg 0/45 3.45mg 12/75 7.50mg
0/60 1.48mg 2/45 3.45mg 10/75 7.50mg
0/60 1.48mg 0/45 3.45mg 8/75 7.50mg
0/60 1.48mg 0/45 3.45mg 6/75 7.50mg
2/60 1.48mg 4/45 3.45mg 6/75 7.50mg
1/60 1.48mg 1/45 3.45mg 8/75 7.50mg
0/60 1.48mg 0/45 3.45mg 6/75 7.50mg
1/60 1.48mg 0/45 3.45mg 8/75 7.50mg
2/60 1.48mg 4/45 3.45mg 4/75 7.50mg
1/60 1.48mg 0/45 3.45mg 7/75 7.50mg
0/60 1.48mg 0/45 3.45mg 7/75 7.50mg
0/60 1.48mg 0/45 3.45mg 4/75 7.50mg
0/60 1.48mg 0/45 3.45mg 3/75 7.50mg
0/60 1.48mg 0/45 3.45mg 4/75 7.50mg
0/60 1.48mg 1/45 3.45mg 4/75 7.50mg
0/60 1.48mg 0/45 3.45mg 3/75 7.50mg
0/60 1.48mg 2/45 3.45mg 1/75 7.50mg
0/60 1.48mg 0/45 3.45mg 0/75 7.50mg
0/60 1.48mg 0/45 3.45mg 1/75 7.50mg
0/60 1.48mg 0/45 3.45mg 1/75 7.50mg
9/60 1.48mg 25/45 3.45mg 73/75 7.50mg
0/60 1.48mg 0/45 3.45mg 35/75 7.50mg
1,1-DIMETHYLHYDRAZINE... (UDMH) 57-14-7
189 1916m 1.93mg n.s.s. 2/20 .200mg
a 1916m .165mg n.s.s. 0/20 .200mg
b 1916m .165mg n.s.s. 0/20 .200mg
190 1916n 2.41mg 9.38mg 6/50 .200mg
a 1916n 3.37mg 23.0mg 5/50 .200mg
b 1916n 9.61mg 236.mg 1/50 .200mg
c 1916n 13.6mg n.s.s. 3/50 .200mg
d 1916n 14.3mg n.s.s. 4/50 .200mg
e 1916n 15.6mg n.s.s. 5/50 .200mg
f 1916n 17.6mg n.s.s. 4/50 .200mg
g 1916n 15.5mg n.s.s. 4/50 .200mg
h 1916n 30.8mg n.s.s. 1/50 .200mg
i 1916n 1.65mg n.s.s. 1/50 .200mg
j 1916n 15.6mg n.s.s. 7/50 .200mg
k 1916n 27.5mg n.s.s. 3/50 .200mg
191 2013m 1.82mg 43.3mg 3/20 8.00mg
a 2013m 1.92mg 54.2mg 3/20 8.00mg
b 2013m 7.87mg n.s.s. 0/20 8.00mg
c 2013m 7.87mg n.s.s. 0/20 8.00mg
d 2013m 9.77mg n.s.s. 0/20 8.00mg
e 2013m 9.77mg n.s.s. 0/20 8.00mg
f 2013m 13.2mg n.s.s. 0/20 8.00mg
g 2013m 13.2mg n.s.s. 0/20 8.00mg
h 2013m 13.3mg n.s.s. 0/20 8.00mg
192 2013n 7.41mg 18.8mg 6/50 8.00mg
a 2013n 7.72mg 18.6mg 4/50 8.00mg
b 2013n 8.07mg 18.5mg 2/49 8.00mg
c 2013n 8.36mg 18.8mg 1/49 8.00mg
d 2013n 12.4mg n.s.s. 14/49 8.00mg
e 2013n 15.3mg n.s.s. 13/49 8.00mg
f 2013n 19.5mg n.s.s. 2/49 8.00mg
g 2013n 55.4mg n.s.s. 1/49 8.00mg



































































4/60 col:adp; rec:adp. S
3/60 S
6/60
5/60 duo:adc; ilm:adp,mua; jej:adc,adp,muc.
4/60 S
4/60 phr:sqc; ton:sqc. S
4/60 lun:a/a,a/c.





58/60 cec:adp; col:adc,adp,muc; duo:muc; ilm:adc,adp;
mul:msm; phr:sqc,sqp; pre:ade,car; rec:adc,adp; ski:bca,












15/60 cec:adp; col:adc,adp,muc; lgi:adc; rec:adc,adp.
9/60 pre:ade,car.
5/60





8/60 duo:muc; ilm:adc,adp; jej:muc.





7/60 col:adc,muc; lgi:adc; rec:adc. S




















Goldenthal; irdc, 399-065; 1990/pers comm.













































37Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
i M f cdl wat --- hem 24m24 es
j M f cdl wat lun msm 24m24 es
193 M m cdl wat liv hpa 52w52 ek
a M m cdl wat --- vsc 52w52 ek
b M m cdl wat liv hpc 52w52 ek
c M m cdl wat liv mix 52w52 ek
d M m cdl wat lun a/a 52w52 ek
194 M m cdl wat liv hpc 24m24 e
a M m cdl wat --- hes 24m24 e
b M m cdl wat liv mix 24m24 e
c M m cdl wat liv hpa 24m24 e
d M m cdl wat lun mix 24m24 e
e M m cdl wat liv hes 24m24 e
f M m cdl wat lun a/c 24m24 e
g M m cdl wat lun a/a 24m24 e
195 M m cdl wat lun mix 52w52 eks
a M m cdl wat lun a/a 52w52 eks
b M m cdl wat liv hpc 52w52 eks
c M m cdl wat liv vsc 52w52 eks
d M m cdl wat --- vsc 52w52 eks
e M m cdl wat liv hes 52w52 eks
f M m cdl wat --- hes 52w52 eks
g M m cdl wat liv hem 52w52 eks
h M m cdl wat --- hem 52w52 eks
i M m cdl wat lun a/c 52w52 eks
j M m cdl wat liv mix 52w52 eks
k M m cdl wat liv hpa 52w52 eks
196 M m cdl wat --- vsc 24m24 es
a M m cdl wat liv vsc 24m24 es
b M m cdl wat --- hes 24m24 es
c M m cdl wat liv hes 24m24 es
d M m cdl wat lun a/c 24m24 es
e M m cdl wat liv hpc 24m24 es
f M m cdl wat lun mix 24m24 es
g M m cdl wat lun a/a 24m24 es
h M m cdl wat liv hpa 24m24 es
i M m cdl wat liv hem 24m24 es
j M m cdl wat --- hem 24m24 es
k M m cdl wat liv mix 24m24 es
197 R f f34 wat liv hem 52w52 ek
198 R f f34 wat liv mix 24m24 e
a R f f34 wat liv hpc 24m24 e
b R f f34 wat pit ade 24m24 e
c R f f34 wat liv hpa 24m24 e
199 R m f34 wat liv tum 52w52 ek
200 R m f34 wat liv mix 24m24 e
a R m f34 wat liv hpa 24m24 e
b R m f34 wat liv hpc 24m24 e
DIMETHYLNITRAMINE***
201 R f bdf gav nas ene 24m28 a

















4.33mg * P<.04 +























no dre P=1. -
30.9mg * P<.005 -
40.7mg * P<.003 -
14.8mg * P<.06 -
184.mg * P<.5 -
no dre P=1. -
155.mg * P<.5 -
205.mg * P<.6 -
650.mg * P<.8 -
lOOng.. :. lug.... :.*10. :.*100-.--:--_mg-.- -:-*10 . .:100 °O. 1:.*g. :10
+ 10.4mg * P<.0005+
+ 4.74mg * P<.0005+
DIPHENYL-p-PHENYLENEDIAMINE*** lOOng..:. lug. :.*10 . :.*100*.- -:.._mg......10 :...100. Ig. 10
203 R f f3d eat liv clc 24m26 e .>44.8gm * P<.2
204 R m f3d eat liv hnd 24m26 e .> 19.5gm * P<.4
DOXEFAZEPAM
205 R f cdr eat adr phe 24m24 e
a R f cdr eat liv hpa 24m24 e
b R f cdr eat cns gli 24m24 e
c R f cdr eat liv hpc 24m24 e
d R f cdr eat pit ade 24m24 e
e R f cdr eat tba mal 24m24 e
206 R m cdr eat sub mix 24m24 e
a R m cdr eat sub fib 24m24 e
b R m cdr eat liv hpa 24m24 e
c R m cdr eat cns gli 24m24 e
d R m cdr eat liv cho 24m24 e
e R m cdr eat liv hpc 24m24 e
f R m cdr eat tba mal 24m24 e
L-EPINEPHRINE HC1*
207 M f b6c inh ute MXA 24m25
a M f b6c inh ute esp 24m25
b M f b6c inh TBA MXB 24m25
c M f b6c inh liv MXB 24m25
d M f b6c inh lun MXB 24m25
208 M m b6c inh TBA MXB 24m25
a M m b6c inh liv MXB 24m25
lOOng ....: lug. . :.*100 ....:1lmg.. *10. :*100 .... i :.*lg . :10






+ 9.04mg Z P<.002 -
11.8mg Z P<.002 -





10Ong lug.. :.*10 .... :.*100 .... :.*10 .... 1 :100 . ° :lg * :..10










RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
i 2013n 134.mg n.s.s.
j 2013n 134.mg n.s.s.
193 1916m 1.60mg n.s.s.
a 1916m .132mg n.s.s.
b 1916m 2.06mg n.s.s.
c 1916m 1.55mg n.s.s.
d 1916m 1.02mg n.s.s.
194 1916n 4.23mg n.s.s.
a 1916n 7.82mg n.s.s.
b 1916n 2.55mg n.s.s.
c 1916n 4.60mg n.s.s.
d 1916n 2.67mg n.s.s.
e 1916n 9.43mg n.s.s.
f 1916n 5.75mg n.s.s.
g 1916n 3.47mg n.s.s.
195 2013m 1.84mg n.s.s.
a 2013m 2.02mg n.s.s.
b 2013m 2.66mg n.s.s.
c 2013m 4.79mg n.s.s.
d 2013m 4.79mg n.s.s.
e 2013m 6.56mg n.s.s.
f 2013m 6.56mg n.s.s.
g 2013m 8.21mg n.s.s.
h 2013m 8.21mg n.s.s.
i 2013m 11.0mg n.s.s.
j 2013m 7.02mg n.s.s.
k 2013m 9.85mg n.s.s.
196 2013n 4.28mg 9.51mg
a 2013n 4.54mg 10.Omg
b 2013n 4.54mg 10.3mg
c 2013n 4.80mg 10.8mg
d 2013n 12.3mg n.s.s.
e 2013n 12.3mg n.s.s.
f 2013n 9.70mg n.s.s.
g 2013n 12.3mg n.s.s.
h 2013n 32.9mg n.s.s.
i 2013n 83.4mg n.s.s.
j 2013n 83.4mg n.s.s.
k 2013n 29.8mg n.s.s.
197 2012m 57.2ug n.s.s.
198 2012n 14.5mg 310.mg
a 2012n 17.6mg 197.mg
b 2012n 5.82mg n.s.s.
c 2012n 38.9mg n.s.s.
199 2012m 50.Oug n.s.s.
200 2012n 26.3mg n.s.s.
a 2012n 30.0mg n.s.s.















































































































































































































































Goldenthal; irdc, 399-062; 1989/pers .comm.
DIMETHYLNITRAMINE*** 4164-28-7
201 1931 4.98mg 27.4mg 0/10
202 1931 2.26mg 10.7mg 0/10
6.43mg 3/10 12.9mg 8/10
6.43mg 6/10 12.9mg 10/10
Scherf;carc,10,1977-1981;1989/pers.comm.
DIPHENYL-p-PHENYLENEDIAMINE*** (Agerite DPPD) 74-31-7
203 1943 7.30gm n.s.s. 0/47 232.mg 0/49 929.mg 1/49
204 1943 4.40gm n.s.s. 0/50 186.mg 1/49 743.mg 1/49
DOXEFAZEPAM 40762-15-0
205 1983 88.5mg 1.38gm
a 1983 84.6mg n.s.s.
b 1983 124.mg n.s.s.
c 1983 158.mg n.s.s.
d 1983 28.9mg n.s.s.
e 1983 55.4mg n.s.s.
206 1983 4.30mg 41.2mg
a 1983 5.33mg 41.1mg
b 1983 122.mg n.s.s.
c 1983 86.2mg n.s.s.
d 1983 235.mg n.s.s.
e 1983 133.mg n.s.s.





















































Hasegawa; txcy, 54,69-78; 1989














207 c55663 2.61mg n.s.s. 0/50
a c55663 2.94mg n.s.s. 0/50
b c55663 1.19mg n.s.s. 36/50
c c55663 2.42mg n.s.s. 3/50
d c55663 4.44mg n.s.s. 5/50
208 c55663 .993mg n.s.s. 38/50

















liv: hpa, hpc, nnd.
lun: a/a, a/c.
liv:hpa,hpc,nnd.
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Brkly Code
39Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
b M m b6c inh lun MXB 24m25
209 R f f34 inh TBA MXB 24m24
a R f f34 inh liv MXB 24m24
210 R m f34 inh TBA MXB 24m24
a R m f34 inh liv MXB 24m24
ERYTHORBATE, SODIUM-**
211 M f b6c wat liv hem 22m26 e
a M f b6c wat lun a/c 22m26 e
b M f b6c wat liv hpa 22m26 e
c M f b6c wat liv hpc 22m26 e
d M f b6c wat lun a/a 22m26 e
e M f b6c wat --- lkm 22m26 e
f M f b6c wat tba mix 22m26 e
212 M m b6c wat liv hem 22m26 e
a M m b6c wat liv hpa 22m26 e
b M m b6c wat liv hpc 22m26 e
c M m b6c wat lun a/c 22m26 e
d M m b6c wat lun a/a 22m26 e
e M m b6c wat tba mix 22m26 e
ESTAZOLAM
213 M f b6c eat liv agm 24m24 e
a M f b6c eat liv hpc 24m24 e
b M f b6c eat lun a/a 24m24 e
c M f b6c eat liv ang 24m24 e
d M f b6c eat lun a/c 24m24 e
e M f b6c eat tba ben 24m24 e
f M f b6c eat tba mal 24m24 e
g M f b6c eat tba mix 24m24 e
214 M m b6c eat lun a/a 24m24 e
a M m b6c eat liv agm 24m24 e
b M m b6c eat liv hpc 24m24 e
c M m b6c eat lun a/c 24m24 e
d M m b6c eat tba ben 24m24 e
e M m b6c eat tba mal 24m24 e
f M m b6c eat tba mix 24m24 e
215 R f cdr eat liv nnd 24m24 e
a R f cdr eat liv hpc 24m24 e
b R f cdr eat tba mix 24m24 e
c R f cdr eat tba ben 24m24 e
d R f cdr eat tba mal 24m24 e
216 R m cdr eat ski fib 24m24 e
a R m cdr eat liv nnd 24m24 e
b R m cdr eat liv hpc 24m24 e
c R m cdr eat tba mal 24m24 e
d R m cdr eat tba ben 24m24 e
e R m cdr eat tba mix 24m24 e
ETHYL ALCOHOL***
217 R f cdr wat liv nnd 24m24 e
a R f cdr wat tba tum 24m24 e
218 R m cdr wat liv nnd 24m24 e
a R m cdr wat liv hpc 24m24 e
b R m cdr wat tba tum 24m24 e
ETHYLENE GLYCOL
219 M f b6c eat TBA MXB 24m24
a M f b6c eat liv MXB 24m24
b M f b6c eat lun MXB 24m24
220 M m b6c eat hag MXA 24m24
a M m b6c eat TBA MXB 24m24
b M m b6c eat liv MXB 24m24
c M m b6c eat lun MXB 24m24
ETHYLENE THIOUREA***
221 M f b6c eat liv MXA 25m25
a M f b6c eat MXB MXB 25m25
b M f b6c eat liv hpa 25m25
c M f b6c eat liv hpc 25m25
d M f b6c eat thy MXA 25m25
e M f b6c eat thy fca 25m25
f M f b6c eat psd ade 25m25
g M f b6c eat psd MXA 25m25
h M f b6c eat thy fcc 25m25
i M f b6c eat TBA MXB 25m25
j M f b6c eat liv MXB 25m25
k M f b6c eat lun MXB 25m25
222 M m b6c eat MXB MXB 25m25
a M m b6c eat liv MXA 25m25









































































lbOng..: .lug.. .-10.:. -100 * :. 1mg... -10 * : .100 : * -lg * :. 10











































liv: hpa, hpc, nnd.
liv:hpa,hpc,nnd.




























213 1984 80.8mg n.s.s.
a 1984 40.6mg n.s.s.
b 1984 85.7mg n.s.s.
c 1984 102.mg n.s.s.
d 1984 64.4mg n.s.s.
e 1984 18.1mg n.s.s.
f 1984 21.Omg n.s.s.
g 1984 15.1mg n.s.s.
214 1984 28.5mg n.s.s.
a 1984 64.2mg n.s.s.
b 1984 33.9mg n.s.s.
c 1984 35.6mg n.s.s.
d 1984 24.9mg n.s.s.
e 1984 25.2mg n.s.s.
f 1984 21.4mg n.s.s.
215 1984 73.8mg n.s.s.
a 1984 77.5mg n.s.s.
b 1984 1.21mg n.s.s.
c 1984 4.35mg n.s.s.
d 1984 27.3mg n.s.s.
216 1984 33.4mg n.s.s.
a 1984 53.3mg n.s.s.
b 1984 76.1mg n.s.s.
c 1984 18.3mg n.s.s.
d 1984 14.5mg n.s.s.





















































0/50 3.00mg 0/50 10.Omg
4/50 3.00mg 4/50 10.Omg
0/50 3.00mg 0/50 10.Omg
1/50 3.00mg 0/50 10.Omg
0/50 3.00mg 3/50 10.Omg
6/50 3.00mg 13/50 10.Omg
21/50 3.00mg 20/50 10.Omg
24/50 3.00mg 28/50 10.Omg
1/50 3.00mg 2/50 10.Omg
0/50 3.00mg 1/50 10.Omg
11/50 3.00mg 12/50 10.Omg
6/50 3.00mg 7/50 10.Omg
5/50 3.00mg 11/50 10.Omg
20/50 3.00mg 28/50 10.Omg
57/100 10.Omg 23/50
0/50 2.00mg 2/50 10.Omg
1/50 2.00mg 1/50 10.Omg
46/50 2.00mg 49/50 10.Omg
43/50 2.00mg 47/50 10.Omg
16/50 2.00mg 17/50 10.Omg
6/49 2.00mg 3/49 10.Omg
2/50 2.00mg 1/50 10.Omg
0/50 2.00mg 1/50 10.Omg
11/50 2.00mg 9/50 10.Omg
36/50 2.00mg 42/50 10.Omg
44/50 2.00mg 43/50 10.Omg


























217 1962 28.9gm n.s.s.
a 1962 2.70gm n.s.s.
218 1962 13.8gm n.s.s.
a 1962 25.8gm n.s.s.

















219 c00920 8.40gm n.s.s.
a c00920 12.7gm n.s.s.
b c00920 4.83gm n.s.s.
220 c00920 7.26gm n.s.s.
a c00920 1.83gm n.s.s.
b c00920 3.13gm n.s.s.








ETHYLENE THIOUREA*** (ETU) 96-45-7
221 c03372 12.7mg 38.1mg 4/50
a c03372 14.5mg 96.7mg
b c03372 19.1mg 59.9mg
c c03372 28.4mg 62.9mg
d c03372 55.5mg 128.mg
e c03372 60.6mg 144.mg
f c03372 74.6mg 973.mg
g c03372 76.7mg 1.57gm
h c03372 246.mg 1.69gm
i c03372 46.2mg n.s.s.
j c03372 12.7mg 38.1mg
k c03372 93.4mg n.s.s.
222 c03372 30.6mg 159.mg





















33/50 3.19gm 31/51 6.37gm 36/50
9/50 3.19gm 14/51 6.37gm 10/50
6/50 3.19gm 6/51 (6.37gm 1/50)
0/54 1.48gm 2/54 2.96gm 3/54
36/54 1.48gm 31/54 2.96gm 33/54
23/54 1.48gm 16/54 2.96gm 18/54
3/54 1.48gm 9/54 2.96gm 3/54
42.9mg 44/50 (130.mg 48/50)
42.9mg 47/50 (130.mg 48/50)
42.9mg 33/50 (130.mg 14/50)
42.9mg 29/50 130.mg 47/50
42.9mg 2/50 130.mg 38/50
42.9mg 2/50 130.mg 35/50
42.9mg 19/50 130.mg 26/50
42.9mg 19/50 130.mg 26/50
42.9mg 0/50 130.mg 8/50
42.9mg 49/50 130.mg 48/50
42.9mg 44/50 (130.mg 48/50)
42.9mg 8/50 (130.mg 0/50)
39.6mg 32/50 120.mg 47/50












liv:hpa,hpc; psd:ade; thy:fca,fcc. C
liv:hpa,hpc.



























































41Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
b M m b6c eat liv hpc 25m25
c M m b6c eat thy MXA 25m25
d M m b6c eat thy fca 25m25
e M m b6c eat psd ade 25m25
f M m b6c eat thy fcc 25m25
g M m b6c eat MXA hem 25m25
h M m b6c eat TBA MXB 25m25
i M m b6c eat liv MXB 25m25
j M m b6c eat lun MXB 25m25
223 R f f34 eat thy MXA 25m25
a R f f34 eat thy MXA 25m25
b R f f34 eat thy MXA 25m25
c R f f34 eat TBA MXB 25m25
d R f f34 eat liv MXB 25m25
224 R m f34 eat thy MXA 25m25
a R m f34 eat thy MXA 25m25
b R m f34 eat thy MXA 25m25
c R m f34 eat TBA MXB 25m25
d R m f34 eat liv MXB 25m25
DI(2-ETHYLHEXYL)NPHTHALATE-** lOOng.... ...... ................ :*g . . . . . :100 .1.g
225 R m f34 eat liv mix 25m25 er +
1-ETHYLNITROSO-3- (2-HYDROXYETHYL) UREA
226 R f f34 wat ner tum 7m24 e
a R f f34 wat mam car 7m24 e
b R f f34 wat ski tum 7m24 e
c R f f34 wat ute tum 7m24 e
d R f f34 wat liv tum 7m24 e
227 R m f34 wat tnv mso 7m24 e
a R m f34 wat lun tum 7m24 e
b R m f34 wat ski tum 7m24 e
c R m f34 wat ner tum 7m24 e
d R m f34 wat liv tum 7m24 e
1-ETHYLNITROSO-3- (2-OXOPROPYL) UREA
228 R f f34 gav mam car 7m24 e
a R f f34 gav lun tum 7m24 e
b R f f34 gav ner tum 7m24 e
c R f f34 gav ute tum 7m24 e
d R f f34 gavliv tum 7m24 e
229 R f f34 wat ner tum 7m24 e
a R f f34 wat mam car 7m24 e
b R f f34 wat lun tum 7m24 e
c R f f34 wat thy fct 7m24 e
d R f f34 wat col tum 7m24 e
e R f f34 wat ute tum 7m24 e
f R f f34 wat ski tum 7m24 e
g R f f34 wat liv tum 7m24 e
230 R m f34 gav lun tum 7m24 e
a R m f34 gav tnv mso 7m24 e
b R m f34 gav zym tum 7m24 e
c R m f34 gav col tum 7m24 e
d R m f34 gav thy fct 7m24 e
e R m f34 gav for tum 7m24 e
f R m f34 gav ner tum 7m24 e
g R m f34 gavliv tum 7m24 e
231 R m f34 wat ner tum 7m24 e
a R m f34 wat lun tum 7m24 e
b R m f34 wat tnv mso 7m24 e
c R m f34 wat col tum 7m24 e
d R m f34 wat zym tum 7m24 e
e R m f34 wat ski tum 7m24 e






















* -:-lug...... : . -10 * . ... : 100. : _mg . : . -10 . . : . -100 *:* . lg... :.10
+ .714mg * P<.0005
.748mg * P<.004 +
.956mg * P<.004 +
.972mg * P<.07 +
no dre P=1.





* -: lug.* : . -10.* : 100 .mg ..10 * : .100.: *1-g. : 10
+ .192mg * P<.0005+




*+ * .605mg \ P<.005 +
.748mg P<.0005+
.885mg P<.002 +
.804mg \ P<.02 +
1.13mg \ P<.04 +
1.49mg P<.09 +

















ETHYLPHENYLACETYLUREA 100ng -lug.... :.-10.... :.-100.... :._mg :.- 10 . ...:.-100 . ... :. - g :.-10
232 R m f34 eat liv hpt 71w71 e .> no dre P=1.
FENVALERATE***
233 M f cb6 gav --- lym 24m26 e
a M f cb6 gav liv lct 24m26 e
b M f cb6 gav lun ade 24m26 e
c M f cb6 gav tba tum 24m26 e
234 M m cb6 gav liv lct 24m26 e
a M m cb6 gav --- lym 24m26 e
b M m cb6 gav lun ade 24m26 e
c M m cb6 gav tba tum 24m26 e
1O0ng.. -lug .... -10 *..... -100 ....:.._mg....: .-10 ....1. -100 ....:*ilg . - :.. 10












RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
b c03372 33.5mg 116.mg
c c03372 60.7mg 172.mg
d c03372 69.6mg 194.mg
e c03372 173.mg 1.20gm
f c03372 246.mg n.s.s.
g c03372 284.mg n.s.s.
h c03372 38.6mg n.s.s.
i c03372 30.6mg 158.mg
j c03372 156.mg n.s.s.
223 c03372 4.74mg 13.2mg
a c03372 4.64mg 14.2mg
b c03372 15.9mg n.s.s.
c c03372 5.13mg n.s.s.
d c03372 82.4mg n.s.s.
224 c03372 2.08mg 5.23mg
a c03372 3.28mg 9.00mg
b c03372 3.29mg 10.4mg
c c03372 3.49mg n.s.s.


















































































thy: fab, fca, fcy, fdc.
thy:fcy, fdc.
liv:hpa,hpc,nnd.




DI (2-ETHYLHEXYL) PHTHALATE*** (di-sec-octyl phthalate) 117-81-7
225 1982 178.mg 1.59gm 1/10 800.mg 11/14
































228 2010m 98.9ug .388mg
a 2010m .383mg n.s.s.
b 2010m .407mg n.s.s.
c 2010m .501mg n.s.s.
d 2010m .728mg n.s.s.
229 2010n .225mg 4.85mg
a 2010n .366mg 2.03mg
b 2010n .424mg 3.41mg
c 2010n .274mg n.s.s.
d 2010n .340mg n.s.s.
e 2010n .529mg n.s.s.
f 2010n .438mg n.s.s.
g 2010n 1.36mg n.s.s.
230 2010m n.s.s. .135mg
a 2010m .121mg .472mg
b 2010m .245mg 1.50mg
c 2010m .269mg 1.77mg
d 2010m .344mg 5.51mg
e 2010m .367mg 3.21mg
f 2010m .519mg n.s.s.
g 2010m .757mg n.s.s.
231 2010n 53.lug .354mg
a 2010n .123mg .480mg
b 2010n .144mg .605mg
c 2010n .256mg 1.42mg
d 2010n .455mg 5.71mg
e 2010n .421mg n.s.s.


























































































































































232 1951 25.6mg n.s.s. 0/15 17.8mg 0/15




FENVALERATE*** (cyano- (3-phenoxyphenyl)methyl-4-chloro-alpha- (1-methylethyl) benzene acetate) 51630-58-1
233 1963 67.5mg n.s.s. 19/49 26.1mg 24/47 52.1mg 18/41 Cabral;clet,49,13-18;1990/pers.comm.
a 1963 555.mg n.s.s. 2/49 26.1mg 0/47 52.1mg 1/41
b 1963 193.mg n.s.s. 2/49 26.1mg 0/47 52.1mg 0/41
c 1963 62.6mg n.s.s. 22/49 26.1mg 27/47 52.1mg 20/41
234 1963 125.mg n.s.s. 4/48 26.1mg 5/47 52.1mg 10/48
a 1963 93.6mg n.s.s. 15/48 26.1mg 17/47 52.1mg 17/48
b 1963 385.mg n.s.s. 2/48 26.1mg 3/47 52.1mg 1/48
c 1963 88.7mg n.s.s. 25/48 26.1mg 22/47 52.1mg 24/48
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Brkly Code
43Spe Strain Site Xpo+Xpt




235 M f b6c wat TBA MXB 24m24
a M f b6c wat liv MXB 24m24
b M f b6c wat lun MXB 24m24
236 M m b6c wat TBA MXB 24m24
a M m b6c wat liv MXB 24m24
b M m b6c wat lun MXB 24m24
237 R f f34 wat TBA MXB 24m24
a R ff34 wat liv MXB 24m24
238 R m f34 wat MXA ost 24m24
a R m f34 wat MXA ost 24m24
b R m f34 wat TBA MXB 24m24
c R m f34 wat liv MXB 24m24
2-FLUOROETHYL-NITROSOUREA
239 R m f34 gav for tum 9m24
a R m f34 gav lun mix 9m24
b R m f34 gav liv tum 9m24
5-FLUOROURACIL***
240 M f bal ipj lmr mix
a M f bal ipj lun mix
b M f bal ipj lun sqc
c M f bal ipj tba tum
241 M m bal ipj lun ade








242 R f wal wat for exp 24m24 e
a R f wal wat stg tum 24m24 e
b R f wal wat liv hpc 24m24
c R f wal wat pit het 24m24
d R f wal wat tba mix 24m24
e R f wal wat tba ben 24m24
f R f wal wat tba mal 24m24
243 R m wal wat stg tum 24m24 e
a R m wal wat for exp 24m24e
b R m wal wat liv hpc 24m24
c R m wal wat tba mix 24m24
d R m wal wat tba ben 24m24
e R m wal wat tba mal 24m24
244 R m wal inh nac sqc 28m29 r
FURAN
245 M f b6c gav liv MXA 24m24
a M fb6c gav MXB MXB 24m24
b M f b6c gav liv hpa 24m24
c M fb6c gav liv MXA 24m24
d M fb6c gav for sqp 24m24
e M fb6c gav amd pob 24m24
f M fb6c gav TBA MXB 24m24
g M fb6c gav liv MXB 24m24
h M fb6c gav lun MXB 24m24
246 M m b6c gav MXB MXB 24m24
a M m b6c gav liv MXA 24m24
b M m b6c gav liv hpa 24m24
c M m b6c gav liv hpc 24m24
d M m b6c gav amd pob 24m24
e M m b6c gav mul MXA 24m24
f M m b6c gav lun a/a 24m24
g M m b6c gav for sqp 24m24
h M m b6c gav TBA MXB 24m24
i M m b6c gav liv MXB 24m24
j M m b6c gav lun MXB 24m24
247 R f f34 gav liv clc 24m24
a R ff34 gav MXB MXB 24m24
b R ff34 gav mul mnl 24m24
c R ff34 gavliv MXA 24m24
d R f f34 gav liv hpa 24m24
e R f f34 gav ubl tpp 24m24
f R ff34 gav TBA MXB 24m24
g R ff34 gav liv MXB 24m24
248 R m f34 gav liv clc 24m24
a R m f34 gav MXB MXB 24m24
b R m f34 gav liv MXA 24m24
c R m f34 gav liv hpa 24m24
d R m f34 gav mul mnl 24m24
e R m f34 gav liv hpc 24m24
f R m f34 gav tes MXA 24m24
g R m f34 gav amd pob 24m24
1O0ng* :.-lug.. . . : .-10 .... :.- 100* ......:mg.. :.-10 .... :.-100* .... g :..g :.-10
> no dre P=l.
no dre P=1.
no dre P=l.
: > no dre P=1.
no dre P=1.
no dre P=1.
:> 73.9mg * P<.8
no dre P=1.
+ 82.7mg * P<.009
109.mg * P<.03 e
147.mg * P<l.
no dre P=l.



































bOng*. l ug.... :..10 :.-100 . . . .:1.0mg.... :..1 0:.-100 .... :* lg ..... : 10







































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
FLUORIDE, SODIUM... 7681-49-4
235 c55221 38.Omg n.s.s. 72/80
a c55221 59.1mg n.s.s. 55/80
b c55221 138.mg n.s.s. 8/80
236 c55221 33.2mg n.s.s. 71/79
a c55221 36.2mg n.s.s. 62/79
b c55221 96.2mg n.s.s. 23/79
237 c55221 7.56mg n.s.s. 73/80
a c55221 83.0mg n.s.s. 2/80
238 c55221 30.6mg 2.86gm 0/80
a c55221 36.4mg n.s.s. 0/80
b c55221 6.37mg n.s.s. 71/80





















































liv: hpa, hpc, nnd.
cyx:ost; hum:ost; sub:ost; ver:ost. S
cyx:ost; hum:ost; ver:ost.
liv: hpa, hpc, nnd.
2-FLUOROETHYL-NITROSOUREA 69112-98-7
239 1915 42.8ug n.s.s. 0/12 74.2ug 4/12
a 1915 68.3ug n.s.s. 0/12 74.2ug 2/12
b 1915 .184mg n.s.s. 1/12 74.2ug 0/12
5-FLUOROURACIL*** (fluracil) 51-21-8
240 1964 1.46mg 11.2mg
a 1964 2.43mg n.s.s.
b 1964 9.52mg n.s.s.
c 1964 1.09mg 14.2mg
241 1964 1.42mg n.s.s.
a 1964 1.28mg 69.1mg
FORMALDEHYDE*** 50-00-0
242 1918 16.7mg n.s.s.
a 1918 16.7mg n.s.s.
b 1918 17.2mg n.s.s.
c 1918 410.mg n.s.s.
d 1918 136.mg n.s.s.
e 1918 144.mg n.s.s.
f 1918 418.mg n.s.s.
243 1918 10.4mg n.s.s.
a 1918 913.mg n.s.s.
b 1918 981.mg n.s.s.
c 1918 182.mg n.s.s.
d 1918 242.mg n.s.s.
e 1918 263.mg n.s.s.






















































































































1/30 Woutersen; japt, 9,39-46;1989
FURAN 110-00-9
245 c56202 1.52mg 3.36mg
a c56202 1.56mg 3.53mg
b c56202 1.57mg 3.44mg
c c56202 4.20mg 12.4mg
d c56202 8.90mg n.s.s.
e c56202 12.6mg n.s.s.
f c56202 1.65mg 6.99mg
g c56202 1.52mg 3.36mg
h c56202 11.3mg n.s.s.
246 c56202 2.17mg 8.50mg
a c56202 2.17mg 8.50mg
b c56202 2.40mg 9.61mg
c c56202 3.37mg 9.50mg
d c56202 10.3mg 72.7mg
e c56202 4.46mg n.s.s.
f c56202 7.89mg n.s.s.
g c56202 21.4mg n.s.s.
h c56202 2.65mg 106.mg
i c56202 2.17mg 8.50mg
j c56202 8.12mg n.s.s.
247 c56202 .273mg .598mg
a c56202 .342mg 1.04mg
b c56202 3.31mg 18.Omg
c c56202 6.00mg 28.1mg
d c56202 6.20mg 32.8mg
e c56202 15.4mg n.s.s.
f c56202 1.38mg 67.Omg
g c56202 6.00mg 28.1mg
248 c56202 .268mg .620mg
a c56202 .323mg 1.06mg
b c56202 1.65mg 3.45mg
c c56202 2.13mg 4.94mg
d c56202 2.71mg 12.3mg
e c56202 3.79mg 10.9mg
f c56202 1.42mg n.s.s.
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Brkly Code
45Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
h R m f34 gav ski ker 24m24
i R m f34 gav sub fib 24m24
j R m f34 gav pre MXA 24m24
k R m f34 gav TBA MXB 24m24
1 R m f34 gav liv MXB 24m24
FURFURAL***
249 M f b6c gav liv hpa 24m24
a M f b6c gav liv MXA 24m24
b M f b6c gav for sqp 24m24
c M f b6c gav TBA MXB 24m24
d M f b6c gav liv MXB 24m24
e M f b6c gav lun MXB 24m24
250 M m b6c gav liv MXA 24m24
a M m b6c gav liv hpc 24m24
b M m b6c gav sub MXA 24m24
c M m b6c gav sub MXA 24m24
d M m b6c gav sub MXA 24m24
e M m b6c gav liv hpa 24m24
f M m b6c gav sub fbs 24m24
g M m b6c gav kcx MXA 24m24
h M m b6c gav TBA MXB 24m24
i M m b6c gav liv MXB 24m24
j M m b6c gav lun MXB 24m24
251 R f f34 gav TBA MXB 24m24
a R f f34 gav liv MXB 24m24
252 R m f34 gav liv clc 24m24
a R m f34 gav TBA MXB 24m24
b R m f34 gav liv MXB 24m24
GLYCIDOL
253 H f syg gav spl hes 14m24 e
a H f syg gav liv hcs 14m24 e
b H f syg gav liv cho 14m24 e
c H f syg gav lun adc 14m24 e
d H f syg gav tba tum 14m24 e
254 H m syg gav for mal 14m24 e
a H m syg gav spl hes 14m24 e
b H m syg gav liv hes 14m24 e
c H m syg gav tba tum 14m24 e
255 M f b6c gav MXB MXB 24m24


































a M f b6c gav hag MXA 24m24
b M f b6c gav hag adn 24m24
c M f b6c gav mgl acn 24m24
d M f b6c gav mgl MXA 24m24
e M f b6c gav sub MXA 24m24
f M f b6c gav sub srn 24m24
g M f b6c gav ute MXA 24m24
h M f b6c gav MXA MXA 24m24
i M f b6c gav ute acn 24m24
j M f b6c gav sub fbs 24m24
k M f b6c gav ski MXA 24m24
1 M f b6c gav TBA MXB 24m24
m M f b6c gav liv MXB 24m24
n M f b6c gav lun MXB 24m24
256 M m b6c gav hag MXA 24m24
a M m b6c gav for sqp 24m24
b M m b6c gav for MXA 24m24
c M m b6c gav MXB MXB 24m24
d M m b6c gav liv MXA 24m24
e M m b6c gav MXA MXA 24m24
f M m b6c gav liv hpa 24m24
g M m b6c gav hag adn 24m24
h M m b6c gav lun MXA 24m24
i M m b6c gav hag acn 24m24
j M in b6c gav ski sqp 24m24
k M m b6c gav mul mlh 24m24
1 M m b6c gav epy srn 24m24
m M m b6c gav ubl tcc 24m24
n M m b6c gav TBA MXB 24m24
o M m b6c gav liv MXB 24m24
p M m b6c gav lun MXB 24m24






































a R f f34 gav mgl MXA 23m24 a
b R f f34 gav mgl fba 23m24 a
c R f f34 gav cli MXA 23m24 a
d R f f34 gav ute esp 23m24 a




















































































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
h c56202 7.84mg n.s.s.
i c56202 8.52mg n.s.s.
j c56202 8.50mg n.s.s.
k c56202 1.11mg 6.22mg
1 c56202 1.65mg 3.45mg
FURFURAL*** 98-01-1
249 c56177 177.mg 26.3gm
a c56177 160.mg n.s.s.
b c56177 355.mg n.s.s.
c c56177 118.mg n.s.s.
d c56177 160.mg n.s.s.
e c56177 585.mg n.s.s.
250 c56177 65.9mg 3.47gm
a c56177 107.mg 3.10gm
b c56177 75.6mg n.s.s.
c c56177 86.4mg n.s.s.
d c56177 80.9mg n.s.s.
e c56177 91.8mg n.s.s.
f c56177 93.6mg n.s.s.
g c56177 425.mg n.s.s.
h c56177 52.4mg n.s.s.
i c56177 65.9mg 3.47gm
j c56177 166.mg n.s.s.
251 c56177 20.4mg n.s.s.
a c56177 n.s.s. n.s.s.
252 c56177 162.mg n.s.s.
a c56177 20.9mg n.s.s.


















































































2.82mg 5/50 5.64mg 2/50
2.82mg 4/50 5.64mg 3/50
2.82mg 4/50 5.64mg 4/50
2.82mg 48/50 5.64mg 49/50





70.5mg 5/50 123.mg 8/50
70.5mg 7/50 123.mg 12/50
70.5mg 1/50 123.mg 6/50
70.5mg 24/50 123.mg 31/50
70.5mg 7/50 123.mg 12/50
70.5mg 1/50 123.mg 3/50
70.7mg 17/50 123.mg 32/50
70.7mg 6/50 123.mg 21/50
70.7mg 13/50 (123.mg 3/50)
70.7mg 11/50 (123.mg 2/50)
70.7mg 12/50 (123.mg 3/50)
70.7mg 11/50 123.mg 19/50
70.7mg 10/50 (123.mg 2/50)
70.7mg 1/50 123.mg 1/50
70.7mg 42/50 123.mg 42/50
70.7mg 17/50 123.mg 32/50




















253 2042 19.3mg n.s.s.
a 2042 39.8mg n.s.s.
b 2042 39.8mg n.s.s.
c 2042 75.3mg n.s.s.
d 2042 8.94mg n.s.s.
254 2042 19.4mg n.s.s.
a 2042 24.3mg n.s.s.
b 2042 33.2mg n.s.s.
c 2042 14.Omg n.s.s.

































































a c55549 2.40mg 7.58mg
b c55549 2.52mg 8.70mg
c c55549 5.27mg 36.5mg
d c55549 6.57mg 39.2mg









































































































Lij insky; txih, 8,267-271;1992
35.4mg 37/50 hag:acn,adn; mgl:acn,adn,fba; ski:sqc,sqp; sub:fbs,srn; ute:acn,
can. C
11/50 35.4mg 17/50 hag:acn,adn.
10/50 35.4mg 16/50 S
5/50 35.4mg 15/50 S
6/50 35.4mg 15/50 mgl:acn,adn,fba.
3/50 35.4mg 9/50 sub:fbs,srn.
1/50 35.4mg 6/50 S
3/50 35.4mg 3/50 ute:acn,can.
3/50 35.4mg 5/50 liv:hem,hes; ova:hem; pec:hes; sub:hes; ute:hem,hes. S
3/50 35.4mg 2/50 S
2/50 35.4mg 3/50 S
0/50 35.4mg 2/50 ski:sqc, sqp.
46/50 35.4mg 47/50
7/50 35.4mg 14/50 liv:hpa,hpc,nnd.
10/50 35.4mg 8/50 lun:a/a,a/c.
12/50 35.4mg 22/50 hag:acn,adn.
2/50 35.4mg 9/50 S
2/50 35.4mg 10/50 for:sqc,sqp.
41/50 35.4mg 46/50 for:sqc,sqp; hag:acn,adn; liv:hpa,hpc; lun:a/a,a/c; ski:sqp. C
31/50 35.4mg 35/50 liv:hpa,hpc.
12/50 (35.4mg 7/50) mul:mlh,mlm,mlp; thm:mlm. S
16/50 35.4mg 30/50 S
10/50 35.4mg 16/50 S
11/50 35.4mg 21/50 lun:a/a,a/c.
2/50 35.4mg 7/50 S
0/50 35.4mg 4/50




31/50 35.4mg 35/50 liv:hpa,hpc,nnd.
11/50 35.4mg 21/50 lun:a/a,a/c.
39/50 53.6mg 42/50 bra:gln; cli:acn,adn,can; for:sqc,sqp; mgl:acn,fba; mth:sqc,sqp;
mul:mnl; thy:fca,fcc; ton:sqp. C
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Brkly Code
47Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
f R f f34 gav cli adn 23m24 a
g R f f34 gav mgl acn 23m24 a
h R f f34 gav for MXA 23m24 a
i R f f34 gav for sqp 23m24 a
i R f f34 gav bra gln 23m24 a
k R f f34 gav MXA MXA 23m24 a
1 R f f34 gav MXA sqp 23m24 a
m R f f34 gav ton sqp 23m24 a
n R f f34 gav cli MXA 23m24 a
0 R f f34 gav cli can 23m24 a
p R f f34 gav thy MXA 23m24 a
q R f f34 gav pta adn 23m24 a
r R f f34 gav sub MXA 23m24 a
s R f f34 gav adr MXA 23m24 a
t R f f34 gav ute MXA 23m24 a
u R f f34 gav for sqc 23m24 a
v R f f34 gav thy fcc 23m24 a
w R f f34 gav stg fbs 23m24 a
x R f f34 gav TBA MXB 23m24 a
y R f f34 gav liv MXB 23m24 a
258 R m f34 gav tes ict 93w98 a
a R m f34 gav MXB MXB 93w98 a
b R m f34 gav mul mnl 93w98 a
c R m f34 gav tnv MXA 93w98 a
d R m f34 gav tnv msm 93w98 a
e R m f34 gav ski sqp 93w98 a
f R m f34 gav bra gln 93w98 a
g R m f34 gav mgl fba 93w98 a
h R m f34 gav lun MXA 93w98 a
i R m f34 gav pre adn 93w98 a
j R m f34 gav pre MXA 93w98 a
k R m f34 gav pta MXA 93w98 a
1 R m f34 gav pta adn 93w98 a
m R m f34 gav thy MXA 93w98 a
n R m f34 gav lun a/a 93w98 a
0 R m f34 gav thy fcc 93w98 a
p R m f34 gav ski ker 93w98 a
q R m f34 gav sub MXA 93w98 a
r R m f34 gav for MXA 93w98 a
s R m f34 gav tnv men 93w98 a
t R m f34 gav ski MXA 93w98 a
u R m f34 gav sub MXA 93w98 a
v R m f34 gav ski MXA 93w98 a
w R m f34 gav ton MXA 93w98 a
x R m f34 gav ski bct 93w98 a
y R m f34 gav thy cca 93w98 a
z R m f34 gav sub MXA 93w98 a
A R m f34 gav zym can 93w98 a
B R m f34 gav sub fib 93w98 a
C R m f34 gav for sqp 93w98 a
D R m f34 gav MXA MXA 93w98 a
E R m f34 gav MXA MXA 93w98 a
F R m f34 gav TBA MXB 93w98 a
G R m f34 gav liv MXB 93w98 a
HEXACHLOROBENZENE***
259 M m c5c eat liv hnd 52w52 ekr
a M m c5c eat liv hpc 52w52 ekr
260 M m c5c eat liv tum 78w78 er
N-HEXYLNITROSOUREA
261 R f f34 gav ute mix 12m24
a R f f34 gav for tum 12m24
b R f f34 gav mgl adc 12m24
c R f f34 gav lun mix 12m24
d R f f34 gav liv tum 12m24
262 R m f34 gav for tum 12m24
a R m f34 gav lun mix 12m24
b R m f34 gav --- mso 12m24
c R m f34 gav col tum 12m24
d R m f34 gav liv tum 12m24
HYDRAZINE***
263 M f nmb wat tba ben 24m24
a M f nmb wat tba mal 24m24
264 M m nmb wat tba mal 24m24



















































































lOnung.:.-ug .. : .u-g10 ... :..-100 .... :._mg. :.-10 ... :.-100 .... :l.-g ..... 10
*> 58.5mg * P<.5
no dre P=1.





















liv: hpa, hpc, nnd.
S
bra:gln; col:adc,adp; for:sqc,sqp; mgl:fba; ski:bct,sea,sec;





























259 1938m 2.83mg n.s.s. 0/9
a 1938m 5.56mg n.s.s. 0/9
260 1938n 15.3mg n.s.s. 0/11
N-HEXYLNITROSOUREA 18774-85-1
261 1915 .226mg 2.72mg 2/12
a 1915 .361mg 2.59mg 0/12
b 1915 .644mg 13.9mg 0/12
c 1915 .677mg n.s.s. 1/12
d 1915 3.36mg n.s.s. 0/12
262 1915 n.s.s. .460mg 0/12
a 1915 n.s.s. .460mg 0/12
b 1915 .308mg 2.60mg 0/12
c 1915 .681mg n.s.s. 0/12
d 1915 1.38mg n.s.s. 1/12
























263 1960 12.Omg n.s.s. 21/50
a 1960 17.1mg n.s.s. 27/50
264 1960 20.7mg n.s.s. 17/50
a 1960 28.3mg n.s.s. 26/50
.400mg 18/50 2.00mg 21/50 10.Omg 23/50
.400mg 37/50 2.00mg 27/50 10.Omg 27/50
.333mg 26/50 1.67mg 22/50 8.33mg 17/50
.333mg 24/50 1.67mg 22/50 8.33mg 16/50
Steinhoff;expl, 39, 1-9; 1990




























































































































































































































































































































































































49Spe Strain Site Xpo+Xpt




265 M f c56 wat duo car 23m23 ej
a M f c56 wat duo ade 23m23 ej
b M f c56 wat duo mix 23m23 ej
c M f c56 wat liv tum 23m23 ej
266 M m c56 wat duo mix 23m23 ej
a M m c56 wat duo ade 23m23 ej
b M m c56 wat duo car 23m23 ej
c M m c56 wat liv hem 23m23 ej
HYDROQUINONE***
267 M f b6c eat liv hpa 96w96 e
a M f b6c eat kid ade 96w96 e
b M f b6c eat liv hpc 96w96 e
268 M m b6c eat liv hpa 96w96 e
a M m b6c eat kid ade 96w96 e
b M m b6c eat liv hpc 96w96 e
269 R f f3d eat liv hpc 24m24 e
a R ff3d eat liv hnd 24m24 e
b R f f3d eat kid ade 24m24 e
270 R m f3d eat kid ade 24m24 e
a R m f3d eat liv hnd 24m24 e
b R m f3d eat liv hpc 24m24 e
1-HYDROXYANTHRAQUINONE
271 R m ain eat lgi mix 68w68 e
a R m ain eat col ade 68w68 e
b R m ain eat liv nnd 68w68 e
c R m ain eat liv mix 68w68 e
d R m ain eat col adc 68w68 e
e R m ain eat cec ade 68w68 e
f R m ain eat cec adc 68w68 e
g R m ain eat sto mix 68w68 e
h R m ain eat liv hpc 68w68 e
i R m ain eat for pam 68w68 e
j R m ain eat stg ade 68w68 e
Ong..*. ..ug...:.-10 ....:..100 ...1: * -mg .... -10 ..... -100 ....: * -g :*.10

































1-(2-HYDROXYETHYL)-NITROSO-3-CHLOROETHYLUREA .... 10..lo..... : 1000.. :._mg. 10. :100 .. :Ig. :10
272 R f f34 wat ute tum 7m24 e _ .669mg
a R f f34 wat liv tum 7m24 e 1.19mg



























1-(2-HYDROXYETHYL)-NITROSO-3-ETHYLUREA .. -lug .... -10 ..... -100 ....:.._mg....:.-10*..... -100 .... -lg ....:..10
274 R f f34 wat mam car 7m24 e + .501mg * P<.0005+
a R f f34 wat liv tum 7m24 e no dre P=l.
275 R m f34 wat lun tum 7m24 e . + . .446mg * P<.0005
a R m f34 wat tnv mso 7m24 e .576mg * P<.002
b R m f34 wat ski tum 7m24 e .641mg * P<.002 +
c R m f34 wat ner tum 7m24 e .754mg * P<.003
d R m f34 wat liv tum 7m24 e 1.09mg * P<.02
1-2-HYDROXYETHYL)-l--NITROSOUREA*g.* *-:* g.... :*10 . -:*100.... -:...mg.... :.lg.. 1
276 M f swi wat --- lym 5Ow5l e . (+) . .603mg
a M f swi wat lun ade 50w5l e 1.97mg
b M f swi wat tba tum 50w5l e noTD50
277 M m swi wat lun ade 5Ow5l e . (+) .382mg
a M m swi wat --- lym 5Ow51 e 1.27mg
b M m swi wat tba tum 5Ow5l e .353mg
1-(2-HYDROXYPROPYL)-NITROSO-3-CHLOROETHYLUREA .......10. :100 .. mg.. :10. :100 :... .... :*10
278 R f f34 wat liv tum 7m24 e .> nc
279 R m f34 wat liv tum 7m24 e .> nc
1-(3-HYDROXYPROPYL)-l-NITROSOUREA lbOng....:lug. 10. :100.. :.mg. 10. :100 .... :... .... :*10
280 R f f34 gav for tum 7m24 _ 1.
a R f f34 gav liv tum 7m24 1.
b R f f34 gav lun mix 7m24 no
281 R f f34 gav liv tum 9m24 .> nc
282 R m f34 gav ski mix 7m24 + ..6
a R m f34 gav stg tum 7m24 .8
b R m f34 gav for tum 7m24 1.
c R m f34 gav lun mix 7m24 1.
d R m f34 gav liv tum 7m24 3.
283 R m f34 gav for tum 9m24 + .8


































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
HYDROGEN PEROXIDE*** 7722-84-1
265 1381m 2.60gm 151.gm 0/50
a 1381m 561.mg n.s.s. 1/50
b 1381m 2.02gm n.s.s. 1/50
c 1381m 1.52gm n.s.s. 0/50
266 1381m 1.75gm n.s.s. 0/48
a 1381m 2.25gm n.s.s. 0/48
b 1381m 3.23gm n.s.s. 0/48
c 1381m 4.80gm n.s.s. 0/48
200.mg 0/50 800.mg 4/49
200.mg 4/50 (800.mg 0/49)
200.mg 4/50 800.mg 4/49
200.mg 0/50 800.mg 0/49
167.mg 3/51 667.mg 3/50
167.mg 2/51 667.mg 2/50
167.mg 1/51 667.mg 1/50
167.mg 1/51 667.mg 0/50
Ito;gann,72,174-175;1981/1981a/pers.comm.
HYDROQUINONE* 123-31-9
267 1929 2.92gm n.s.s.
a 1929 5.48gm n.s.s.
b 1929 5.48gm n.s.s.
268 1929 572.mg n.s.s.
a 1929 1.61gm n.s.s.
b 1929 1.69gm n.s.s.
269 1929 1.32gm n.s.s.
a 1929 1.20gm n.s.s.
b 1929 2.47gm n.s.s.
270 1929 185.mg 766.mg
a 1929 1.32gm n.s.s.














271 1937 32.9mg 112.mg 0/30
a 1937 112.mg 517.mg 0/30
b 1937 112.mg 517.mg 0/30
c 1937 112.mg 517.mg 0/30
d 1937 122.mg 605.mg 0/30
e 1937 134.mg 726.mg 0/30
f 1937 235.mg 7.54gm 0/30
g 1937 235.mg 7.54gm 0/30
h 1937 272.mg n.s.s. 0/30
i 1937 272.mg n.s.s. 0/30
























1- (2-HYDROXYETHYL) -NITROSO-3-CHLOROETHYLUREA --
272 2010 .214mg n.s.s. 2/12 .499mg 6/12
a 2010 .357mg n.s.s. 0/12 .499mg 3/12
273 2010 .201mg n.s.s. 0/12 .349mg 4/12
1- (2-HYDROXYETHYL) -NITROSO-3-ETHYLUREA --
274 2010 .261mg 1.22mg 0/12 .443mg 6/12
a 2010 .730mg n.s.s. 0/12 .443mg 0/12
275 2010 .224mg 1.28mg 0/12 .310mg 5/12
a 2010 .276mg 2.22mg 0/12 .310mg 4/12
b 2010 .297mg 2.13mg 0/12 .310mg 2/12
c 2010 .337mg 3.30mg 0/12 .310mg 2/12








1- (2-HYDROXYETHYL) -1-NITROSOUREA** (N-nitroso-2-hydroxethylurea) 13743-07-2
276 1967 .327mg 1.28mg 1/15 4.29mg 11/14 8.57mg 13/15
a 1967 1.00mg 6.03mg 0/15 4.29mg 5/14 8.57mg 7/15
b 1967 n.s.s. .453mg 2/15 4.29mg 14/14 8.57mg 15/15
277 1967 .173mg .988mg 0/12 3.57mg 11/14 (7.14mg 6/15)
a 1967 .671mg 3.06mg 0/12 3.57mg 4/14 7.14mg 10/15
b 1967 .170mg .832mg 2/12 3.57mg 11/14 7.14mg 15/15
1- (2-HYDROXYPROPYL) -NITROSO-3 -CHLOROETHYLUREA --
278 2010 1.32mg n.s.s. 0/12 .535mg 0/12
279 2010 .926mg n.s.s. 0/12 .374mg 0/12
1- (3-HYDROXYPROPYL) -1-NITROSOUREA
280 1915m .433mg n.s.s. 0/12
a 1915m .433mg n.s.s. 0/12
b 1915m 1.86mg n.s.s. 1/12
281 1915n 1.29mg n.s.s. 0/12
282 1915m .249mg 5.36mg 0/12
a 1915m .303mg n.s.s. 0/12
b 1915m .484mg n.s.s. 0/12
c 1915m .405mg n.s.s. 1/12
d 1915m .531mg n.s.s. 1/12
283 1915n .260mg n.s.s. 0/12













Shibata;gann, 82, 1211-1219; 1991
Mori;carc, 11,799-802;1990
Lijinsky;vivo, 4,1-6; 1990
Lij insky;vivo, 4,1-6; 1990
Mirvish;clet, 54, 101-106;1990/pers.comm.
Lij insky;vivo, 4,1-6; 1990
Lij insky; txih, 5,925-935;1989
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284 M f b6c gav MXB MXB 24m24
a M f b6c gav pta adn 24m24
b M f b6c gav hag MXA 24m24
c M f b6c gav liv MXA 24m24
d M f b6c gav liv hpa 24m24
e M f b6c gav for sqp 24m24
f M f b6c gav TBA MXB 24m24
g M f b6c gav liv MXB 24m24
h M f b6c gav lun MXB 24m24
285 M m b6c gav TBA MXB 24m24
a M m b6c gav liv MXB 24m24
b M m b6c gav lun MXB 24m24
286 R f f34 gav TBA MXB 24m24
a R f f34 gav liv MXB 24m24
287 R m f34 gav tes ict 24m24
a R m f34 gav MXB MXB 24m24
b R m f34 gav mul mnl 24m24
c R m f34 gav thy fcc 24m24
d R m f34 gav nas adn 24m24
e R m f34 gav TBA MXB 24m24
f R m f34 gav liv MXB 24m24
IQ***
288 P b cym gav liv hpc 8y8 u
a P b cym gav tba mal 8y8 u
289 R f f3d eat zym sqc 72w72 j
a R f f3d eat cli sqc 72w72 j
b R f f3d eat liv hpc 72w72 j
c R f f3d eat lgi adc 72w72 j
d R f f3d eat ski sqc 72w72 j
e R f f3d eat smi adc 72w72 j
f R f f3d eat orc sqc 72w72 j
290 R m f3d eat zym sqc 55w55 j
a R m f3d eat liv hpc 55w55 j
b R m f3d eat lgi adc 55w55 j
c R m f3d eat ski sqc 55w55 j
d R m f3d eat smi adc 55w55 j
e R m f3d eat orc sqc 55w55 j
ISOMALT
291 M f scp eat lun act 24m24 e
a M f scp eat liv tum 24m24 e
b M f scp eat tba tum 24m24 e
292 M m scp eat lun act 94w94 e
a M m scp eat liv nnd 94w94 e
b M m scp eat liv hpc 94w94 e
c M m scp eat tba tum 94w94 e
LEAD ACETATE***
293 R f f34 eat kid mal 24m24 e
a R f f34 eat liv hpc 24m24 e
294 R m f34 eat kid mal 24m24 e
a R m f34 eat liv hpc 24m24 e
D-LIMONENE
295 M f b6c gav liv hpc 24m24
a M f b6c gav TBA MXB 24m24
b M f b6c gav liv MXB 24m24
c M f b6c gav lun MXB 24m24
296 M m b6c gav TBA MXB 24m24
a M m b6c gav liv MXB 24m24
b M m b6c gav lun MXB 24m24
297 R f f34 gav ute esp 24m24
a R f f34 gav TBA MXB 24m24
b R f f34 gav liv MXB 24m24
298 R m f34 gav kid MXA 24m24
a R m f34 gav kid tla 24m24
b R m f34 gav kid uac 24m24
c R m f34 gav TBA MXB 24m24
d R m f34 gav liv MXB 24m24
MAGNESIUM CHLORIDE HEXAHYDRATE
299 M f b6c eat liv hes 22m24 e
a M f b6c eat liv hnd 22m24 e
b M f b6c eat lun ade 22m24 e
c M f b6c eat lun adc 22m24 e
d M f b6c eat liv hpc 22m24 e
e M f b6c eat liv hem 22m24 e
f M f b6c eat --- lkm 22m24 e
































































































: > no dre P=l.
no dre P=l.
no dre P=l.
+ #533.mg \ P<.009
1.33gm * P<.6
no dre P=1.
















RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
IODINATED GLYCEROL (Organidin) 5634-39-9
284 c55469 47.4mg 806.mg 15/50 43.4mg
a c55469 67.Omg n.s.s. 10/50 43.4mg
b c55469 107.mg n.s.s. 6/50 43.4mg
c c55469 175.mg n.s.s. 0/50 43.4mg
d c55469 203.mg n.s.s. 0/50 43.4mg
e c55469 218.mg n.s.s. 1/50 43.4mg
f c55469 50.Omg n.s.s. 37/50 43.4mg
g c55469 175.mg n.s.s. 0/50 43.4mg
h c55469 315.mg n.s.s. 4/50 43.4mg
285 c55469 184.mg n.s.s. 33/50 87.6mg
a c55469 273.mg n.s.s. 10/50 87.6mg
b c55469 341.mg n.s.s. 9/50 87.6mg
286 c55469 41.1mg n.s.s. 44/50 43.9mg
a c55469 406.mg n.s.s. 0/50 43.9mg
287 c55469 23.1mg 110.mg 46/50 88.4mg
a c55469 47.3mg 223.mg 14/50 88.4mg
b c55469 55.2mg 303.mg 14/50 88.4mg
c c55469 111.mg 2.52gm 0/50 88.4mg
d c55469 259.mg n.s.s. 0/50 88.4mg
e c55469 27.5mg 198.mg 45/50 88.4mg










































































































































Ohgaki; enhp, 67,129-134; 1986/1991
ISOMALT 64519-82-0
291 1979 22.5gm n.s.s.
a 1979 16.9gm n.s.s.
b 1979 11.8gm n.s.s.
292 1979 8.30gm n.s.s.
a 1979 48.6gm n.s.s.
b 1979 90.4gm n.s.s.




















































293 1947 598.mg 6.55gm
a 1947 92.4mg n.s.s.
294 1947 80.1mg 222.mg















295 c55572 3.18gm n.s.s.
a c55572 532.mg n.s.s.
b c55572 1.84gm n.s.s.
c c55572 4.74gm n.s.s.
296 c55572 134.mg n.s.s.
a c55572 862.mg n.s.s.
b c55572 1.01gm n.s.s.
297 c55572 240.mg 14.6gm
a c55572 224.mg n.s.s.
b c55572 4.07gm n.s.s.
298 c55572 119.mg 644.mg
a c55572 167.mg 1.90gm
b c55572 257.mg n.s.s.
c c55572 102.mg n.s.s.































MAGNESIUM CHLORIDE HEXAHYDRATE 7791-18-6
299 1945 12.5gm n.s.s. 0/49 600.mg
a 1945 7.51gm n.s.s. 1/50 600.mg
b 1945 16.3gm n.s.s. 0/49 600.mg
c 1945 9.45gm n.s.s. 0/49 600.mg
d 1945 18.6gm n.s.s. 0/49 600.mg
e 1945 15.8gm n.s.s. 1/49 600.mg
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Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
300 M m b6c eat --- lkm 22m24 e
a M m b6c eat liv hes 22m24 e
b M m b6c eat liv hem 22m24 e
c M m b6c eat lun ade 22m24 e
d M m b6c eat liv hpc 22m24 e
e M m b6c eat lun adc 22m24 e
f M m b6c eat liv hnd 22m24 e
MeIQx* * * 1
301 M f cdf eat liv mix 84w84 ej
a M f cdf eat liv hpa 84w84 ej
b M f cdf eat liv hpc 84w84 ej
c M f cdf eat lun mix 84w84 ej
d M f cdf eat lun ade 84w84 ej
e M f cdf eat lun adc 84w84 ej
f M f cdf eat --- lkm 84w84 ej
302 M m cdf eat liv hpa 84w84 ej
a M m cdf eat liv hpc 84w84 ej
b M m cdf eat --- lkm 84w84 ej
c M m cdf eat liv mix 84w84 ej
d M m cdf eat lun mix 84w84 ej
e M m cdf eat lun adc 84w84 ej
f M m cdf eat lun ade 84w84 ej
6-MERCAPTOPURINE*** 1
303 R f f3d eat adr phe 24m26
a R f f3d eat cns mix 24m26
b R f f3d eat ute adc 24m26
c R f f3d eat liv hpc 24m26
d R f f3d eat liv hpa 24m26
e R ff3d eat tba mix 24m26
f R f f3d eat tba mal 24m26
304 R m f3d eat liv hpa 24m26
a R m f3d eat tba mix 24m26
b R m f3d eat tba mal 24m26
MERCURIC CHLORIDE***
305 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
306 M m b6c gav kid MXA 24m24
a M m b6c gav kid rua 24m24
b M m b6c gav kid uac 24m24
c M m b6c gav TBA MXB 24m24
d M m b6c gav liv MXB 24m24
e M m b6c gav lun MXB 24m24
307 R f f34 gav for sqp 24m24
a R ff34 gav TBA MXB 24m24
b R ff34 gav liv MXB 24m24
308 R m f34 gav tes MXA 24m24
a R m f34 gav amd MXA 24m24
b R m f34 gav amd MXA 24m24
c R m f34 gav for sqp 24m24
d R m f34 gav thy MXA 24m24
e R m f34 gav thy fcc 24m24
f R m f34 gav thy fca 24m24
g R m f34 gav TBA MXB 24m.24
h R m f34 gav liv MXB 24m24
MERCURYMETHYL CHLORIDE*** 1
309 M f b6c eat kid rca 24m24 er
310 M m b6c eat kid mix 24m24 ers
a M m b6c eat kid rcc 24m24 ers
b M m b6c eat kid rca 24m24 ers
311 M f icm eat lun adc 80w80 e
a M ficm eat liv hem 80w80 e
b M f icm eat kid ade 80w80 e
c M f icm eat liv hpa 80w80 e
d M f icm eat liv hpc 80w80 e
e M ficm eat lun ade 80w80 e
312 M m icm eat kid mix 80w80 e
a M m icm eat kid adc 80w80 e
b M m icm eat lun adc 80w80 e
c M m icm eat kid ade 80w80 e
d M m icm eat liv hpa 80w80 e
e M m icm eat liv hpc 80w80 e
f M m icm eat liv hpb 80w80 e
g M m icm eat lun ade 80w80 e
10.7gm * P<.1
























































L00ng.. lug....:.-10... :.-100 .... :.;Lmg.. :.-10 .... :.-100 .... :*lg.... : 10
















5.25mg * P<.006 e
7.32mg * P<.005 e
5.98mg \ P<.05 e
1.04mg P<.002
10.3mg P<.02


















































301 1820m 7.95mg 25.6mg 0/39 78.Omg 32/35
a 1820m 7.95mg 25.6mg 0/39 78.Omg 32/35
b 1820m 16.6mg 50.3mg 0/39 78.Omg 25/35
c 1820m 37.2mg 370.mg 4/39 78.Omg 15/35
d 1820m 59.2mg n.s.s. 2/39 78.Omg 9/35
e 1820m 83.2mg n.s.s. 2/39 78.0mg 6/35
f 1820m 83.2mg n.s.s. 11/39 78.Omg 10/35
302 1820m 38.8mg 10.9gm 5/36 72.Omg 15/37
a 1820m 49.6mg 273.mg 0/36 72.Omg 10/37
b 1820m 48.9mg 1.23gm 2/36 72.0mg 11/37
c 1820m 37.Omg n.s.s. 6/36 72.Omg 16/37
d 1820m 42.9mg n.s.s. 10/36 72.Omg 16/37
e 1820m 60.9mg n.s.s. 7/36 72.Omg 11/37
f 1820m 77.2mg n.s.s. 3/36 72.0mg 7/37
6-MERCAPTOPURINE*** 50-44-2
303 1980 9.17mg n.s.s. 0/50
a 1980 11.8mg n.s.s. 0/50
b 1980 11.8mg n.s.s. 0/50
c 1980 22.6mg n.s.s. 0/50
d 1980 9.33mg n.s.s. 1/50
e 1980 1.27mg n.s.s. 39/50
f 1980 3.31mg n.s.s. 14/50
304 1980 20.6mg n.s.s. 3/50
a 1980 .616mg n.s.s. 50/50
b 1980 4.44mg n.s.s. 20/50
MERCURIC CHLORIDE*** 7487-94-7
305 c60173 2.18mg n.s.s. 23/50
a c60173 33.4mg n.s.s. 3/50
b c60173 12.4mg n.s.s. 3/50
306 c60173 24.7mg n.s.s. 0/50
a c60173 30.7mg n.s.s. 0/50
b c60173 39.Omg n.s.s. 0/50
c c60173 12.2mg n.s.s. 28/50
d c60173 18.5mg n.s.s. 7/50
e c60173 18.4mg n.s.s. 10/50
307 c60173 12.7mg n.s.s. 0/50
a c60173 2.12mg n.s.s. 46/50
b c60173 17.2mg n.s.s. 0/50
308 c60173 .437mg 2.88mg 45/50
a c60173 .770mg 6.42mg 21/50
b c60173 .767mg 8.98mg 24/50
c c60173 1.48mg 7.20mg 0/50
d c60173 2.14mg 68.4mg 2/50
e c60173 2.71mg 71.8mg 1/50
f c60173 1.65mg n.s.s. 1/50
g c60173 .521mg 4.77mg 45/50









































































































liv: hpa, hpc, nnd.









































































0/60 .260mg 0/60 1.30mg 1/60
0/60 .240mg 1/60 1.20mg 16/60
0/60 .240mg 0/60 1.20mg 13/60















Mitsumori; faat, 14, 179-190;1990
Hirano;jjvs, 50, 886-893;1988
Volume 103, Supplement8, November 1995
300 1945 3.73gm n.s.s. 5/50
a 1945 11.5gm n.s.s. 0/50
b 1945 6.05gm n.s.s. 2/50
c 1945 9.95gm n.s.s. 1/49
d 1945 2.72gm n.s.s. 13/50
e 1945 11.5gm n.s.s. 2/49
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313 M m cen eat liv hpc 52w52 r
a M m cen eat liv mix 52w52 r
b M m cen eat liv hpa 52w52 r
c M m cen eat lun mix 52w52 r
4-METHOXYPHENOL
314 R m f3d eat for pam 51w52
a R m f3d eat stg tum 51w52
315 R m f3d eat for tum 51w52 er
a R m f3d eat stg tum 51w52 er
METHYL BROMIDE
316 M f b6c inh TBA MXB 17m24 as
a M f b6c inh liv MXB 17m24 as
b M f b6c inh lun MXB 17m24 as
317 M m b6c inh TBA MXB 17m24 as
a M m b6c inh liv MXB 17m24 as
b M m b6c inh lun MXB 17m24 as
318 R f wsr inh liv nnd 30m30 e
a R f wsr inh liv clc 30m30 e
b R f wsr inh nof tum 3Om30 e
c R f wsr inh nre tum 3Om30 e
d R f wsr inh tba mal 3Om30 e
e R f wsr inh tba tum 3Om30 e
319 R m wsr inh nof tum 30m30 e
a R m wsr inh pit het 30m30 e
b R m wsr inh nre fbs 3Om30 e
c R m wsr inh nre ost 3Om30 e
d R m wsr inh liv hpc 30m30 e
e R m wsr inh liv nnd 30m30 e
f R m wsr inh liv clc 30m30 e
g R m wsr inh nre sqc 3Om30 e
h R m wsr inh tba tum 3Om30 e
i R m wsr inh tba mal 3Om30 e

































3'-METHYL-4-DIMETHYLAMINOAZOBENZENE*** .....: 10 :.-100 :._mg :..10 :.-100 :*lg 0.10
320 P b rhe eat liv hpc 5y24 w : 67.1mg P<.06
a P b rhe eat --- hem 5y24 w
b P b rhe eat tba mix 5y24 w
c P b rhe eat tba mal 5y24 w










321 M f b6c eat liv hpc 22m24 e
a M f b6c eat liv hnd 22m24 e
b M f b6c eat liv hes 22m24 e
c M f b6c eat liv hem 22m24 e
d M f b6c eat lun ade 22m24 e
322 M m b6c eat liv hpc 22m24 e
a M m b6c eat liv hnd 22m24 e
b M m b6c eat liv hem 22m24 e
c M m b6c eat lun adc 22m24 e
d M m b6c eat lun ade 22m24 e











N-METHYL-N' -NITRO-N-NITROSOGUANIDINE***..: .-lug ... 10. -1*....:..100 ....1:. - mg ...:.-10 ....:0. 1° .... - lg ....:.. 10
323 P b rhe eat liv hpa 23y23 Ww : 3.03mg P<.06
a P b rhe eat tba ben 23y23 Ww
b P b rhe eat tba mal 23y23 Ww
c P b rhe eat tba mix 23y23 Ww
324 R f f34 eat sto car 24m24 es
a R f f34 eat liv hpc 24m24 es
325 R m f34 eat sto car 24m24 es
a R m f34 eat liv hpc 24m24 es
alpha-METHYLBENZYL ALCOHOL
326 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
327 M m b6c gav TBA MXB 24m24
a M m b6c gav liv MXB 24m24
b M m b6c gav lun MXB 24m24
328 R f f34 gav pni isa 24m24 s
a R f f34 gav TBA MXB 24m24 s
b R f f34 gav liv MXB 24m24 s
329 R m f34 gav tes ict 24m24 s
a R m f34 gav amd MXA 24m24 s



































































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
DL-METHIONINE*** 59-51-8
313 1992 1.10gm n.s.s. 0/30
a 1992 625.mg n.s.s. 2/30
b 1992 854.mg n.s.s. 2/30





Fullerton;carc, 11, 1301-1305; 1990
4-METHOXYPHENOL 150-76-5
314 1950 238.mg n.s.s.
a 1950 455.mg n.s.s.
315 1990 29.6mg n.s.s.
a 1990 29.6mg n.s.s.
0/10 588.mg 1/15
0/10 588.mg 0/15
0/10 98.1mg 0/11 196.mg
0/10 98.1mg 0/11 196.mg
Hirose;canr,48, 5310-5315;1988
0/11 392.mg 0/11 785.mg 0/11
0/11 392.mg 0/11 785.mg 0/11
Wada;carc, 11, 1891-1894;1990
METHYL BROMIDE 74-83-9
316 c04148 65.4mg n.s.s.
a c04148 149.mg n.s.s.
b c04148 202.mg n.s.s.
317 c04148 27.7mg n.s.s.
a c04148 45.Omg n.s.s.
b c04148 60.1mg n.s.s.
318 2017 365.mg n.s.s.
a 2017 611.mg n.s.s.
b 2017 14.2mg n.s.s.
c 2017 14.2mg n.s.s.
d 2017 141.mg n.s.s.
e 2017 56.5mg n.s.s.
319 2017 8.08mg n.s.s.
a 2017 19.8mg n.s.s.
b 2017 205.mg n.s.s.
c 2017 341.mg n.s.s.
d 2017 346.mg n.s.s.
e 2017 346.mg n.s.s.
f 2017 346.mg n.s.s.
g 2017 353.mg n.s.s.
h 2017 .807mg n.s.s.




























































































Reuzel; fctx, 29,31-39; 1991/pers. comm.
3 -N
320 2001 10.9mg n.s.s.
a 2001 3.35mg n.s.s.
b 2001 7.82mg n.s.s.
c 2001 14.8mg n.s.s.







321 1987 29.5gm n.s.s. 1/50
a 1987 28.8gm n.s.s. 3/50
b 1987 45.7gm n.s.s. 1/50
c 1987 65.1gm n.s.s. 2/50
d 1987 45.5gm n.s.s. 3/50
322 1987 10.8gm n.s.s. 10/50
a 1987 9.74gm n.s.s. 17/50
b 1987 32.1gm n.s.s. 3/50
c 1987 45.2gm n.s.s. 5/50







































N-METHYL-N' -NITRO-N-NITROSOGUANIDINE*** (MENG) 70-25-7
323 2001 .493mg n.s.s. 0/23 .964mg 1/4
a 2001 .880mg n.s.s. 7/110 .964mg
b 2001 1.97mg n.s.s. 5/76 .964mg
c 2001 1.14mg n.s.s. 11/110 .964mg
324 1954 .961mg 2.25mg 1/119 1.00mg
a 1954 7.25mg 64.3mg 0/120 1.00mg
325 1954 .486mg 1.11mg 0/119 .800mg








Kurata; fctx, 28,613-618; 1990
Adamson;ossc, 129-156;
1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
2.00mg 16/24 4.00mg 20/24
2.00mg 3/24 4.00mg 3/24
1.60mg 18/23 3.20mg 22/24
1.60mg 0/23 3.20mg 0/24
Fears; txih, 4,221-255; 1988
alpha-METHYLBENZYL ALCOHOL 98-85-1
326 c55685 870.mg n.s.s. 33/50 265.mg 23/50
a c55685 4.97gm n.s.s. 2/50 265.mg 1/50
b c55685 2.76gm n.s.s. 7/50 265.mg 1/50
327 c55685 321.mg n.s.s. 39/50 265.mg 40/50
a c55685 711.mg n.s.s. 20/50 265.mg 22/50
b c55685 1.07gm n.s.s. 17/50 265.mg 14/50
328 c55685 791.mg 60.5gm 0/50 265.mg 1/50
a c55685 190.mg n.s.s. 46/50 265.mg 40/50
b c55685 1.41gm n.s.s. 0/50 265.mg 1/50
329 c55685 31.1mg 98.Omg 46/50 265.mg 36/50
a c55685 62.4mg 508.mg 16/50 265.mg 20/50
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Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
c R m f34 gav kid tla 24m24 s
d R m f34 gav lun MXA 24m24 s
e R m f34 gav pre can 24m24 s
f R m f34 gav TBA MXB 24m24 s
g R m f34 gav liv MXB 24m24 s
330 R m f34 gav kid uac 24m24 with step
3-METHYLBUTANAL METHYLFORMYLHYDRAZONE
331 M f swa gav lun mix 12m30 e
a M f swa gav lun ade 12m30 e
b M f swa gav liv mix 12m30 e
c M f swa gav lun adc 12m3O e
d M f swa gav liv hpt 12m30 e
e M f swa gav gal mix 12m30 e
f M f swa gav gal ade 12m30 e
g M f swa gav liv hpc 12m30 e
h M f swa gav gal adc 12m30 e
332 M m swa gav lun mix 12m28 e
a M m swa gav lun ade 12m28 e
b M m swa gav pre mix 12m28 e
c M m swa gav pre sqc 12m28 e
d M m swa gav liv mix 12m28 e
e M m swa gav liv hpt 12m28 e
f M m swa gav lun adc 12m28 e
g M m swa gav liv hpc 12m28 e
h M m swa gav pre sqp 12m28 e
i M m swa gav gal ade 12m28 e
3-METHYLCHOLANTHRENE*** 100n
333 P b cym eat tba mal 5y27 w
334 P b rhe eat tba mal 5y26 w
METHYLHYDROQUINONE
335 R m f3d eat for tum 51w52
a R m f3d eat stg tum 51w52
METHYLNITRAMINE
336 R f bdf gav spd nim 27m30 a
a R f bdf gav spn nim 27m30 a
b R fbdf gav pnr nim 27m30 a
337 R m bdf gav spd nim 26m29 a
a R mbdf gav spn nim 26m29 a
b R m bdf gav pnr nim 26m29 a
MIREX***
338 R f f34 eat MXA mnl 24m25
a R f f34 eat TBA MXB 24m25
b R f f34 eat liv MXB 24m25
339 R f f34 eat liv MXA 24m24
a R f f34 eat liv nnd 24m24
b R f f34 eat MXB MXB 24m24
c R f f34 eat MXA mnl 24m24
d R f f34 eat TBA MXB 24m24
e R f f34 eat liv MXB 24m24
340 R m f34 eat MXB MXB 24m24
a R m f34 eat tes ict 24m24
b R m f34 eat liv MXA 24m24
c R m f34 eat liv nnd 24m24
d R m f34 eat adr MXA 24m24
e R m f34 eat liv hpc 24m24
f R m f34 eat thy MXA 24m24
g R m f34 eat thy fca 24m24
h R m f34 eat k/p tpp 24m24
i R m f34 eat TBA MXB 24m24
j R m f34 eat liv MXB 24m24
MONOCHLOROACETIC ACID***
344 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
345 M m b6c gav TBA MXB 24m24
a M m b6c gav liv MXB 24m24
b M m b6c gav lun MXB 24m24
346 R f f34 gav ute esp 24m24
a R f f34 gav ute MXA 24m24
b R f f34 gav TBA MXB 24m24














































.g lug.. 10 : .1° .... :.-100....1 :._mg :..10 . *100 .. .:_g.... : 10
> ...............no dre P=l.
> ................ no dre P=l.
00ng..:. lug.:10 ... 100. mg.... 10 . :100 .. :_mg . :..10
> no dre P=l.
no dre P=l.













0Ong.. :.lug. :..10. :--100 .... 1 :.-lmg. .10..... :.10 . ... :. - 10 ::.10

















13.5mg * P<.002 c
.618mg * P<.0005
.825mg * P<.0005
0O0ng . lug.. : *10. : .100.* :1*mg ... :.*10 . :.. *100. : *.lg.- : .10
> no dre P=l. -
2.05gm * P<.7
640.mg * P<.2
:> 159.mg * P<.3 -
no dre P=1.
no dre P=1.







RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
c c55685 176.mg 2.50gm 0/50
d c55685 243.mg n.s.s. 1/50
e c55685 276.mg n.s.s. 0/50
f c55685 46.3mg 249.mg 43/50
g c55685 456.mg n.s.s. 2/50








331 1966 1.19mg 3.85mg
a 1966 1.48mg 4.33mg
b 1966 4.39mg 16.3mg
c 1966 4.26mg 54.6mg
d 1966 4.98mg 20.2mg
e 1966 11.0mg 559.mg
f 1966 12.6mg n.s.s.
g 1966 18.4mg n.s.s.
h 1966 24.6mg n.s.s.
332 1966 1.48mg 5.47mg
a 1966 1.88mg 8.11mg
b 1966 2.66mg 7.83mg
c 1966 3.28mg 10.6mg
d 1966 3.46mg 11.6mg
e 1966 4.37mg 17.Omg
f 1966 5.10mg 69.2mg
g 1966 11.8mg n.s.s.
h 1966 11.8mg n.s.s.

















































































333 2001 9.28mg n.s.s. 2/10 8.37mg 0/3
334 2001 8.96mg n.s.s. 5/76 10.7mg 0/7
METHYLHYDROQUINONE 95-71-6
335 1950 455.mg n.s.s. 0/10 588.mg 0/15
a 1950 455.mg n.s.s. 0/10 588.mg 0/15
METHYLNITRAMINE (N-nitromethylamine) 598-57-2
336 1931 10.8mg 271.mg 0/10 5.43mg 0/10
a 1931 13.7mg n.s.s. 0/10 5.43mg 3/10
b 1931 27.9mg n.s.s. 0/10 5.43mg 1/10
337 1931 5.72mg 39.8mg 0/10 5.43mg 2/10
a 1931 6.31mg 265.mg 0/10 5.43mg 5/10





































a c06428 .392mg 2.25mg
b c06428 .545mg 1.39mg
c c06428 .574mg 1.47mg
d c06428 .840mg 3.18mg
e c06428 2.70mg 356.mg
f c06428 3.67mg 100.mg
g c06428 4.33mg 88.7mg
h c06428 4.58mg 72.4mg
i c06428 .374mg 1.39mg



















































11/52 .481mg 14/52 1.21mg 18/52 2.41mg 18/52 mul:mnl; spl:mnl.
49/52 .481mg 47/52 1.21mg 50/52 2.41mg 49/52
4/52 .481mg 5/52 1.21mg 10/52 2.41mg 9/52 liv:hpa,hpc,nnd.
31/52 liv:hpc,nnd.
30/52
















































344 c60231 49.7mg n.s.s. 41/60
a c60231 312.mg n.s.s. 1/60
b c60231 243.mg n.s.s. 0/60
345 c60231 46.4mg n.s.s. 31/60
a c60231 150.mg n.s.s. 12/60
b c60231 135.mg n.s.s. 12/60
346 c60231 21.4mg 193.mg 1/53
a c60231 22.5mg 816.mg 2/53
b c60231 10.4mg n.s.s. 50/53
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Brkly Code
59Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
347 R m f34 gav TBA MXB 24m24
a R m f34 gav liv MXB 24m24
MONOSODIUM SUCCINATE
348 R f f3d wat liv tum 24m26 e
a R f f3d wat tba tum 24m26 e
349 R m f3d wat liv hpc 24m26 e
a R m f3d wat liv hpa 24m26 e
b R m f3d wat tba tum 24m26 e
NAPHTHALENE
350 M f b6c inh lun MXA 24m24
a M f b6c inh lun a/a 24m24
b M f b6c inh lun a/c 24m24
c M fb6c inh TBA MXB 24m24
d M fb6c inh liv MXB 24m24
e M fb6c inh lun MXB 24m24
351 M m b6c inh TBA MXB 24m24
a M mb6c inh liv MXB 24m24
b M mb6c inh lun MXB 24m24
NITRILOTRIACETIC ACID***
352 R f f34 eat kur mal 24m24 e
a R f f34 eat liv hpc 24m24 e
353 R m f34 eat kur mal 24m24 es
a R m f34 eat liv hpc 24m24 es
NITRITE, SODIUM-**
354 M f cb6 wat lun tum 27m29 g
a M fcb6 wat liv mix 27m29 g
355 R m f34 eat tes ict 27m27 ef
a R m f34 eat --- mnl 27m27 ef
b R m f34 eat mix lym 27m27 ef
c R m f34 eat --- grl 27m27 ef
d R m f34 eat tba tum 27m27 ef
356 R m wis wat liv tum 24m24 r
357 R m wis wat liv hpc 94w94
a R m wis wat lun tum 94w94
b R m wis wat nas tum 94w94
p-NITROANILINE
358 M f b6c gav TBA MXB 24m24
a M fb6c gav liv MXB 24m24
b M fb6c gav lun MXB 24m24
359 M m b6c gav --- MXA 24m24
a M m b6c gav liv hes 24m24
b M m b6c gav TBA MXB 24m24
c M m b6c gav liv MXB 24m24
d M m b6c gav lun MXB 24m24
360 R f cdr gav liv nnd 24m24 e
a R f cdr gav liv hpc 24m24 e
b R f cdr gav tba mix 24m24 e
c R fcdr gav tba ben 24m24 e
d R fcdr gav tba mal 24m24 e
361 R m cdr gav liv hpc 24m24 e
a R m cdr gav liv nnd 24m24 e
b R m cdr gav tba mix 24m24 e
c R m cdr gav tba mal 24m24 e
d R m cdr gav tba ben 24m24 e
53.3mg * P<.7
623.mg * P<.7
O0ng..:,..lug....:..10 ..... -100 ....:.._mg....:.10.*....:. -100...: * -lg .... 10. -1°
























































O0ng..:. .lug....:..10 ....1. -100 ....:.._mg....:..10 ..... -100 ....: ig ....:..10
:> 487.mg * P<.8
no dre P=1.
2.37gm * P<.8
:i 374.mg * P<.l e











12.2mg * P<.08 -
41.6mg * P<.09 -
16.2mg * P<.2
1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN*** .ug........ . . ...10-100 : .-lmg.... : .-10 ..... :..-100 . ... :1.0g 10
362 M f b6c eat cvu lei 64w64 er .> 4.00gm * P<.3
a M f b6c eat ova gct 64w64 er 4.02gm * P<.5
363 M f cdl eat liv hem 22m23 e ± 4.46gm * P<.07
a M f cdl eat liv hes 22m23 e no dre P=1.
b M f cdl eat liv hpa 22m23 e no dre P=1.
c M f cdl eat lun ala 22m23 e no dre P=l.
d M f cdl eat lun alc 22m23 e no dre P=1.
364 M m cdl eat --- myl 22m23 e . i 588.mg * P<.02
a M m cdl eat lun ala 22m23 e 833.mg * P<.05
b M m cdl eat liv hpa 22m23 e 1.20gm * P<.2
c M m cdl eat lun alc 22m23 e 17.Ogm * P<.9
d M m cdl eat liv hes 22m23 e no dre P=1.
e M m cdl eat liv hpc 22m23 e no dre P=1.
365 R f cdr eat mgl mix 24m24 e .> no dre P=l.
a R f cdr eat tba tum 24m24 e no dre P=1.
b R f cdr eat tba mal 24m24 e no dre P=1.
366 R m cdr eat mgl fba 24m24 e .> 878.mg * P<.2




RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
347 c60231 8.54mg n.s.s. 49/53 10.7mg 45/53 21.3mg 34/53
a c60231 60.9mg n.s.s. 1/53 10.7mg 1/53 21.3mg 1/53
MONOSODIUM SUCCINATE 2922-54-5
348 1977 4.12gm n.s.s. 0/49
a 1977 655.mg n.s.s. 40/49
349 1977 8.91gm n.s.s. 0/50
a 1977 6.14gm n.s.s. 2/50
b 1977 n.s.s. n.s.s. 50/50
NAPHTHALENE 91-20-3
350 c52904 91.2mg 572.mg 5/70
a c52904 94.4mg 662.mg 5/70
b c52904 654.mg n.s.s. 0/70
c c52904 58.4mg n.s.s. 23/70
d c52904 457.mg n.s.s. 2/70
e c52904 91.2mg 572.mg 5/70
351 c52904 30.Omg n.s.s. 36/70
a c52904 182.mg n.s.s. 8/70
b c52904 116.mg n.s.s. 7/70
NITRILOTRIACETIC ACID*** 139-13-9
352 1954 1.08gm 10.6gm 1/120
a 1954 43.7mg n.s.s. 0/120
353 1954 610.mg 3.57gm 0/120
a 1954 33.6mg n.s.s. 1/120
NITRITE, SODIUM*** 7632-00-0
354 1925 788.mg n.s.s. 1/20
a 1925 1.33gm n.s.s. 3/20
355 1920 109.mg n.s.s. 16/20
a 1920 348.mg n.s.s. 9/18
b 1920 371.mg n.s.s. 15/20
c 1920 1.63gm n.s.s. 0/18
d 1920 389.mg n.s.s. 20/20
356 1910 216.mg n.s.s. 0/21
357 1914 168.mg n.s.s. 0/20
a 1914 168.mg n.s.s. 0/20



















































0/24 100.mg 0/24 1.00gm 6/24
0/24 100.mg 0/24 1.00gm 0/24
0/24 80.Omg 0/24 800.mg 9/24












Fears; txih, 4,221-255; 1988





358 c60786 57.7mg n.s.s.
a c60786 104.mg n.s.s.
b c60786 178.mg n.s.s.
359 c60786 126.mg n.s.s.
a c60786 171.mg n.s.s.
b c60786 135.mg n.s.s.
c c60786 28.9mg n.s.s.
d c60786 193.mg n.s.s.
360 1985 29.9mg n.s.s.
a 1985 115.mg n.s.s.
b 1985 2.90mg n.s.s.
c 1985 3.15mg n.s.s.
d 1985 13.6mg n.s.s.
361 1985 30.7mg n.s.s.
a 1985 49.9mg n.s.s.
b 1985 4.41mg n.s.s.
c 1985 14.6mg n.s.s.























































21.1mg 34/49 70.3mg 36/50
21.1mg 21/49 70.3mg 16/50
21.1mg 5/49 70.3mg 4/50
21.1mg 4/50 70.5mg 10/50
21.1mg 2/50 70.5mg 4/50
21.1mg 36/50 70.5mg 28/50
21.1mg 25/50 (70.5mg 13/50)
21.1mg 9/50 70.5mg 9/50
1.50mg 10/60 9.00mg 13/60
1.50mg 1/60 9.00mg 0/60
1.50mg 45/60 9.00mg 56/60
1.50mg 45/60 9.00mg 55/60
1.50mg 13/60 9.00mg 23/60
1.50mg 4/60 9.00mg 3/60
1.50mg 3/60 9.00mg 7/60
1.50mg 39/60 9.00mg 50/60
1.50mg 12/60 9.00mg 17/60






Nair; faat, 15, 607-621; 1990
1-[ (5-NITROFURFURYLIDENE)AMINO]HYDANTOIN*** (macrodantin, nitrofurantoin) 67-20-9
Stitzel; txpy, 17,774-781; 1989
Butler; fctx, 28,49-54; 1990
Butler; fctx, 28,269-277; 1990
















































































































































61Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
b R m cdr eat tba tum 24m24 e
367 R m f34 eat ubl tum 24m24 r
N-NITROSO-ETHYL-2-OXOPROPYLUREA
368 H f syg gav spl vsc 30w85 e
a H f syg gav for mix 30w85 e
b H f syg gav for car 30w85 e
c H f syg gav liv cho 30w85 e
369 H m syg gav for mix 30w85 e
a H m syg gav spl hes 30w85 e
b H m syg gav for car 30w85 e
c H m syg gav liv cho 30w85 e
N-NITROSO-ETHYLHYDROXYETHYLUREA
370 H f syg gav cvu tum 30w75 e
a H f syg gav for ben 30w75 e
b H f syg gav spl vsc 30w75 e
c H f syg gav liv cho 30w75 e
no dre P=1.
no dre P=1.


























N-NITROSO-2-HYDROXYMORPHOLINE 1OOng....:ug .... :.-10 ..... :.-100 .... : _mg :.-10 ..... : .-100 .... ..... :g10
371 R f f34 wat liv hpc 12m28 e .> 14.9mg * P<1.
N-NITROSO-N-METHYL-N-DODECYLAMINE*** ..: ..lug.... :.10. . . . . :.g-100 .... :1.0mg : .100 * :.- g* 10
372 R m f34 gav ubl tcc 28w66 er <+ noTD50
N-NITROSO-N-METHYLUREA*** 1Ong . -lug . - :* 10 ..... -100.... -:.*-mg...:.-10: *- ....:-100° ....:j.-g ..... -10
373 P b cym eat ugi sqc 18y22 jw + 4.52mg
a P b cym eat eso sqc 18y22 jw
b P b cym eat orc mix 18y22 jw
c P b cym eat sto adc 18y22 jw
d P b cym eat hea rhml 18y22 jw
e P b cym eat phr sqc 18y22 jw
f P b cym eat pls sqc 18y22 jw
g P b cym eat ton sqp 18y22 jw
h P b cym eat sku rhb 18y22 jw
i P b cym eat eso sqp 18y22 jw
j P b cym eat col lei 18y22 jw
k P b cym eat tba mix 18y22 jw
1 P b cym eat tba mal 18y22 jw
m P b cym eat tba ben 18y22 jw
374 P b rhe eat ugi sqc 18y22 jw
a P b rhe eat eso sqc 18y22 jw
b P b rhe eat orc mix 18y22 jw
c P b rhe eat phr sqc 18y22 jw
d P b rhe eat sto adc 18y22 jw
e P b rhe eat epg sqc 18y22 jw
f P b rhe eat gnv sqc 18y22 jw
g P b rhe eat lar sqc 18y22 jw
h P b rhe eat chp sqc 18y22 jw
i P b rhe eat pls sqc 18y22 jw
j P b rhe eat ton sqc 18y22 jw
k P b rhe eat tba mal 18y22 jw
375 R m f34 gav for tum 6m24
a R m f34 gav lun mix 6m24
b R m f34 gav ner mix 6m24






























N-NITROSO-OXOPROPYLCHLOROETHYLUREA * -: *-lug *10 . 100 *mg . 10 :10 *g .:*10
376 H f syg gav spl vsc 43w75 e + .774mg
a H f syg gav liv cho 43w75 e no dre
377 H m syg gav spl hes 43w75e + .216mg
a H m syg gav liv cho 43w75 e no dre
N-NITROSO-OXOPROPYLUREA 1 O0ng -lug.... :.10..... :.-100 .... :._mg.. :.-10 .... :.100.... :.lg .10
378 H f syg gav spl vsc 40w55 e + .121mg
a H f syg gav liv cho 40w55 e no dre
379 H m syg gav spl hes 40w75e + .140mg
a H m syg gav liv cho 40w75 e no dre
N-NITROSO-2-PHENYLETHYLUREA b00ng....:ug.... :.- 1* .. . . . : * - 10 ..... :. -100 . :j.-g..... :*10
380 H f syg gav spl vsc 30w75 e + .801mg
a H f syg gav for mix 30w75 e .939mg
b H f syg gav liv cho 30w75 e 6.51mg
c H f syg gav for car 30w75 e 7.77mg
381 H m syg gav for mix 30w75 e + 1.21mg
a H m syg gav for car 30w75 e 2.27mg
b H m syg gav spl hes 30w75 e 2.27mg





















































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
b 1978 97.2mg n.s.s. 39/50 12.4mg 38/50 22.3mg 32/50 43.1mg 28/50
367 1986 370.mg n.s.s. 0/30 74.8mg 0/24
N-NITROSO-ETHYL-2-OXOPROPYLUREA --
368 1956 .159mg 2.42mg 1/12 .871mg 8/12
a 1956 .335mg n.s.s. 0/12 .871mg 4/12
b 1956 .536mg n.s.s. 0/12 .871mg 2/12
c 1956 .845mg n.s.s. 1/12 .871mg 1/12
369 1956 .201mg 2.27mg 0/12 .766mg 6/12
a 1956 .295mg n.s.s. 0/12 .766mg 4/12
b 1956 .471mg n.s.s. 0/12 .766mg 2/12
c 1956 .313mg n.s.s. 1/12 .766mg 4/12
N-NITROSO-ETHYLHYDROXYETHYLUREA --
370 1956 .480mg 3.62mg 0/12 1.87mg 9/19
a 1956 .710mg 141.mg 0/12 1.87mg 6/19
b 1956 .893mg n.s.s. 1/12 1.87mg 5/19
c 1956 1.69mg n.s.s. 1/12 1.87mg 2/19
N-NITROSO-2-HYDROXYMORPHOLINE 67587-52-4
371 1928 2.42mg n.s.s. 0/20 .265mg 1/20 .530mg 0/20
N-NITROSO-N-METHYL-N-DODECYLAMINE* ** 55090-44-3
372 1912 n.s.s. .497mg 0/5 2.91mg 15/15




Reznik; acnr, 1,389-392; 1981
N-NITROSO-N-METHYLUREA*** 684-93-5
373 2001 1.22mg 17.Omg 0/90
a 2001 3.75mg 41.3mg
b 2001 .652mg n.s.s.
c 2001 10.8mg n.s.s.
d 2001 10.8mg n.s.s.
e 2001 13.4mg n.s.s.
f 2001 1.29mg n.s.s.
g 2001 1.29mg n.s.s.
h 2001 3.88mg n.s.s.
i 2001 4.75mg n.s.s.
j 2001 5.61mg n.s.s.
k 2001 .755mg 11.8mg
1 2001 1.14mg 20.4mg
m 2001 1.70mg n.s.s.
374 2001 3.40mg 19.3mg
a 2001 3.58mg 22.4mg
b 2001 5.42mg 81.5mg
c 2001 10.8mg 1.35gm
d 2001 6.98mg n.s.s.
e 2001 6.98mg n.s.s.
f 2001 10.2mg n.s.s.
g 2001 15.6mg n.s.s.
h 2001 15.6mg n.s.s.
i 2001 16.6mg n.s.s.
j 2001 16.6mg n.s.s.
k 2001 2.78mg 25.7mg
375 1915 44.lug .203mg
a 1915 .165mg 1.33mg
b 1915 .498mg n.s.s.





























































1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
Lijinsky;txih, 5,925-935;1989
N-NITROSO-OXOPROPYLCHLOROETHYLUREA --
376 1956 .299mg 15.1mg 1/12 1.71mg 7/12
a 1956 2.20mg n.s.s. 1/12 1.71mg 0/12
377 1956 79.5ug .610mg 0/12 1.51mg 11/12
a 1956 1.94mg n.s.s. 1/12 1.51mg 0/12
Lijinsky;bmes,2, 167-173;1989
N-NITROSO-OXOPROPYLUREA --
378 1956 43.4ug .384mg 1/12 1.51mg 11/12
a 1956 1.05mg n.s.s. 1/12 1.51mg 0/12
379 1956 51.5ug .394mg 0/12 .975mg 11/12
a 1956 .737mg n.s.s. 1/12 .975mg 1/12
N-NITROSO-2-PHENYLETHYLUREA --
380 1956 .308mg 7.43mg 1/12
a 1956 .369mg 3.87mg 0/12
b 1956 .984mg n.s.s. 1/12
c 1956 1.26mg n.s.s. 0/12
381 1956 .450mg 9.70mg 0/12
a 1956 .680mg n.s.s. 0/12
b 1956 .680mg n.s.s. 0/12
c 1956 .732mg n.s.s. 1/12
Lijinsky;bmes,2, 167-173;1989
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Brkly Code
63Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
N-NITROSOBIS(2-OXOPROPYL)AMINE*** lOOng..:. * lug. . . . :.*10 :.100 ..... lmg.... : 10 -.. :.*100.... 1 :.g - .... 10
382 R f mrc gav liv mix 73w77 as + . .283mg Z P<.0005+
a R f mrc gav thy mix 73w77 as 1.39mg * P<.02
b R f mrc gav lun ade 73w77 as 14.Omg * P<.7
c R f mrc gav npc mix 73w77 as 14.Omg * P<.7
d R f mrc gav tba tum 73w77 as .171mg * P<.0005
383 R m mrc gav urt pam 72w80 as . + .878mg * P<.0005+
a R m mrc gav liv mix 72w80 as .989mg * P<.005 +
b R m mrc gav lun mix 72w80 as 1.10mg * P<.0005+
c R m mrc gav npc mix 72w80 as 1.23mg * P<.0005+
d R m mrc gav col mix 72w80 as 1.60mg * P<.002 +
e R m mrc gav pro sqc 72w80 as 2.21mg * P<.003
f R m mrc gav thy mix 72w80 as .968mg * P<.04
g R m mrc gav tba tum 72w80 as 99.5ug * P<.0005
N-NITROSOCIMETIDINE*** 1 0ng....:lug*.... :.-10 :.-100 .... :. _mg.g.110 . g .10 .... 100°. :.- lg .*..10
384 M f cb6 wat liv mix 24m24 g .> no dre P=1. -
a M f cb6 wat lun tum 24m24 g no dre P=l. -
N-NITROSODIETHANOLAMINE***
385 R f f34 wat liv hpc 12m28 e
a R f f34 wat liv hes 12m28 e
lbOng..:..lug .... -10 ....:..100 ....1:.*Img...:.-10 ..... -100 ....:* Ig ....:..10
+ 1.94mg P<.0005+
45.4mg P<.3
N-NITROSODIETHYLAMINE*** 1 0 ng..:..:.ug :.-10 :.-100 .... :..umg.0..10 0 g 10 .... :.-100.... :.lg .... : 10
386 N b bbb ipj nac mec 32m32 Wjw (+) 12.2ug P<.0005+
a N b bbb ipj liv hpc 32m32 Wjw
b N b bbb ipj tba mal 32m32 Wjw
387 P b cym ipj liv hpc l3yl3 Wjuw
a P b cym ipj tba mal 13y13 Wjuw
388 P b cym eat liv hpc 16y16 Wjw
a P b cym eat tba mal l6yl6 Wjw
389 P b rhe ipj liv hpc 2Oy2O Wjuw
a P b rhe ipj tba mal 20y20 Wjuw
390 P b rhe eat liv hpc 22y22 Wjw











N-NITROSODIMETHYLAMINE*** 1b00ng..: -ug. 10.... :.-100 .... m : g.lg....:10
391 P b rhe ipj tba mal lOylO Ww (:>) no dre P=1.
N-NITROSODIPROPYLAMINE*** lOng.*:. lug.... :..10 ..... : 0 . 1 - mg.... :.-10... :.-100 .... :.-lg ..... 10
392 P b rhe ipj liv hpc 31m31 Ww (+) 12.lug P<.0005+
a P b rhe ipj tba mal 31m31 Ww 12.lug P<.0005
NITROSOETHYLURETHAN*** 1 Ong. .:. lug . - *-10.......0.... 1m..!mg.... :.-10 . ...... lg....g...... :*.10
393 R f f3d wat ugi mix 23m26 es + 55.3ug * P<.0005+
a R f f3d wat for pam 23m26 es
b R f f3d wat eso sqc 23m26 es
c R f f3d wat for sqc 23m26 es
d R f f3d wat eso pam 23m26 es
e R f f3d wat orc sqc 23m26 es
f R f f3d wat orc pam 23m26 es















N-NITROSOMETHYL(2-OXOPROPYL)AMINE lOng..: . lug.... - 10 ..... - 100 ....:.._mg....:.-10 ..... - 100 ....:. - lg ....:..10
394 R f mrc gav npc mix 67w76 as + 16.7ug Z P<.0005+
a R f mrc gav phr mix 67w76 as 75.8ug * P<.0005+
b R f mrc gav eso mix 67w76 as .160mg * P<.0005+
c R f mrc gav liv mix 67w76 as .268mg * P<.002 +
d R f mrc gav lun ade 67w76 as no dre P=l.
e R f mrc gav nsp pam 67w76 as no dre P=l.
f R f mrc gav tba tum 67w76 as noTD50 P<.0005
395 R m mrc gav npc mix 51w58 as + 17.8ug * P<.0005+
a R m mrc gav phr mix 51w58 as 23.Oug Z P<.0005+
b R m mrc gav eso mix 51w58 as 64.2ug * P<.0005+
c R m mrc gav liv mix 51w58 as .252mg Z P<.07 +
d R m mrc gav nsp pam 51w58 as .942mg * P<.4
e R m mrc gav lun ade 51w58 as no dre P=1.






RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
N-NITROSOBIS (2 -OXOPROPYL) AMINE***
382 1911 .167mg .511mg 0/15
a 1911 .651mg n.s.s. 0/15
b 1911 2.27mg n.s.s. 0/15
c 1911 2.27mg n.s.s. 0/15
d 1911 90.5ug .399mg 5/15
383 1911 .458mg 2.02mg 0/15
a 1911 .476mg 9.48mg 1/15
b 1911 .548mg 2.94mg 0/15
c 1911 .594mg 3.45mg 0/15
d 1911 .719mg 5.63mg 0/15
e 1911 .898mg 12.1mg 0/15
f 1911 .508mg n.s.s. 0/15
















384 1925 558.mg n.s.s. 3/20 22.6mg 1/17
a 1925 714.mg n.s.s. 1/20 22.6mg 2/17
N-NITROSODIETHANOLAMINE*** 1116-54-7
385 1928 .988mg 4.36mg 0/20 2.56mg 14/20
a 1928 7.40mg n.s.s. 0/20 2.56mg 1/20
N-NITROSODIETHYLAMINE*** (DEN) 55-18-5
386 2001s 3.36ug 46.Oug 0/9 .897mg 10/13
a 2001s 3.57ug 1.03mg
b 2001s 3.36ug 46.Oug
387 2001m 8.7lug 76.8ug
a 2001m 8.7lug 76.8ug
388 2001n 1.01mg 4.44mg
a 2001n 1.01mg 4.44mg
389 2001m 24.9ug .118mg
a 2001m 12.8ug 92.Oug
390 2001n 1.04mg 5.89mg
























































Pour; clet, 45,49-57; 1989
Anderson;canr, 45, 3561-3566; 1985
Hecht;carc, 10, 1475-1477;1989/pers.comm.
Adamson;ossc, 129-156;
1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
.322mg 3/3 .910mg 5/5 1.35mg 5/5 2.29mg 37/40
.322mg 3/3 .910mg 5/5 1.35mg 5/5 2.29mg 37/40
80.Oug 2/8 .340mg 6/6 .650mg 5/5 1.59mg 6/6
80.Oug 2/8 .340mg 6/6 .650mg 5/5 1.59mg 6/6
N-NITROSODIMETHYLAMINE*** (DMN) 62-75-9
391 2001 .108mg n.s.s. 1/76 1.01mg 0/2
N-NITROSODIPROPYLAMINE** 621-64-7
392 2001 3.14ug 59.9ug 0/104 3.52mg 4/4
a 2001 3.14ug 59.9ug 0/104 3.52mg 4/4
Adamson;ossc, 129-156;
1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
Adamson;ossc, 129-156;
1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
NITROSOETHYLURETHAN*** (1-ethyl-1-nitrosourethan) 614-95-9
393 1939 37.8ug 83.4ug 1/40 7.96ug 0/39 31.8ug 16/38 .133mg 38/39 .571mg 37/38
a 1939 41.9ug .180mg
b 1939 87.Oug .242mg
c 1939 .125mg .405mg
d 1939 .241mg 1.72mg
e 1939 .475mg 1.42mg
f 1939 1.30mg 9.75mg






















13/38 (.133mg 14/39 .571mg 19/38)
1/38 .133mg 26/39 (.571mg 23/38)
2/38 .133mg 18/39 (.571mg 9/38)
1/38 .133mg 9/39 (.571mg 6/38)
0/38 .133mg 6/39 .571mg 17/38
0/38 .133mg 1/39 .571mg 6/38




394 1911 6.68ug 36.8ug 0/15
a 1911 47.6ug .149mg 0/15
b 1911 90.8ug .314mg 0/15
c 1911 .143mg 1.05mg 0/15
d 1911 1.09mg n.s.s. 6/15
e 1911 .618mg n.s.s. 0/15
f 1911 n.s.s. 34.9ug 5/15
395 1911 9.79ug 32.5ug 0/15
a 1911 12.7ug 44.4ug 0/15
b 1911 38.9ug .120mg 0/15
c 1911 82.7ug n.s.s. 1/15
d 1911 .270mg n.s.s. 0/15
e 1911 64.7ug n.s.s. 0/15






























Pour; clet, 45,49-57; 1989
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Brkly Code
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396 H f syg wat trh mem 24m24 er
a H f syg wat lar mix 24m24 er
397 H m syg wat trh mem 24m24 er
a H m syg wat lar mix 24m24 er
398 R f f34 wat liv mix 50w73 e
a R f f34 wat liv hpc 50w73 e
b R f f34 wat liv hes 50w73 e
N-NITROSOPIPERIDINE***
399 H f syg wat trh mem 24m24 er
a H f syg wat lar mix 24m24 er
400 H m syg wat lar mix 24m24 er
a H m syg wat trh mem 24m24 er
401 P b cym eat liv hpc l2yl2 Wjv
a P b cym eat
b P b cym eat
402 P b rhe eat
a P b rhe eat
403 P b rhe ipj
a P b rhe ipj
b P b rhe ipj
c P b rhe ipj
d P b rhe ipj
404 R b clw wat
liv hes l2yl2 Wjw
tba mal 12y12 Wjw
liv hpc l2yl2 Wjw
tba mal l2yl2 Wjw
liv hpc 2Oy2O Wjw
bil hmt 20y2O Wjw
tba mix 2Oy20 Wjw
tba mal 20y20 Wjw
tba ben 2Oy2O Wjw
eso mix 3Om30 e
lO0ng..:. lug.. .-10 . :.. 100. : 1 mg :. -10 * :..100. :.* -lg..... : 10
+ 11.3mg * P<.0005+
15.4mg * P<.0005+




































a R b clw wat liv hct 30m30 e 1.41mg * P<.0005+
b R b clw wat liv hpc 30m30 e 1.51mg * P<.0005+
c R b clw wat eso mal 30m30 e 10.3mg * P<.0005+
d R b clw wat nsp mix 30m30 e 27.4mg Z P<.0005+
e R b clw wat nsp mal 3Om30 e
f R b clw wat ski mal 30m30 e
g R b clw wat lgi mal 3Om30 e
77.1mg Z P<.02 +
222.mg * P<.07
224.mg Z P<.8
N-NITROSOPYRROLIDINEa*** 1 O0ng. .: lug.... :.10.... :.-100.... :1.-mg.... : 0 . -100.... :.-10g ..... :..10
405 R b clw wat liv hct 30m30 e +. 1.70mg * P<.0005+
2.20mg * P<.0005+ a R b clw wat liv hpc 30m30 e
b R b clw wat bil ben 30m30 e
c R b clw wat nsp tum 3Om30 e
406 R f f34 wat liv hpc 12m26 e
a R f f34 wat liv mix 12m26 e
b R f f34 wat liv clc 12m26 e
c R f f34 wat liv cho 12m26 e
d R f f34 wat liv lyp 12m26 e
e R f f34 wat liv sar 12m26 e
f R f f34 wat tba tum 12m26 e
NIVALENOL
407 M f c6s eat liv mfh 24m24 e
a M f c6s eat lun mix 24m24 e
b M f c6s eat tba tum 24m24 e
















100ng..:.. .lug.*-:*-10.* :* 100 .- - -: ....mg .:.10 ..... -100 ..- i.:Ig :*.10








RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
N-NITROSOMORPHOLINE*** 59-89-2
396 1998 6.50mg 29.Omg 0/25
a 1998 8.95mg 44.7mg 0/25
397 1998 5.21mg 14.9mg 0/25
a 1998 7.14mg 20.2mg 0/25
398 1928 n.s.s. .129mg 0/20
a 1928 33.lug .184mg 0/20



















Cardesa; expl, 401,267-281; 1990
Hecht;carc, 10,1475-1477; 1989/pers.comm.
N-NITROSOPIPERIDINE*** 100
399 1998 99.9mg 1.93gm
a 1998 117.mg 1.10gm
400 1998 45.2mg 146.mg
a 1998 87.5mg 569.mg
401 2001 3.30mg 47.3mg
a 2001 3.53mg 3.31gm
b 2001 3.30mg 47.3mg
402 2001 2.35mg 28.4mg
a 2001 3.05mg 46.5mg
403 2001m .454mg 11.7mg
a 2001m .174mg n.s.s.
b 2001m .285mg 10.5mg
c 2001m .351mg 19.8mg
d 2001m .457mg n.s.s.
404 1958 .970mg 1.82mg
a 1958 1.04mg 2.00mg
b 1958 1.11mg 2.10mg
c 1958 6.07mg 19.5mg
d 1958 12.Omg 110.mg
e 1958 22.7mg n.s.s.
f 1958 36.2mg n.s.s.









































405 1958 1.24mg 2.36mg
a 1958 1.63mg 3.03mg
b 1958 40.1mg 814.mg
c 1958 86.1mg n.s.s.
406 2022 .179mg 1.04mg
a 2022 .179mg 1.04mg
b 2022 1.70mg 51.8mg
c 2022 2.40mg n.s.s.
d 2022 2.40mg n.s.s.
e 2022 4.10mg n.s.s.

















































































Cardesa; expl, 401,267-281; 1990
Adamson;ossc, 129-156;





































1/12 87.Oug 0/12 .174mg 1/12
.872mg 10/12 1.05mg 10/12
2.79mg 12/12 5.58mg 9/12 Gray;canr,51,6470-6491;1991
1/12 87.Oug 3/12 .174mg 3/12
.872mg 9/12 1.05mg 11/12
2.79mg 9/12 5.58mg 8/12
1/12 87.Oug 3/12 .174mg 2/12
.872mg 7/12 1.05mg 10/12
2.79mg 9/12 5.58mg 8/12
0/12 87.Oug 0/12 .174mg 1/12
.872mg 3/12 1.05mg 3/12
2.79mg 3/12 5.58mg 1/12
0/12 87.Oug 0/12 .174mg 0/12
.872mg 2/12 1.05mg 1/12
2.79mg 0/12 5.58mg 1/12
0/12 87.Oug 0/12 .174mg 0/12
.872mg 0/12 1.05mg 0/12
2.79mg 0/12 5.58mg 1/12
0/12 87.Oug 0/12 .174mg 0/12
.872mg 0/12 1.05mg 0/12
2.79mg 1/12 5.58mg 0/12
0/12 87.Oug 0/12 .174mg 0/12
.872mg 0/12 1.05mg 0/12
2.79mg 0/12 5.58mg 0/12
1/12 .275mg 5/12 .550mg 6/12
2.75mg 11/12 3.30mg 10/12
8.80mg 11/12 17.6mg 12/12 Gray;canr,51,6470-6491;1991
1/12 .275mg 5/12 .550mg 4/12
2.75mg 10/12 3.30mg 9/12
8.80mg 11/12 17.6mg 12/12
0/12 .275mg 1/12 .550mg 0/12
2.75mg 0/12 3.30mg 1/12
8.80mg 2/12 17.6mg 0/12
0/12 .275mg 0/12 .550mg 0/12
2.75mg 1/12 3.30mg 0/12
8.80mg 1/12 17.6mg 0/12
Lij insky; clet, 12,99-103; 1981
NIVALENOL 23282-20-4
407 1946 28.3mg n.s.s.
a 1946 45.3mg n.s.s.
b 1946 4.58mg n.s.s.
0/38 .780mg 2/38 1.56mg 0/41 3.90mg 0/41
2/38 .780mg 1/38 1.56mg 0/41 3.90mg 0/41
22/38 .780mg 25/38 1.56mg 23/41 3.90mg 23/41
Ohtsubo;fctx,27,591-598;1989/pers.comm.
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Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
1-(2-OXOPROPYL)NITROSO-3-(2-CHLOROETHYL)TUREA .... 10.. :.-100...1. :._mg. :.10.... :.-100.... :.-lg.... 1 10
408 R f f34 gav liv tum 7m24 e + 1.36mg
a R f f34 gav ner tum 7m24 e 4.49mg
409 R f f34 wat lun tum 7m24 e .> 4.49mg
a R f f34 wat ner tum 7m24 e 4.49mg
b R f f34 wat liv tum 7m24 e no dre
410 R m f34 gav ner tum 7m24 e ± .951mg
a R m f34 gav lun tum 7m24 e 3.14mg
b R m f34 gav liv tum 7m24 e no dre
411 R m f34 wat lun tum 7m24 e + 1.50mg
a R m f34 wat liv tum 7m24 e 3.14mg
b R m f34 wat ner tum 7m24 e 3.14mg
2-OXOPROPYLNITROSOUREA
412 R f f34 gav kid mnp
a R f f34 gav liv tum
413 R m f34 gav kid mnp






414 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
415 M m b6c gav MXB MXB 24m24
a M m b6c gav amd pob 24m24
b M m b6c gav liv hes 24m24
c M m b6c gav TBA MXB 24m24
d M m b6c gav liv MXB 24m24
e M m b6c gav lun MXB 24m24
416 R f f34 gav amd pob 24m24
a R f f34 gav TBA MXB 24m24
b R f f34 gavliv MXB 24m24
417 R m f34 gav amd pob 24m24 s
a R m f34 gav amd MXA 24m24 s
b R m f34 gav TBA MXB 24m24 s
c R m f34 gav liv MXB 24m24 s
PHENOBARBITAL***
418 M m cen eat liv mix 52w52 r
a M m cen eat liv hpc 52w52 r
b M m cen eat lun mix 52w52 r
c M m cen eat liv hpa 52w52 r
419 R m f34 eat liv hpt 71w71 e
PHENOBARBITAL, SODIUM***
420 R m f34 eat ubl tum 56w56 e
PHENYLBUTAZONE***
421 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
422 M m b6c gav liv hpa 24m24
a M m b6c gav liv MXA 24m24
b M m b6c gav TBA MXB 24m24
c M m b6c gav liv MXB 24m24
d M m b6c gav lun MXB 24m24
423 R f f34 gav kid tcc 24m24
a R ff34 gav TBA MXB 24m24
b R ff34 gav liv MXB 24m24
424 R m f34 gav kid MXA 24m24
a R m f34 gav kid MXA 24m24
b R m f34 gav TBA MXB 24m24
c R m f34 gav liv MXB 24m24
425 R m f34 gav kid MXA 24m24









1O0ng. ug.... .-10.:. -100.* :*-l1mg.... -10 ..... -100 -lg * .: 10
:> 47.5mg * P<.4
63.Omg * P<.2
776.mg * P<.8
+ 38.3mg * P<.0005
77.4mg * P<.002 p




174.mg * P<.4 e
no dre P=1.
1.18gm * P<.3
:+ 24.8mg * P<.03 p
30.0mg * P<.08 p
no dre P=1.
6.46gm * P<1.











lbOng..:. .lug :* 10 ..... -100.- .- -:1*-_mg ....:..10 1... -100 ...:* lg ....:* 10
. > no dre P=1.
lbOng ..: ug .... -10 ..... -100 ....: ..mg ....: .10 ..... .100 ...: * lg ....:..10
: > no dre P=1.
6.01gm * P<.9
no dre P=1.
+ 323.mg * P<.007




: +hist 1.16gm P<.09 p
1.58gm * P<1.
no dre P=1.




with step 382.mg * P<.02 e
o-PHENYLPHENATE, SODIUM*** 1 O0ng -ug :* 10 ..... :.-100 -:*-lmg......lo :. -1 :. :..10
426 R m f3d eat ubl car 24m24 er + 1.03gm P<.0005+
a R m f3d eat ubl pam 24m24 er 5.02gm P<.05
o-PHENYLPHENOL*** lbOng -lug .... :.-10 :.-100 : _mg :..l10 :.-100*.... :. lg : 10
427 R m f3d eat ubl tum 24m24 r .> no dre P=1.
PhIP HC1
428 M f cdf eat --- lym 82w82 e
429 M m cdf eat --- lym 82w82 e
430 R f f3d eat mgl adc 52w52 e
a R f f3d eat col adc 52w52 e
b R f f3d eat liv tum 52w52 e
431 R f f3d eat mgl adc 24m24 e
a R f f3d eat col adc 24m24 e
1O0ng ..lug :* 10 ....:-100.- .- -:1*-_mg....:..10o ....: * -100 * ...:lg.... :* 10
+ 22.4mg P<.0005+
+ 63.9mg P<.004 +
+ . 5.45mg P<.0005+
49.7mg P<.07 +
no dre P=1.
+ 6.34mg * P<.0005+
















RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
1- (2-OXOPROPYL)NITROSO-3- (2-CHLOROETHYL)UREA 110559-85-8
408 2010m .408mg n.s.s.
a 2010m .730mg n.s.s.
409 2010n .730mg n.s.s.
a 2010n .730mg n.s.s.
b 2010n 1.41mg n.s.s.
410 2010m .286mg n.s.s.
a 2010m .511mg n.s.s.
b 2010m .987mg n.s.s.
411 2010n .368mg n.s.s.
a 2010n .511mg n.s.s.













412 2010 .136mg .977mg 0/12
a 2010 .656mg n.s.s. 0/12
413 2010 .170mg 3.66mg 0/12























Lij insky;vivo, 4,1-6; 1990





414 c56520 11.7mg n.s.s. 32/50
a c56520 19.8mg n.s.s. 11/50
b c56520 66.1mg n.s.s. 2/50
415 c56520 21.8mg 124.mg 2/50
a c56520 38.5mg 189.mg 0/50
b c56520 32.6mg n.s.s. 2/50
c c56520 11.9mg n.s.s. 38/50
d c56520 25.8mg n.s.s. 26/50
e c56520 50.9mg n.s.s. 11/50
416 c56520 50.8mg n.s.s. 3/50
a c56520 14.7mg n.s.s. 45/50
b c56520 192.mg n.s.s. 0/50
417 c56520 10.8mg n.s.s. 12/50
a c56520 11.5mg n.s.s. 15/50
b c56520 15.0mg n.s.s. 47/50





























17/50 14.Omg 23/50 28.2mg 15/50
18/50 14.Omg 25/50 28.2mg 15/50
49/50 14.0mg 44/50 28.2mg 23/50










418 1992 3.75mg 13.3mg 2/30 60.0mg
a 1992 4.47mg 14.7mg 0/30 60.Omg
b 1992 28.5mg n.s.s. 2/30 60.Omg
c 1992 44.9mg n.s.s. 2/30 60.Omg





0/15 Diwan;carc, 10, 189-194; 1989
PHENOBARBITAL, SODIUM` (phenobarbitone, sodium) 57-30-7
420 1942 35.9mg n.s.s. 0/15 40.Omg 0/15 Diwan; txap, 98,269-277;1989
PHENYLBUTAZONE*** 50-33-9
421 c56531 323.mg n.s.s.
a c56531 405.mg n.s.s.
b c56531 704.mg n.s.s.
422 c56531 160.mg 4.75gm
a c56531 157.mg n.s.s.
b c56531 136.mg n.s.s.
c c56531 157.mg n.s.s.
d c56531 616.mg n.s.s.
423 c56531 276.mg n.s.s.
a c56531 40.3mg n.s.s.
b c56531 339.mg n.s.s.
424 c56531 158.mg n.s.s.
a c56531 187.mg n.s.s.
b c56531 31.1mg n.s.s.
c c56531 261.mg n.s.s.


















































426 1930 523.mg 2.42gm 0/27 800.mg 12/29
a 1930 1.52gm n.s.s. 0/27 800.mg 3/29
o-PHENYLPHENOL*** (orthoxenol, Dowicide-1) 90-43-7
427 1930 3.19gm n.s.s. 0/30 500.mg 0/31
PhIP.HC1 (2-amino-1-methyl-6-phenylimidazo [4,5-b] -pyridine.HC1) --
428 1872 12.6mg 50.4mg 6/40 52.Omg 26/38
429 1872 28.9mg 513.mg 2/36 48.Omg 11/35
430 1922 2.90mg 12.Omg 0/40 20.Omg 14/30
a 1922 12.2mg n.s.s. 0/40 20.Omg 2/30
b 1922 30.9mg n.s.s. 0/40 20.Omg 0/30
431 2062 3.51mg 13.1mg 0/30 1.25mg 2/30 5.00mg 14/30
a 2062 10.5mg 584.mg 0/30 1.25mg 0/30 5.00mg 4/30






kid: rab, rua, ruc.
kid:rab,rua. S
liv:hpa,hpc,nnd.
kid: rab, rua, ruc.
Fukushima;carc, 10, 1635-1640; 1989
Fukushima;carc,10,1635-1640; 1989
Esumi;gann, 80,1176-1178;1989/pers.comm.
Ito; carc, 12,1503-1506; 1991/pers comm.
Hasegawa;carc,14,2553-2557;1993/pers.comm.
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Sex Route Hist Nc
TD50 2Tailpvl
DR AuOp
b R f f3d eat liv nnd 24m24 e
c R f f3d eat mgl ade 24m24 e
d R f f3d eat mgl fba 24m24 e
432 R m f3d eat col adc 52w52 e
a R m f3d eat liv tum 52w52 e
433 R m f3d eat --- lle 24m24 e
a R m f3d eat col adc 24m24 e
b R m f3d eat liv nnd 24m24 e
c R m f3d eat mgl fba 24m24 e
PICLORAM, TECHNICAL GRADE*
434 R f f34 eat liv hpa 24m24
a R f f34 eat thy pfa 24m24
435 R m f34 eat liv hpa 24m24
a R m f34 eat liv hpc 24m24
POLYSORBATE 80
436 M f b6c eat TBA MXB 24m24
a M f b6c eat liv MXB 24m24
b M f b6c eat lun MXB 24m24
437 M m b6c eat TBA MXB 24m24
a M m b6c eat liv MXB 24m24
b M m b6c eat lun MXB 24m24
438 R f f34 eat liv hpa 24m24
a R f f34 eat TBA MXB 24m24
b R f f34 eat liv MXB 24m24
439 R m f34 eat amd MXA 99w99
a R m f34 eat TBA MXB 99w99
b R m f34 eat liv MXB 99w99
PROBENECID
440 M f b6c gav liv MXA 24m24
a M f b6c gav liv hpa 24m24
b M f b6c gav TBA MXB 24m24
c M f b6c gav liv MXB 24m24
d M f b6c gav lun MXB 24m24
441 M m b6c gav sub fib 24m24
a M m b6c gav TBA MXB 24m24
b M m b6c gav liv MXB 24m24
c M m b6c gav lun MXB 24m24
442 R f f34 gav TBA MXB 24m24
a R f f34 gav liv MXB 24m24
443 R m f34 gav tes MXA 24m24
a R m f34 gav TBA MXB 24m24











1O0ng . -lug.... -10 ..... -100 ....:..mg ....:..10 ..... -100 ...:.* -lg ....:..10




1O0ng..:. .lug.... -10 ..... -100 ...: ....mg .:*10 . - :.* 100.- - -:* lg ..... * -10
:> 42.9gm / P<.8
no dre P=1.
332.gm P<.9






: 2.58gm * P<.07 e
3.29gm * P<.5
217.gm * P<.9





























PROCARBAZINE.HC1*** l0ng..:* lug......10 .... :.u10g . . . . :*10 . ... :.. 10..... :.-100 :.-lg 10
444 P b cym mix --- ost 16y19 Wjmw + 5.91mg P<.003
a P b cym mix --- lna l6yl9 Wjmw
b P b cym mix bra ast 16y19 Wjmw
c P b cym mix --- lcl l6yl9 Wjmw
d P b cym mix kid hes l6yl9 Wjmw
e P b cym mix tba mal l6yl9 Wjmw
445 P b rhe mix --- lna 16y23 jmw
a P b rhe mix cec adc 16y23 jmw
b P b rhe mix hum ost 16y23 jmw
c P b rhe mix kid hes 16y23 jmw





















QUERCETIN' * Ong. .:.*lug....... . . .... ....0........ :-_100 .... lg..Ig .......100-
446 R f f34 eat ton sqc 24m24 #36.5gm * P<.04 -
a R f f34 eat TBA MXB 24m24 no dre P=l.
b R f f34 eat liv MXB 24m24 75.7gm * P<.6
447 R m f34 eat kid MXA 24m24 : +8.99gm * P<.003 p
a R m f34 eat kid rua 24m24 12.5gm * P<.009 p
b R m f34 eat TBA MXB 24m24 no dre P=l.
c R m f34 eat liv MXB 24m24 no dre P=1.
448 R m f34 eat kid MXA 24m24 with step + 5.25gm * P<.004
a R m f34 eat kid rua 24m24 6.03gm * P<.009 p
449 R f f3d eat --- lkm 24m26 e i 7.86gm * P<.06
a R f f3d eat ute esp 24m26 e 19.3gm * P<.4
b R f f3d eat liv hnd 24m26 e no dre P=l.
450 R m f3d eat --- lkm 24m26 e + 1.16gm \ P<.005




RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
b 2062 28.8mg n.s.s.
c 2062 20.3mg n.s.s.
d 2062 3.19mg n.s.s.
432 1922 1.87mg 7.13mg
a 1922 23.9mg n.s.s.
433 2062 2.85mg 38.2mg
a 2062 3.37mg 14.6mg
b 2062 1.51mg n.s.s.






























PICLORAM, TECHNICAL GRADE*** 1918-02-1
434 1981 1.27gm n.s.s.
a 1981 909.mg n.s.s.
435 1981 759.mg n.s.s.













Stott; jtxe, 30, 91-104; 1990
POLYSORBATE 80 9005-65-6
436 c60286 5.34gm n.s.s.
a c60286 23.6gm n.s.s.
b c60286 18.lgm n.s.s.
437 c60286 5.33gm n.s.s.
a c60286 12.5gm n.s.s.
b c60286 15.7gm n.s.s.
438 c60286 5.46gm n.s.s.
a c60286 1.41gm n.s.s.
b c60286 5.46gm n.s.s.
439 c60286 1.02gm n.s.s.
a c60286 781.mg n.s.s.
b c60286 8.20gm n.s.s.
PROBENECID 57-66-9
440 c56097 256.mg 3.80gm
a c56097 273.mg 2.65gm
b c56097 161.mg n.s.s.
c c56097 256.mg 3.80gm
d c56097 488.mg n.s.s.
441 c56097 643.mg n.s.s.
a c56097 122.mg n.s.s.
b c56097 241.mg n.s.s.
c c56097 466.mg n.s.s.
442 c56097 129.mg n.s.s.
a c56097 543.mg n.s.s.
443 c56097 85.3mg n.s.s.
a c56097 107.mg n.s.s.


















































































































liv: hpa, hpc, nnd.
lun:a/a,a/c.
S




























































1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
QUERCETIN-** 117-39-5
446 c60106 8.92gm n.s.s. 0/50
a c60106 1.27gm n.s.s. 49/50
b c60106 7.97gm n.s.s. 0/50
447 c60106 3.06gm 58.8gm 0/50
a c60106 3.72gm 393.gm 0/50
b c60106 1.19gm n.s.s. 46/50
c c60106 5.34gm n.s.s. 3/50
448 c60106 2.40gm 45.6gm 1/50
a c60106 2.59gm 305.gm 1/50
449 1934 3.04gm n.s.s. 8/50
a 1934 4.71gm n.s.s. 8/50
b 1934 5.55gm n.s.s. 2/50
450 1934 550.mg 11.6gm 6/50















0/50 500.mg 0/50 2.00gm 2/50
48/50 500.mg 43/50 2.00gm 44/50
1/50 500.mg 0/50 2.00gm 1/50
0/50 400.mg 0/50 1.60gm 4/50
0/50 400.mg 0/50 1.60gm 3/50
40/50 400.mg 46/50 1.60gm 39/50
4/50 400.mg 4/50 1.60gm 1/50
2/50 400.mg 7/50 1.60gm 9/50
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Brkly Code
71Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
C.I. ACID RED 114 lOOng..:. lug :* 10 :* 0 *.. . . . :._mg :* 10 ... .. *g100 :* I-- ..... :.10
451 R f f34 wat MXB MXB 23m24 a :+ : 3.11mg Z P<.0005
a R f f34 wat cli MXA 23m24 a
b R f f34 wat cli MXA 23m24 a
c R f f34 wat mul MXA 23m24 a
d R f f34 wat psd ade 23m24 a
e R f f34 wat mgl fba 23m24 a
f R f f34 wat cli MXA 23m24 a
g R f f34 wat liv MXA 23m24 a
h R f f34 wat zym MXA 23m24 a
i R f f34 wat ute MXA 23m24 a
j R f f34 wat liv nnd 23m24 a
k R f f34 wat zym car 23m24 a
1 R f f34 wat ute esp 23m24 a
m R f f34 wat ski MXA 23m24 a
n R f f34 wat lun MXA 23m24 a
o R f f34 wat lun a/a 23m24 a
p R f f34 wat ski bca 23m24 a
q R f f34 wat thy MXA 23m24 a
r R f f34 wat MXA MXA 23m24 a
s R f f34 wat amd MXA 23m24 a
t R f f34 wat MXA sqp 23m24 a
u R f f34 wat amd pob 23m24 a
v R f f34 wat mgl adc 23m24 a
w R f f34 wat liv hpc 23m24 a
x R f f34 wat ski MXA 23m24 a
y R f f34 wat thy fca 23m24 a
z R f f34 wat ski sqc 23m24 a
A R f f34 wat zym ade 23m24 a
B R f f34 wat ton MXA 23m24 a
C R f f34 wat phr sqp 23m24 a
D R f f34 wat ton sqp 23m24 a
E R f f34 wat MXA MXA 23m24 a
F R f f34 wat thy cca 23m24 a
G R f f34 wat mgl ade 23m24 a
H R f f34 wat thy fcc 23m24 a
I R f f34 wat sub MXA 23m24 a
J R f f34 wat MXA MXA 23m24 a
K R f f34 wat MXA sqc 23m24 a
L R f f34 wat TBA MXB 23m24 a
M R f f34 wat liv MXB 23m24 a


























































47.2mg Z P<.1 e
71.0mg Z P<.02 e
3.23mg Z P<.0005
7.02mg Z P<.0005
a R m f34 wat ski MXA 24m24
b R m f34 wat tes MXA 24m24
c R m f34 wat ski bca 24m24
d R m f34 wat amd MXA 24m24
e R m f34 wat amd pob 24m24
f R m f34 wat liv MXA 24m24
g R m f34 wat liv nnd 24m24
h R m f34 wat ski MXA 24m24
i R m f34 wat ski sqc 24m24
j R m f34 wat liv hpc 24m24
k R m f34 wat ski ker 24m24
1 R m f34 wat ski bcc 24m24
m R m f34 wat ski MXA 24m24
n R m f34 wat zym MXA 24m24
o R m f34 wat zym car 24m24
p R m f34 wat lun a/a 24m24
q R m f34 wat mul mnl 24m24
r R m f34 wat lun MXA 24m24
s R m f34 wat MXA sqp 24m24
t R m f34 wat TBA MXB 24m24
u R m f34 wat liv MXB 24m24
C.I. PIGMENT RED 3
453 M f b6c eat lyd MXA 24m24
a M f b6c eat TBA MXB 24m24
b M f b6c eat liv MXB 24m24
c M f b6c eat lun MXB 24m24
454 M m b6c eat MXB MXB 24m24
a M m b6c eat kcx ade 24m24
b M m b6c eat thy fca 24m24
c M m b6c eat --- MXA 24m24
d M m b6c eat TBA MXB 24m24
e M m b6c eat liv MXB 24m24
f M m b6c eat lun MXB 24m24
455 R f f34 eat liv hpa 24m24
a R f f34 eat TBA MXB 24m24
lOOng... .:lug.... :*10 ..... :..100. . . . :I.g.. :..10 ..... :.-100*.... :. -g ... 10





35.5gm * P<.003 p











RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
C.I. ACID RED 114 6459-94-5
451 c61096 2.14mg 4.68mg 12/50
a c61096 2.95mg 8.36mg 11/50
b c61096 5.19mg 17.Omg 4/50
c c61096 5.10mg 24.3mg 12/50
d c61096 5.14mg 73.3mg 25/50
e c61096 4.86mg 282.mg 19/50
f c61096 6.08mg 30.5mg 7/50
g c61096 8.08mg 26.Omg 0/50
h c61096 8.95mg 25.7mg 0/50
i c61096 7.79mg 63.7mg 5/50
j c61096 9.57mg 35.4mg 0/50
k c61096 9.72mg 31.6mg 0/50
1 c61096 9.03mg 98.6mg 4/50
m c61096 10.2mg 51.Omg 0/50
n c61096 11.2mg 62.9mg 1/50
o c61096 12.1mg 75.Omg 1/50
p c61096 11.6mg 82.7mg 0/50
q c61096 11.0mg 125.mg 0/50
r c61096 13.7mg 71.1mg 0/50
s c61096 12.3mg 220.mg 1/50
t c61096 14.6mg 102.mg 0/50
u c61096 13.4mg 763.mg 1/50
v c61096 16.7mg 124.mg 0/50
w c61096 17.7mg 121.mg 0/50
x c61096 16.5mg 264.mg 0/50
y c61096 16.2mg 878.mg 0/50
z c61096 17.2mg 705.mg 0/50
A c61096 20.9mg 210.mg 0/50
B c61096 21.3mg 300.mg 0/50
C c61096 21.7mg 566.mg 0/50
D c61096 22.Omg 509.mg 0/50
E c61096 31.5mg 3.20gm 0/50
F c61096 13.9mg n.s.s. 6/50
G c61096 19.9mg n.s.s. 1/50
H c61096 17.6mg n.s.s. 0/50
I c61096 20.9mg n.s.s. 3/50
J c61096 46.1mg n.s.s. 0/50
K c61096 81.3mg n.s.s. 0/50
L c61096 1.58mg 3.59mg 47/50
M c61096 8.08mg 26.Omg 0/50
452 c61096 1.96mg 4.26mg 6/50
a c61096 2.29mg 5.00mg
b c61096 1.97mg 8.88mg
c c61096 2.45mg 5.50mg
d c61096 3.39mg 15.5mg
e c61096 3.71mg 19.5mg
f c61096 4.34mg 12.7mg
g c61096 5.97mg 21.8mg
h c61096 6.90mg 30.1mg
i c61096 8.33mg 37.2mg
j c61096 9.95mg 48.9mg
k c61096 9.42mg 73.Omg
1 c61096 10.8mg 61.Omg
m c61096 10.5mg 100.mg
n c61096 13.3mg 62.3mg
o c61096 14.1mg 76.6mg
p c61096 15.1mg 1.09gm
q c61096 4.95mg n.s.s.
r c61096 14.5mg n.s.s.
s c61096 20.Omg n.s.s.
t c61096 1.95mg 7.30mg






















C.I. PIGMENT RED 3 2425-85-6
453 c60366 31.Ogm n.s.s. 0/51
a c60366 4.15gm n.s.s. 36/51
b c60366 10.9gm n.s.s. 10/51
c c60366 24.6gm n.s.s. 4/51
454 c60366 9.79gm 49.6gm 0/50
a c60366 14.5gm 176.gm 0/50
b c60366 15.6gm 271.gm 0/50
c c60366 9.42gm n.s.s. 2/50
d c60366 3.15gm n.s.s. 25/50
e c60366 5.12gm n.s.s. 12/50
f c60366 9.86gm n.s.s. 2/50
455 c60366 2.63gm 13.4gm 0/50
a c60366 1.41gm n.s.s. 46/50
8.42mg 22/35 16.8mg 54/65 34.3mg 39/50 cli:ade,anb,car,cnb; col:adp,muc; duo:adp,muc;
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Brkly Code
73Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
b R f f34 eat liv MXB 24m24
456 R m f34 eat amd MXA 24m24
a R m f34 eat amd pob 24m24
b R m f34 eat ski sqp 24m24
c R m f34 eat ski MXA 24m24
d R m f34 eat zym car 24m24
e R m f34 eat TBA MXB 24m24
f R m f34 eat liv MXB 24m24
C.I. PIGMENT RED 23
457 M f b6c eat TBA MXB 24m24
a M f b6c eat liv MXB 24m24
b M f b6c eat lun MXB 24m24
458 M m b6c eat TBA MXB 24m24
a M m b6c eat liv MXB 24m24
b M m b6c eat lun MXB 24m24
459 R f f34 eat TBA MXB 24m24
a R ff34 eat liv MXB 24m24
460 R m f34 eat kid MXA 24m24
a R m f34 eat TBA MXB 24m24
b R m f34 eat liv MXB 24m24
461 R m f34 eat kid MXA 24m24
RESORCINOL
462 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
463 M m b6c gav TBA MXB 24m24
a M m b6c gav liv MXB 24m24
b M m b6c gav lun MXB 24m24
464 R f f34 gav TBA MXB 24m24 s
a R f f34 gav liv MXB 24m24 s
465 R m f34 gav tes ica 24m24 s
a R m f34 gav TBA MXB 24m24 s
b R m f34 gav liv MXB 24m24 s
RHODAMINE 6G
466 M f b6c eat TBA MXB 24m24
a M f b6c eat liv MXB 24m24
b M f b6c eat lun MXB 24m24
467 M m b6c eat thy MXA 24m24
a M m b6c eat TBA MXB 24m24
b M m b6c eat liv MXB 24m24
c M m b6c eat lun MXB 24m24
468 R f f34 eat amd MXA 24m24
a R f f34 eat TBA MXB 24m24
b R f f34 eat liv MXB 24m24
469 R m f34 eat ski ker 24m24
a R m f34 eat TBA MXB 24m24
b R m f34 eat liv MXB 24m24
5.24gm * P<.0005
: + : 661.mg * P<.005 p
674.mg * P<.004
2.54gm * P<.004 e
3.66gm * P<.04
9.01gm * P<.02 e
906.mg * P<.2
5.17gm * P<.08
1O0ng..:. .lug....:..10 ..... -100 ....:..mg ....:..10 ....:..100 ....:1*-g ....:..10
:> 29.7gm * P<.6
no dre P=1.
45.2gm * P<.09
:> 20.2gm * P<.6
15.1gm * P<.2
112.gm * P<.8
:> no dre P=1.
no dre P=1.
19.8gm * P<.04 e
no dre P=1.
no dre P=1.
with step 16.3gm P<.09 e


























SACCHARIN, SODIUM*** 10Ong.:. lug.... :*10... :*-100 . -...:...!mg.... : *-10 .-: *-100 .... : * -lg ..... : 10

























471 M f b6c eat for sqc 96w96
a M f b6c eat for sar 96w96
b M f b6c eat liv hnd 96w96
c M f b6c eat liv hpc 96w96
d M f b6c eat lun adc 96w96
472 M m b6c eat for sqc 96w96
a M m b6c eat stg sar 96w96
b M m b6c eat lun ade 96w96
c M m b6c eat liv hnd 96w96
d M m b6c eat liv hpc 96w96
473 R f f3d eat for pam 24m24
a R f f3d eat for sqc 24m24
b R f f3d eat liv hnd 24m24
474 R m f3d eat for pam 24m24
a R m f3d eat for sqc 24m24
b R m f3d eat stg ade 24m24
c R m f3d eat liv hpc 24m24
d R m f3d eat liv hnd 24m24



















SODIUM BICARBONATE 10Ong. .:. :ug : 10. :100 :1mg :10.- :. ........... g..... :10






















RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
b c60366 2.63gm 13.4gm 0/50
456 c60366 332.mg 6.55gm 24/50
a c60366 343.mg 5.48gm 22/50
b c60366 1.30gm 21.7gm 0/50
c c60366 1.49gm n.s.s. 1/50
d c60366 3.34gm n.s.s. 0/50
e c60366 332.mg n.s.s. 47/50
f c60366 2.08gm n.s.s. 0/50
C.I. PIGMENT RED 23 6471-49-4
457 c60377 5.16gm n.s.s. 27/50
a c60377 16.2gm n.s.s. 5/50
b c60377 15.9gm n.s.s. 1/50
458 c60377 3.71gm n.s.s. 35/52
a c60377 5.46gm n.s.s. 13/52
b c60377 10.Ogm n.s.s. 5/52
459 c60377 2.99gm n.s.s. 48/50
a c60377 n.s.s. n.s.s. 0/50
460 c60377 6.85gm n.s.s. 0/50
a c60377 2.64gm n.s.s. 46/50
b c60377 9.92gm n.s.s. 3/50









































































462 c05970 140.mg n.s.s. 35/60
a c05970 441.mg n.s.s. 2/60
b c05970 465.mg n.s.s. 0/60
463 c05970 251.mg n.s.s. 33/60
a c05970 447.mg n.s.s. 12/60
b c05970 412.mg n.s.s. 6/60
464 c05970 49.5mg n.s.s. 49/50
a c05970 1.20gm n.s.s. 1/50
465 c05970 35.2mg n.s.s. 45/50
a c05970 51.Omg n.s.s. 42/50


















70.5mg 44/50 106.mg 42/50











RHODAMINE 6G (C.I. basic red 1.HC1) 989-38-8
466 c56122 144.mg n.s.s. 29/50 63.8mg 33/50
a c56122 481.mg n.s.s. 8/50 63.8mg 4/50
b c56122 397.mg n.s.s. 4/50 63.8mg 6/50
467 c56122 523.mg n.s.s. 0/50 118.mg 4/50
a c56122 351.mg n.s.s. 39/50 118.mg 33/50
b c56122 527.mg n.s.s. 13/50 118.mg 12/50
c c56122 831.mg n.s.s. 9/50 118.mg 7/50
468 c56122 18.8mg n.s.s. 3/50 5.89mg 3/50
a c56122 7.23mg n.s.s. 48/50 5.89mg 47/50
b c56122 n.s.s. n.s.s. 0/50 5.89mg 1/50
469 c56122 14.9mg n.s.s. 1/50 4.71mg 2/50
a c56122 6.86mg n.s.s. 48/50 4.71mg 49/50
b c56122 23.7mg n.s.s. 5/50 4.71mg 0/50
SACCHARIN, SODIUM*** 128-44-9
470 1986 16.5gm n.s.s. 0/40 2.00gm 0/40
SESAMOL (3,4-(methylenedioxy)-phenol) 533-31-3
471 2011 3.15gm 124.gm
a 2011 7.29gm n.s.s.
b 2011 7.29gm n.s.s.
c 2011 13.7gm n.s.s.
d 2011 8.27gm n.s.s.
472 2011 1.53gm 7.58gm
a 2011 6.73gm n.s.s.
b 2011 6.73gm n.s.s.
c 2011 4.87gm n.s.s.
d 2011 7.75gm n.s.s.
473 2011 579.mg 2.40gm
a 2011 1.97gm n.s.s.
b 2011 6.18gm n.s.s.
474 2011 655.mg 3.56gm
a 2011 720.mg 4.43gm
b 2011 2.63gm n.s.s.
c 2011 4.95gm n.s.s.
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Brkly Code
75Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
STERIGMATOCYSTIN*** bOng ..:..lug. : 10. :100 ... mg. : 10. :100 . g. :*10
476 P b cym eat MXB MXB 17y2l Ww + .218mg * P<.0005
a P b cym eat liv hpc 17y2l Ww
b P b cym eat liv clc 17y2l Ww
c P b cym eat ute ley 17y2l Ww
d P b cym eat liv ade 17y2l Ww
e P b cym eat kid rcc 17y2l Ww
f P b cym eat adr coa 17y2l Ww
g P b cym eat liv chc 17y2l Ww
h P b cym eat tba mix 17y2l Ww
i P b cym eat tba mal 17y2l Ww
j P b cym eat tba ben 17y2l Ww
SUCCINIC ANHYDRIDE
477 M f b6c gav TBA MXB 24m24
a M f b6c gav liv MXB 24m24
b M f b6c gav lun MXB 24m24
478 M m b6c gav TBA MXB 24m24
a M m b6c gav liv MXB 24m24
b M m b6c gav lun MXB 24m24
479 R f f34 gav TBA MXB 24m24
a R f f34 gav liv MXB 24m24
480 R m f34 gav TBA MXB 24m24
a R m f34 gav liv MXB 24m24
SUCROSE***
481 M f scp eat lun act 24m24 e
a M f scp eat liv nnd 24m24 e
b M f scp eat tba tum 24m24 e
482 M m scp eat lun act 94w94 e
a M m scp eat liv hpc 94w94 e
b M m scp eat liv nnd 94w94 e
c M m scp eat tba tum 94w94 e
SULFAMETHAZINE
483 M f b6c eat lun a/c 52w52 e
a M f b6c eat liv hpa 52w52 e
b M f b6c eat thy fca 52w52 e
484 M f b6c eat thy fca 78w78 e
a M f b6c eat liv hpa 78w78 e
b M fb6c eat lun a/c 78w78 e
485 M f b6c eat thy mix 24m24 e
a M f b6c eat thy fca 24m24 e
b M fb6c eat liv mix 24m24 e
c M fb6c eat liv hpa 24m24 e
d M fb6c eat lun a/c 24m24 e
e M f b6c eat liv hpc 24m24 e
f M f b6c eat thy fcc 24m24 e
486 M m b6c eat lun a/c 52w52 e
a M m b6c eat liv hpa 52w52 e
487 M m b6c eat thy fca 78w78 e
a M m b6c eat liv hpc 78w78 e
b M m b6c eat liv hpa 78w78 e
c M m b6c eat lun a/c 78w78 e
d M m b6c eat liv mix 78w78 e
488 M m b6c eat thy mix 24m24 e
a M m b6c eat thy fca 24m24 e
b M m b6c eat liv mix 24m24 e
c M m b6c eat liv hpa 24m24 e
d M m b6c eat thy fcc 24m24 e
e M m b6c eat liv hpc 24m24 e
f M m b6c eat lun a/c 24m24 e
TEMAZEPAM, PHARMACEUTICAL GRADE
489 M f cdl eat liv hpa 78w78 e
a M fcdl eat lun bro 78w78 e
b M fcdl eat lun alc 78w78 e
c M fcdl eat tba tum 78w78 e
490 M m cdl eat liv hpa 78w78 e
a M m cdl eat lun alc 78w78 e
b M m cdl eat tba tum 78w78 e
2-TERT-BUTYL-4-METHOXYPHENOL
491 R m f3d eat for tum 51w52
a R m f3d eat stg tum 51w52
p-TERT-BUTYLPHENOL
492 R m f3d eat for pam 51w52











lbOng..: . .lug .... -10 ..... -100 ....:.._mg ....: .-10 ..... -100 ....:.g....:*.10

















































+ 618.mg * P<.0005
2.82gm * P<.2
no dre P=1.





















lOng..: . lug...:..10 ..... -100 ....:..mg ....:..10 ..... -100 ...:.* -lg ....:..10
i 1.86gm * P<.03 -
9.61gm * P<.2 -
no dre P=1. -
no dre P=1. -
2.57gm * P<.4 -
no dre P=1. -
no dre P=1. -
1O0ng :. lug......10. :..100....1..: mg. :..10 .... 100 . * lg..... 10
no dre P=1.
no dre P=1.






RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
STERIGMATOCYSTIN*** 10048-13-2
































477 c55696 309.mg n.s.s. 27/50
a c55696 759.mg n.s.s. 2/50
b c55696 424.mg n.s.s. 3/50
478 c55696 118.mg n.s.s. 28/50
a c55696 81.4mg n.s.s. 13/50
b c55696 144.mg n.s.s. 5/50
479 c55696 56.3mg n.s.s. 55/60
a c55696 198.mg n.s.s. 2/60
480 c55696 63.1mg n.s.s. 54/60





































































































SULFAMETHAZINE (4-amino-N- (4, 6-dimethyl-2-pyrimidinyl) -benzenesulfonamide) 57-68-1
483 1924m 505.mg n.s.s. 0/24 39.Omg 0/24 156.mg 0/24 624.mg 1/22 Li
a 1924m 760.mg n.s.s. 0/24 39.Omg 1/24 156.mg 0/24 624.mg 0/22
b 1924m 535.mg n.s.s. 0/24 39.Omg 0/24 156.mg 1/24 624.mg 0/22
484 1924n 299.mg 1.76gm 0/24 39.Omg 1/24 156.mg 0/24 624.mg 9/23
a 1924n 645.mg n.s.s. 0/24 39.Omg 1/24 156.mg 1/24 624.mg 2/23
b 1924n 1.25gm n.s.s. 0/24 39.Omg 0/24 156.mg 1/24 624.mg 0/23
485 1924o 1.33gm 3.54gm 7/184 39.Omg 2/95 78.Omg 1/94 156.mg 0/96 312
a 1924o 1.39gm 3.75gm 7/184 39.0mg 2/95 78.0mg 0/94 156.mg 0/96 312
b 1924o 2.69gm n.s.s. 10/184 39.0mg 6/95 78.0mg 12/94 156.mg 5/96 312
c 1924o 3.26gm n.s.s. 8/184 39.0mg 5/95 78.0mg 8/94 156.mg 4/96 312
d 1924o 3.80gm n.s.s. 5/184 39.Omg 4/95 78.Omg 4/94 156.mg 1/96 312
e 1924o 4.64gm n.s.s. 2/184 39.0mg 1/95 78.0mg 4/94 156.mg 1/96 312
f 1924o 9.74gm n.s.s. 0/184 39.0mg 0/95 78.0mg 1/94 156.mg 0/96 312
486 1924m 33.9mg n.s.s. 1/24 36.Omg 0/24 144.mg 0/24 576.mg 0/24
a 1924m 153.mg n.s.s. 3/24 36.0mg 0/24 144.mg 1/24 (576.mg 0/24)
487 1924n 720.mg n.s.s. 0/24 36.Omg 1/24 144.mg 0/24 576.mg 2/24
a 1924n 1.95gm n.s.s. 3/24 36.0mg 2/24 144.mg 0/24 576.mg 0/24
b 1924n 635.mg n.s.s. 1/24 36.Omg 3/24 144.mg 5/24 576.mg 2/24
c 1924n 1.58gm n.s.s. 3/24 36.0mg 1/24 144.mg 2/24 576.mg 0/24
d 1924n 1.04gm n.s.s. 4/24 36.0mg 5/24 144.mg 2/24 576.mg 2/24
488 1924o 846.mg 1.77gm 3/191 36.0mg 0/96 72.0mg 1/96 144.mg 5/92 288
a 1924o 861.mg 1.81gm 3/191 36.Omg 0/96 72.Omg 1/96 144.mg 5/92 288
b 1924o 1.71gm n.s.s. 44/191 36.0mg 20/96 72.0mg 23/96 144.mg 27/92 288
c 1924o 2.37gm n.s.s. 26/191 36.0mg 12/96 72.0mg 12/96 144.mg 14/92 283
d 1924o 11.7gm n.s.s. 0/191 36.0mg 0/96 72.0mg 0/96 144.mg 0/92 283
e 1924o 3.16gm n.s.s. 21/191 36.0mg 9/96 72.0mg 11/96 144.mg 15/92 283
f 1924o 7.05gm n.s.s. 25/191 36.0mg 7/96 72.0mg 9/96 144.mg 6/92 283
TEMAZEPAM, PHARMACEUTICAL GRADE 846-50-4
489 1994 658.mg n.s.s. 0/100 10.Omg
a 1994 1.56gm n.s.s. 0/100 10.Omg
b 1994 670.mg n.s.s. 11/100 10.Omg
c 1994 546.mg n.s.s. 30/100 10.Omg
490 1994 561.mg n.s.s. 8/100 10.Omg
a 1994 1.76gm n.s.s. 24/100 10.Omg
















ittlefield; fctx, 27,455-463; 1989/1989a/pers comm.
2.mg 2/96 624.mg 34/94
2.mg 2/96 624.mg 33/94
2.mg 7/96 624.mg 11/94
2.mg 6/96 624.mg 8/94
2.mg 5/96 624.mg 6/94
2.mg 2/96 624.mg 4/94
2.mg 0/96 624.mg 1/94
8.mg 4/96 576.mg 44/94
8.mg 3/96 576.mg 44/94
8.mg 28/96 576.mg 22/94
8.mg 15/96 576.mg 14/94
83mg 1/96 576.mg 0/94
8.mg 13/96 576.mg 9/94









491 1950 303.mg n.s.s. 0/10 392.mg 0/15
a 1950 303.mg n.s.s. 0/10 392.mg 0/15
p-TERT-BUTYLPHENOL 98-54-4
492 1950 238.mg n.s.s. 0/10 588.mg 1/15
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493 R f cdr eat liv nnd 24m24 e
a R f cdr eat tba tum 24m24 e
494 R m cdr eat liv nnd 24m24 e
a R m cdr eat liv hpc 24m24 e
b R m cdr eat tba tum 24m24 e
TETRANITROMETHANE
495 M f b6c inh lun MXA 24m24
a M f b6c inh lun a/a 24m24
b M f b6c inh lun a/c 24m24
c M f b6c inh TBA MXB 24m24
d M f b6c inh liv MXB 24m24
e M f b6c inh lun MXB 24m24
496 M m b6c inh lun MXA 24m24
a M m b6c inh lun a/c 24m24
b M m b6c inh lun a/a 24m24
c M m b6c inh TBA MXB 24m24
d M m b6c inh liv MXB 24m24
e M m b6c inh lun MXB 24m24
497 R f f34 inh lun MXB 24m24
a R f f34 inh lun MXA 24m24
b R f f34 inh lun a/c 24m24
c R f f34 inh lun sqc 24m24
d R f f34 inh adr MXA 24m24
e R f f34 inh lun a/a 24m24
f R f f34 inh adr coa 24m24
g R f f34 inh TBA MXB 24m24
h R f f34 inh liv MXB 24m24
498 R m f34 inh lun MXB 24m24
a R m f34 inh lun MXA 24m24
b R m f34 inh lun a/c 24m24
c R m f34 inh tes MXA 24m24
d R m f34 inh lun a/a 24m24
e R m f34 inh lun sqc 24m24
f R m f34 inh pni ade 24m24
g R m f34 inh TBA MXB 24m24
h R m f34 inh liv MXB 24m24





































THIOACETAMIDE*** bO0ng..:. ....:.-10.... :.-100 . ...g... 1 : 0 -..100.. g. 10
499 M m icm eat liv hnd 40w88 er + 12.0mg







































500 R f f34 wat liv tum 26m30 e
501 R m f34 wat ssu tum 26m30 e
a R m f34 wat liv tum 26m30 e
THIOURACIL* **
502 R f f34 eat thy mal 24m24 e
a R f f34 eat liv hpc 24m24 e
503 R m f34 eat thy mal 24m24 es
a R m f34 eat liv hpc 24m24 es
TITANOCENE DICHLORIDE
504 R f f34 gav for sqp 24m25
a R f f34 gav TBA MXB 24m25
b R f f34 gav liv MXB 24m25
505 R m f34 gav for sqp 24m24
a R m f34 gav mul msm 24m24
b R m f34 gav pan ana 24m24
c R m f34 gav for MXA 24m24
d R m f34 gav TBA MXB 24m24
e R m f34 gavliv MXB 24m24
TOLUENE* * *
506 M f b6c inh TBA MXB 24m24
a M f b6c inh liv MXB 24m24
b M f b6c inh lun MXB 24m24
507 M m b6c inh TBA MXB 24m24
a M m b6c inh liv MXB 24m24
b M m b6c inh lun MXB 24m24
508 R f f34 inh TBA MXB 24m24
a R f f34 inh liv MXB 24m24
509 R m f34 inh TBA MXB 24m24
a R m f34 inh liv MXB 24m24
O0ng. . lug. :. -10.*.. .-100 . : 1_mg. :. -10.*.. .-100. : ig. : .10
. > no dre P=1.
+ 224.mg P<.002 -
2.76gm P<.9 -










































RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
TETRAETHYLTHIURAM DISULFIDE*** (ethyl tuads) 97-77-8
493 1962 153.mg n.s.s. 1/50 25.Omg 1/49
a 1962 10.Omg n.s.s. 47/50 25.Omg 46/50
494 1962 110.mg n.s.s. 0/50 20.Omg 1/50
a 1962 206.mg n.s.s. 1/50 20.0mg 0/50
b 1962 34.6mg n.s.s. 42/50 20.0mg 32/50
Cheever; faat,14,243-261;1990
TETRANITROMETHANE 509-14-8
495 c55947 .891mg 2.31mg 4/50
a c55947 1.04mg 2.49mg 1/50
b c55947 1.16mg 2.88mg 3/50
c c55947 1.68mg n.s.s. 40/50
d c55947 12.1mg n.s.s. 13/50
e c55947 .891mg 2.31mg 4/50
496 c55947 .695mg 1.91mg 12/50
a c55947 .771mg 1.90mg 6/50
b c55947 .975mg 2.95mg 7/50
c c55947 .852mg 5.23mg 39/50
d c55947 3.89mg n.s.s. 23/50
e c55947 .695mg 1.91mg 12/50
497 c55947 .513mg .998mg 0/50
a c55947 .516mg 1.01mg 0/50
b c55947 .559mg 1.11mg 0/50
c c55947 2.91mg 13.Omg 0/50
d c55947 6.23mg 1.15gm 0/50
e c55947 3.29mg n.s.s. 0/50
f c55947 7.13mg n.s.s. 0/50
g c55947 .839mg n.s.s. 47/50
h c55947 9.27mg n.s.s. 1/50
498 c55947 .210mg .453mg 1/50
a c55947 .224mg .491mg 1/50
b c55947 .252mg .551mg 0/50
c c55947 .265mg 1.52mg 33/50
d c55947 .655mg 3.33mg 1/50
e c55947 .956mg 3.50mg 0/50
f c55947 1.25mg n.s.s. 3/50
g c55947 .289mg 2.20mg 47/50


















































































499 1959 6.19mg 28.4mg 0/15
a 1959 7.55mg 42.3mg 0/15
THIOCYANATE, SODIUM 540-72-7
500 1898 289.mg n.s.s. 4/24
501 1898 90.8mg 968.mg 0/24







Lij insky; txih, 5,25-29;1989
THIOURACIL*** 141-90-2
502 1947 13.8mg 42.Omg 5/214
a 1947 14.Omg n.s.s. 0/214
503 1947 4.59mg 16.2mg 5/214















504 c04502 114.mg n.s.s. 0/60
a c04502 21.7mg n.s.s. 55/60
b c04502 114.mg n.s.s. 0/60
505 c04502 30.6mg 10.4gm 0/60
a c04502 67.1mg 1.74gm 0/60
b c04502 33.4mg n.s.s. 0/60
c c04502 64.2mg n.s.s. 0/60
d c04502 13.Omg n.s.s. 52/60































TOLUENE** (monomethyl benzene) 108-88-3
506 c07272 607.mg n.s.s. 33/50 151.mg
a c07272 1.57gm n.s.s. 7/50 151.mg
b c07272 2.27gm n.s.s. 5/50 151.mg
507 c07272 511.mg n.s.s. 29/60 126.mg
a c07272 985.mg n.s.s. 19/60 126.mg
b c07272 1.87gm n.s.s. 9/60 126.mg
508 c07272 176.mg n.s.s. 46/50 180.mg
a c07272 1.41gm n.s.s. 2/50 180.mg
509 c07272 94.1mg n.s.s. 43/50 126.mg
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2,4,6-TRINITRO-1,3-DIMETHYL-5-TERT-BUTYLBENZENE.... 10. :*100 .... :._mg.. : 10. :*100 . ... :*-10
510 M f b6c eat liv mix 80w90 + . 203.mg * P<.0005+
a M f b6c eat liv hpa 80w90 234.mg * P<.0005+
b M f b6c eat ute ess 80w90 533.mg \ P<.02
c M f b6c eat lun mix 80w90 1.30gm P<.l
d M f b6c eat lun ade 80w90 1.63gm P<.l
e M f b6c eat liv hpc 80w90 2.19gm P<.l
f M f b6c eat --- lym 80w90 1.30gm P<.3
g M f b6c eat hag mix 80w90 2.25gm P<.5
h M f b6c eat lun car 80w90 6.65gm P<1.
i M f b6c eat tba mal 80w90 418.mg P<.06 +
511 M m b6c eat liv mix 80w90 + 92.1mg P<.0005+
a M m b6c eat liv hpc 80w90 313.mg P<.002 +
b M m b6c eat liv hpa 80w90 232.mg P<.02 +
c M m b6c eat hag ade 80w90 383.mg P<.02 +
d M m b6c eat hag mix 80w90 425.mg P<.04 +
e M m b6c eat lun ade 80w90 1.20gm P<.3
f M m b6c eat hag car 80w90 no dre P=1.
g M m b6c eat tba mal 80w90 334.mg P<.07 +
TRINITROGLYCERIN
512 R f cdr eat liv mix 24m24 e
513 R m cdr eat liv mix 24m24 e
a R m cdr eat tes ict 24m24 e
TRIS (2-CHLOROETHYL) PHOSPHATE
514 M f b6c gav ute esp 24m24
a M f b6c gav mgl adc 24m24
b M f b6c gav hag MXA 24m24
c M f b6c gav TBA MXB 24m24
d M f b6c gav liv MXB 24m24
e M f b6c gav lun MXB 24m24
515 M m b6c gav kid MXA 24m24
a M m b6c gav kid ruc 24m24
b M m b6c gav kid rua 24m24
c M m b6c gav TBA MXB 24m24
d M m b6c gav liv MXB 24m24
e M m b6c gav lun MXB 24m24
516 M m b6c gav kid rua 24m24
517 R f f34 gav kid rua 24m24
a R f f34 gav thy MXA 24m24
b R f f34 gav mul mnl 24m24
c R f f34 gav thy fcc 24m24
d R f f34 gav ute ess 24m24
e R f f34 gav TBA MXB 24m24
f R f f34 gav liv MXB 24m24
518 R m f34 gav kid MXA 24m24
a R m f34 gav kid rua 24m24
b R m f34 gav amd XA 24m24
c R m f34 gav mul mnl 24m24
d R m f34 gav sub fib 24m24
e R m f34 gav thy MXA 24m24
f R m f34 gav MXA grb 24m24
g R m f34 gav kid ruc 24m24
h R m f34 gav TBA MXB 24m24
i R m f34 gav liv MXB 24m24
lbOng..: .lug .... -10 *..... -100 ....1:..lmg ....:.-10 ..... -100 ....j: *-g ....g:..10
+ 329.mg * P<.0005+
+ 221.mg * P<.0005+
405.mg * P<.0005+
lbOng..:.lug.... 10. :100 .._ mg :. - .... :.1-100 .... :-g.10
± + 2.42gm * P<.05
3.05gm * P<.05




:> 6.81gm * P<.6 e





with step .> 5.09gm * P<.3 e
:+ 187.mg * P<.003 c
203.mg * P<.005 e





:+ : 56.4mg / P<.0005c
56.9mg / P<.0005c
49.5mg \ P<.03
107.mg * P<.02 e
246.mg * P<.03
338.mg * P<.06 e
705.mg * P<.04
8.40gm * P<.9 c
56.8mg * P<.08
633.mg * P<.08
TRIS(2-HYDROXYPROPYL)AMINE 1 O0ng .: lug.... :.-10.... :.-100.... :._mg. :.-10... 0 : 01 ° O. -:i.-g .....g..10
519 R m wis eat liv tum 24m24 r .> no dre P=1.
Trp-P-2 ACETATE***
520 R f aci eat liv nnd 29m29 ej
a R f aci eat liv mix 29m29 ej
b R f aci eat jej adc 29m29 ej
c R f aci eat ilm ade 29m29 ej
d R f aci eat liv hms 29m29 ej
521 R m aci eat liv tum 29m29 ej
522 R f f3d eat cli mix 26m26 e
a R f f3d eat mgl mix 26m26 e
b R f f3d eat --- mly 26m26 e
c R f f3d eat ute esp 26m26 e
d R f f3d eat mgl mix 26m26 e
e R f f3d eat cli ade 26m26 e
f R f f3d eat cli adc 26m26 e
g R f f3d eat liv hpa 26m26 e
h R f f3d eat mgl ade 26m26 e
i R f f3d eat ubl tpp 26m26 e
523 R m f3d eat ubl mix 26m26 e
a R m f3d eat ubl tpp 26m26 e
b R m f3d eat mgl mix 26m26 e
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2,4, 6-TRINITRO-1, 3-DIMETHYL-5-TERT-BUTYLBENZENE (musk xylol) 81-15-2
510 1989 125.mg 466.mg
a 1989 140.mg 641.mg
b 1989 184.mg n.s.s.
c 1989 495.mg n.s.s.
d 1989 565.mg n.s.s.
e 1989 662.mg n.s.s.
f 1989 361.mg n.s.s.
g 1989 462.mg n.s.s.
h 1989 1.08gm n.s.s.
i 1989 179.mg n.s.s.
511 1989 57.2mg 207.mg
a 1989 168.mg 1.43gm
b 1989 113.mg n.s.s.
c 1989 189.mg 136.gm
d 1989 192.mg n.s.s.
e 1989 333.mg n.s.s.
f 1989 1.31gm n.s.s.









































































Maekawa; fctx, 28, 581-586; 1990/pers. comm.
TRINITROGLYCERIN 55-63-0
512 1995 184.mg 687.mg 0/29 5.00mg 1/32
513 1995 121.mg 473.mg 1/24 4.00mg 0/28
a 1995 195.mg 1.24gm 2/24 4.00mg 1/28
TRIS (2-CHLOROETHYL) PHOSPHATE 115-96-8
514 c60128 830.mg n. s.
a c60128 923.mg n.s.s.
b c60128 403.mg n.s.s.
c c60128 177.mg n.s.s.
d c60128 543.mg n.s.s.
e c60128 724.mg n.s.s.
515 c60128 934.mg n.s.s.
a c60128 1.38gm n.s.s.
b c60128 1.18gm n.s.s.
c c60128 124.mg n.s.s.
d c60128 147.mg n.s.s.
e c60128 322.mg n.s.s.
516 c60128 1.22gm n.s.s.
517 c60128 80.8mg 900.mg
a c60128 87.3mg 1.50gm
b c60128 40.3mg n.s.s.
c c60128 106.mg n.s.s.
d c60128 174.mg n.s.s.
e c60128 17.2mg n.s.s.
f c60128 n.s.s. n.s.s.
518 c60128 34.7mg 111.mg
a c60128 35.5mg 106.mg
b c60128 20.8mg n.s.s.
c c60128 50.8mg n.s.s.
d c60128 102.mg n.s.s.
e c60128 124.mg n.s.s.
f c60128 209.mg n.s.s.
g c60128 322.mg n.s.s.
h c60128 22.4mg n.s.s.































50.Omg 3/28 500.mg 16/25
40.Omg 4/26 400.mg 15/21

















































































519 1910 3.46gm n.s.s. 0/21 800.mg 0/21 Yamamoto;clet,45,221-225;1989
Trp-P-2 ACETATE*** (3-amino-l-methyl-5H-pyrido[4, 3-b] indole acetate) 72254-58-1
520 1225m 1.68mg 16.4mg 0/30 5.00mg 6/9
a 1225m 1.68mg 16.4mg 0/30 5.00mg 6/9
b 1225m 6.72mg n.s.s. 0/30 5.00mg 1/9
c 1225m 6.72mg n.s.s. 0/30 5.00mg 1/9
d 1225m 6.72mg n.s.s. 0/30 5.00mg 1/9
521 1225m 11.7mg n.s.s. 0/30 4.00mg 0/10
522 2046 4.41mg 419.mg 2/28 1.50mg 8/30 5.00mg 11/30
a 2046 4.48mg 699.mg 3/28 1.50mg 7/30 5.00mg 12/30
b 2046 11.0mg 208.mg 0/28 1.50mg 0/30 5.00mg 5/30
c 2046 1.54mg n.s.s. 2/28 1.50mg 10/30 (5.00mg 8/30)
d 2046 5.02mg n.s.s. 3/28 1.50mg 6/30 5.00mg 11/30
e 2046 5.18mg n.s.s. 2/28 1.50mg 8/30 5.00mg 9/30
f 2046 18.6mg n.s.s. 0/28 1.50mg 0/30 5.00mg 2/30
g 2046 10.5mg n.s.s. 1/28 1.50mg 5/30 5.00mg 3/30
h 2046 18.7mg n.s.s. 0/28 1.50mg 1/30 5.00mg 1/30
i 2046 23.4mg n.s.s. 1/28 1.50mg 1/30 5.00mg 1/30
523 2046 4.87mg 26.7mg 0/30 1.20mg 2/29 4.00mg 9/30
a 2046 5.77mg 48.0mg 0/30 1.20mg 2/29 4.00mg 7/30
b 2046 3.66mg n.s.s. 6/30 1.20mg 5/29 4.00mg 14/30
Hosaka;clet,13,23-28;1981/Ohgaki 1991
Takahashi;gann, 84, 852-858; 1993/pers .comm.
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TD50 2Tailpvl
DR AuOp
c R m f3d eat liv hpa 26m26 e
d R m f3d eat ubl tcc 26m26 e
e R m f3d eat liv hpc 26m26 e
10.7mg * P<.03 +
59.9mg * P<.07
no dre P=1.
URETHANE*** lOOng..:.ug.... :g10 ...: 100 . mg. : .100 .. g. 10
524 M m b6c wat lun mix 65w70 aes + 5.91mg * P<.0005+
a M m b6c wat lun a/a 65w70 aes
b M m b6c wat liv hem 65w70 as
c M m b6c wat liv hes 65w70 as
d M m b6c wat lun a/c 65w70 aes
e M m b6c wat hea hes 65w70 as
f M m b6c wat liv hpa 65w70 as
g M m b6c wat liv hpc 65w70 as
525 P b cym eat MXB MXB 5y23 jw
a P b cym eat pan adc
b P b cym eat liv hes
c P b cym eat liv hpa
d P b cym eat lun bro
e P b cym eat tba mal
f P b cym eat tba mix
g P b cym eat tba ben
526 P b rhe eat MXB MXB
a P b rhe eat jej adc
b P b rhe eat chp sqp
c P b rhe eat adr phe
d P b rhe eat liv hpc
e P b rhe eat liv hes
f P b rhe eat tba mix
g P b rhe eat tba mal

























































VINYL TOLUENE (65-71% m- and 32-35% p-)..:.. ug.. :.10. :100.. mg..:10. :100 ... 1g . :10
527 M f b6c inh TBA MXB 24m24 :> no dre P=1.
a M f b6c inh liv MXB 24m24 no dre P=1.
b M f b6c inh lun MXB 24m24 750.mg * P<.6
528 M m b6c inh TBA MXB 24m24 :> no dre P=1.
a M m b6c inh liv MXB 24m24 no dre P=1.
b M m b6c inh lun MXB 24m24 no dre P=1.
529 R f f34 inh TBA MXB 24m24 :> 312.mg * P<.6
a R f f34 inh liv MXB 24m24 no dre P=1.
530 R m f34 inh TBA MXB 24m24 :> no dre P=1.
a R m f34 inh liv MXB 24m24 no dre P=l.
HC YELLOW 4
531 M f b6c eat TBA MXB 24m24
a M f b6c eat liv MXB 24m24
b M f b6c eat lun MXB 24m24
532 M m b6c eat TBA MXB 24m24
a M m b6c eat liv MXB 24m24
b M m b6c eat lun MXB 24m24
533 R f f34 eat TBA MXB 24m24
a R f f34 eat liv MXB 24m24
534 R m f34 eat psd ade 24m24
a R m f34 eat TBA MXB 24m24
b R m f34 eat liv MXB 24m24
lOng ..: ..lug....:.-10 ..... -100 ....:..lsmg.... -10 ..... -100....:1*Ig ....:..10
:> no dre P=1.
no dre P=1.
no dre P=1.











RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
c 2046 4.47mg n.s.s. 4/30 1.20mg
d 2046 14.7mg n.s.s. 0/30 1.20mg
e 2046 6.45mg n.s.s. 1/30 1.20mg
URETHANE*** (ethyl carbamate) 51-79-6





































































































































7/48 1.00mg 8/50 10.Omg 34/50 100.mg 42/44
0/50 1.00mg 0/50 10.Omg 2/50 100.mg 20/50
0/50 1.00mg 2/50 10.Omg 2/50 100.mg 11/50
0/48 1.00mg 0/50 10.Omg 0/50 100.mg 6/44
0/50 1.00mg 0/50 10.Omg 0/50 100.mg 4/50
8/50 1.00mg 4/50 10.Omg 9/50 (100.mg 0/50)
1/50 1.00mg 0/50 10.Omg 2/50 100.mg 0/50
Adamson;ossc, 129-156;
1982/Thorgeirsson 1994/Dalgard 1991/Thorgeirsson&Seiber pers.comm.
VINYL TOLUENE (65-71% m- and 32-35% p-)
527 c56406 73.Omg n.s.s. 29/50 14.!
a c56406 52.8mg n.s.s. 9/50 14.!
b c56406 112.mg n.s.s. 3/50 14.!
528 c56406 17.4mg n.s.s. 33/50 12.
a c56406 73.7mg n.s.s. 17/50 12.
b c56406 38.9mg n.s.s. 12/50 12.
529 c56406 52.1mg n.s.s. 48/50 35.,
a c56406 n.s.s. n.s.s. 0/50 35.,
530 c56406 41.3mg n.s.s. 48/50 25.
a c56406 213.mg n.s.s. 2/50 25.
HC YELLOW 4 59820-43-8
531 c56019 2.85gm n.s.s. 30/50 642
a c56019 4.37gm n.s.s. 6/50 642
b c56019 8.03gm n.s.s. 4/50 642
532 c56019 1.95gm n.s.s. 28/50 589
a c56019 2.44gm n.s.s. 13/50 589
b c56019 2.71gm n.s.s. 8/50 589
533 c56019 389.mg n.s.s. 49/50 246
a c56019 3.63gm n.s.s. 1/50 246
534 c56019 142.mg n.s.s. 17/51 98.
a c56019 153.mg n.s.s. 47/51 98.
b c56019 1.81gm n.s.s. 1/51 98.
25013-15-4
9mg 27/50 37.3mg 17/50
9mg 5/50 (37.3mg 2/50)
9mg 2/50 37.3mg 4/50
4mg 23/50 (31.1mg 20/50)
4mg 14/50 31.1mg 14/50
4mg 5/50 (31.1mg 2/50)
8mg 41/50 107.mg 46/50
,8mg 0/50 107.mg 0/50
,lmg 48/50 75.2mg 48/50





liv: hpa, hpc, nnd.
liv:hpa,hpc,nnd.
.mg 24/50 1.28gm 21/50
!.mg 8/50 1.28gm 4/50
!.mg 2/50 1.28gm 2/50
).mg 23/50 1.18gm 23/50
).mg 10/50 1.18gm 12/50
).mg 9/50 1.18gm 7/50
;.mg 49/50 495.mg 48/50
5.mg 1/50 495.mg 0/50
.7mg 20/50 198.mg 28/50
,7mg 48/50 198.mg 45/50
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74-31-7 AGERITE DPPD (see DIPHENYL-p-PHENYLENEDIAMINE)




















25013-16-5 BHA(see BUTYLATED HYDROXYANISOLE)
128-37-0 BHT(see BUTYLATED HYDROXYTOLUENE)
110-97-4 BIS(2-HYDROXYPROPYL)AMINE
56-35-9 BIS(TRI-N-BUTYLTIN)OXIDE, TECHNICAL GRADE
2429-74-5 C.I. DIRECT BLUE 15
3844-45-9 FD & C BLUE NO. 1
869-01-2 BNU (see N-N-BUTYL-N-NITROSOUREA)
3844-45-9 BRILLIANT BLUE FCF(see FD & C BLUE NO. 1)
74-83-9 BROMOMETHANE (see METHYL BROMIDE)
106-99-0 1,3-BUTADIENE
























(see :CS2 (94% o-CHLOROBENZALMALONONITRILE,








CS2 (94% o-CHLOROBENZALMALONONITRILE, 5% Cab-O-Sil
COLLOIDAL SILICA, 1% HEXAMETHYLDISILIZANE)
(CAS Number 2698-41-1, 7631-86-9, and 999-97-3)
51630-58-1 CYANO-(3-PHENOXYPHENYL)METHYL-4-CHLORO-a-
(1-METHYLETHYL)BENZENE ACETATE (see FENVALERATE)
mixture CYCASIN AND METHYLAZOXYMETHANOL ACETATE
(CAS Number 592-62-1 and 14901-08-7)
59865-13-3 CYCLOSPORIN A
60-11-7 DAB (see N,N-DIMETHYL-4-AMINOAZOBENZENE)
52918-63-5 DELTAMETHRIN
141-05-9 DEM (see DIETHYLMALEATE)
55-18-5 DEN (see N-NITROSODIETHYLAMINE)
56-53-1 DES (see DIETHYLSTILBESTROL)







55-18-5 DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
55-18-5 N,N-DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
56-53-1 DIETHYLSTILBESTROL







62-75-9 DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
62-75-9 N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
74-31-7 DIPHENYL-p-PHENYLENEDIAMINE
621-64-7 DIPROPYLNITROSAMINE(see N-NITROSODIPROPYLAMINE)
97-77-8 DISULFIRAM (see TETRAETHYLTHIURAM DISULFIDE)
62-75-9 DMN (see N-NITROSODIMETHYLAMINE)
2385-85-5 1,la,2,2,3,3a,4,5,5,5a,5b,6-DODECACHLOROOCTAHYDRO-1,3,4-
METHENO-1H-CYCLOBUTA[cd]PENTALENE (see MIREX)
90-43-7 DOWICIDE 1 (see o-PHENYLPHENOL)
40762-15-0 DOXEFAZEPAM





51-79-6 ETHYL CARBAMATE (see URETHANE)
614-95-9 1-ETHYL-1-NITROSOURETHAN (see NITROSOETHYLURETHAN)
614-95-9 N-ETHYL-N-NITROSOURETHANE (see NITROSOETHYLURETHAN)
97-77-8 ETHYLTUADS (see TETRAETHYLTHIURAM DISULFIDE)







96-45-7 ETU (see ETHYLENETHIOUREA)
51630-58-1 FENVALERATE



















PHENYL)ETHANONE (see COMPOUND LY171883)













88107-10-2 LY171883, COMPOUND (see COMPOUND LY171883)
67-20-9 MACRODANTIN
(see 1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN)
7791-18-6 MAGNESIUM CHLORIDE HEXAHYDRATE
mixture MAM ACETATE AND CYCASIN













mixture METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE





533-31-3 3,4-(METHYLENEDIOXY)-PHENOL (see SESAMOL)
95-71-6 METHYLHYDROQUINONE
115-09-3 METHYLMERCURY CHLORIDE(see MERCURYMETHYL CHLORIDE)
598-57-2 METHYLNITRAMINE
2385-85-5 MIREX
70-25-7 MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
684-93-5 MNU (see N-NITROSO-N-METHYLUREA)
79-11-8 MONOCHLOROACETIC ACID









































































































DI-sec-OCTYL PHTHALATE (see DI(2-ETHYLHEXYL)PHTHALATE)










PHENOBARBITONE, SODIUM (see PHENOBARBITAL, SODIUM)
PHENYLBUTAZONE











C.I. ACID RED 114
C.I. BASIC RED 1.HCI (see RHODAMINE 6G)
C.I. PIGMENT RED 3





SODIUM AZIDE (see AZIDE, SODIUM)
SODIUM BENZOATE (see BENZOATE, SODIUM)
SODIUM BICARBONATE
SODIUM FLUORIDE(see FLUORIDE, SODIUM)











































VINYLTOLUENE (65-71% m- and 32-35% p-)
HC YELLOW 4
CAS, Chemical Abstracts Service registry number
Appendix 2. Chemical Names in This Plot
Listed by CAS Number
CAS
Number Chemical name
mixture CYCASIN AND METHYLAZOXYMETHANOL ACETATE






















































103-90-2 ACETAMINOPHEN (Tylenol, paracetamol)
106-92-3 ALLYL GLYCIDYL ETHER
106-99-0 1,3-BUTADIENE




108-88-3 TOLUENE (monomethyl benzene)
110-00-9 FURAN
110-97-4 BIS(2-HYDROXYPROPYL)AMINE
115-09-3 MERCURYMETHYL CHLORIDE (methylmercuric chloride.)
115-96-8 TRIS(2-CHLOROETHYL)PHOSPHATE
117-39-5 QUERCETIN


































846-50-4 TEMAZEPAM, PHARMACEUTICAL GRADE
869-01-2 N-N-BUTYL-N-NITROSOUREA
930-55-2 N-NITROSOPYRROLIDINE











Number Chemical name Number Chemical name




2425-85-6 C.I. PIGMENT RED 3 1-(2-HYDROXYPROPYL)-NITROSO-3-CHLOROETHYLUREA
2429-74-5 C.l. DIRECT BLUE 15 2-OXOPROPYLNITROSOUREA
2922-54-5 MONOSODIUM SUCCINATE 3-METHYLBUTANAL METHYLFORMYLHYDRAZONE
3817-11-6 N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE N-NITROSO-2-PHENYLETHYLUREA
(butyl-butanol-nitrosamine) N-NITROSO-ETHYL-2-OXOPROPYLUREA
3844-45-9 FD & C BLUE NO. 1 (brilliant blue FCF) N-NITROSO-ETHYLHYDROXYETHYLUREA
4164-28-7 DIMETHYLNITRAMINE N-NITROSO-OXOPROPYLCHLOROETHYLUREA
4180-23-8 trans-ANETHOLE (trans-p-propenylanisole) N-NITROSO-OXOPROPYLUREA
5634-39-9 IODINATED GLYCEROL (Organidin) PhIP.HCI (2-amino-i-methyl-6-phenylimidazo[4,5-b]-pyrid
5989-27-5 D-LIMONENE
6381-77-7 ERYTHORBATE, SODIUM (isoascorbate) CAS, Chemical Abstracts Service registry number
6459-94-5 C.I. ACID RED 114
6471-49-4 C.I. PIGMENT RED 23
7336-20-1 4,4'-DIAMINO-2,2'-STILBENEDISULFONIC ACID, DISODIUM SALT Appendix 3. Strain Codes and Definitions
7487-94-7 MERCURIC CHLORIDE
7631-89-2 ARSENATE, SODIUM Code Strain
7632-00-0 NITRITE, SODIUM
7681-49-4 FLUORIDE, SODIUM aci ACI
7722-84-1 HYDROGEN PEROXIDE ain ACI/n
7791-18-6 MAGNESIUM CHLORIDE HEXAHYDRATE b62 monohybrid cross offspring of B6CF1 (C57BL/6 x BALB/c
9005-65-6 POLYSORBATE 80 b6c 16C3F1
10048-13-2 STERIGMATOCYSTIN bal BALB/c
10108-64-2 CADMIUM CHLORIDE bbb Bush babies [Galago crassicaudatus]
10124-36-4 CADMIUM SULPHATE (1:1) bcn BALB/c StCrIfC3Hf/Nctr
10589-74-9 1-AMYL-1-NITROSOUREA bdf BD VI
11013-97-1 METHYL HESPERIDIN c56 C57BL/6J
13743-07-2 1-(2-HYDROXYETHYL)-1 -NITROSOUREA c5c C57BL/1OScSn
(N-nitroso-2-hydroxethylurea) c6s C57BL/6CrSIc
18774-85-1 N-HEXYLNITROSOUREA c7b (C57BL/6 x BALB/c)F1
20325-40-0 3,3'-DIMETHOXYBENZIDINE.2HCI cb6 C57BL/6
23282-20-4 NIVALENOL cdl Charles River CD1
25013-15-4 VINYLTOLUENE (65-71% m- and 32-35% p-) cdf CDF1
25013-16-5 BUTYLATED HYDROXYANISOLE cdr Charles River CD
(BHA, 2(3)-tert-butyl-4-hydroxyanisole) cen C3H/HeN
26628-22-8 AZIDE, SODIUM clw Colworth (Wistar derived)
29975-16-4 ESTAZOLAM cym Cynomolgus [Macaca fascicularis]
40762-15-0 DOXEFAZEPAM f34 Fischer 344
51481-61-9 CIMETIDINE f3d F344/DuCrj
51630-58-1 FENVALERATE (cyano-(3-phenoxyphenyl)methyl-4-chloro-a- f31 Fischer 344/LATI
(1-methylethyl)benzene acetate) icm ICR
52214-84-3 CIPROFIBRATE mrc MRC
52918-63-5 DELTAMETHRIN nmb Bor:NMRI, SPF-bred NMRI
55090-44-3 N-NITROSO-N-METHYL-N-DODECYLAMINE nmr NMRI
55984-51-5 N-NITROSOMETHYL(2-OXOPROPYL)AMINE of1 OF1
56980-93-9 CELIPROLOL ofs OFA (Sprague-Dawley derived)
59820-43-8 HC YELLOW 4 osm Osborne-Mendel
59865-13-3 CYCLOSPORIN A rhe Rhesus [Macaca mulatta]
60599-38-4 N-NITROSOBIS(2-OXOPROPYL)AMINE scp Cpb:Swiss random
64519-82-0 ISOMALT swa Swiss albino
67587-52-4 N-NITROSO-2-HYDROXYMORPHOLINE swi Swiss
69112-98-7 2-FLUOROETHYL-NITROSOUREA syg Syrian golden
71752-70-0 1-(3-HYDROXYPROPYL)-1-NITROSOUREA wal Wistar albino
72254-58-1 Trp-P-2 ACETATE wis Wistar










CS2 (94% o-CHLOROBENZALMALONONITRILE, 5% Cab-O-Sil
COLLOIDAL SILICA, 1% HEXAMETHYLDISILIZANE)
(CAS Number 2698-41-1, 7631-86-9, and 999-97-3)
DIETHYLACETYLUREA
Jine.HCI)
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Appendix 4. Route of Administration Codes
and Definitions






Used for two compounds: 1) procarbazine.HCI (monkeys): a variety
of combinations of diet, subcutaneous, intraperitoneal, and
intravenous injection; 2) aflatoxin B1 (monkeys): a combination of
diet and intraperitoneal injection.
wat water















































mam mammary tissue (other than or including more than mammary
gland)
mgl mammary gland
mix more than one site; sites specified in published paper
mth mouth
mul multiple organs
MXA more than one site, combined by NCI/NTP
Code Site




nof nasal cavity, olfactory epithelium
npc nasal and paranasal cavity
npl nipple
















psd pituitary gland, pars distalis













TBA all tumor bearing animals, NCI/NTP
































































































































































































mixed cell mucoepidermoid papilloma
mesothelioma, NOS
fibrous histiocytoma, malignant
more than one tumortype; tumortypes specified in published
paper
malignant lymphoma, histiocytic type
malignant lymphoma, mixed type
malignant lymphoma, lymphocytic type












more than one tumortype, combined by NCI/NTP







olfactory lobe, glioma malignant














































































































tum tumor or more than one tumortype; tumortypes not specified in
published paper
uac tubular-cell adenocarcinoma
vsc all vascular tumors
Appendix 7. Note Codes and Definitions
Code Definition
a The exposure time reported on the plot is an average ofthe
different exposure times ofthe individual dose groups in the
experiment. For NCI/NTP, both exposure and experiment times
have been averaged because of differential survival among the
dose groups. (In theTD50calculation forthe NCI/NTP bioassays,
full lifetable data have been used.)
e Forthe general literature we have used an effective number of
animals in a group whenever possible. This effective number is
either: (a) the number ofanimals alive atthetime of appearance
ofthe firsttumor, or ifthat is not reported, then (b)the number of
animals examined.
f Diet was specially prepared to have a lowerthan average protein
level.
g Some or all ofthe animals were used as breeders during the
course ofthe experiment.
j The data forthis test have been previously published in the
database. The experimental results have been revised and repub-
lished bythe authors. In the database, we give the same refer-
ence numberto the test in both publications.
k For interim and serial sacrifice experiments, we have reported, as
a separate experimentwith a k notecode, each sacrifice time that
otherwise metthe inclusion rules ofthe database. Wherever
possible, we have included unscheduled deaths with the terminal
sacrifice data, and when this has been done, there is no "k"
notecode fortheterminal sacrifice experiment.
m The calculated dose level fora group is an average of either(a)
different doses administered to individual animals, or(b)the
range of doses administered.
o Chemical was administered as an aerosol.
r Restricted site analysis; the authors either examined orchose to
report data for only a few selected tissues.
s Authors noted thatsurvival was decreased due totoxicity, disease,
oraccidental death.
u Monkey tests are still in progress for IQ administered by gavage
and diethylnitrosamine by intraperitoneal route.
v Variable or irregulardosing schedules have been used, e.g., dose
level changed during the experiment.
w For experiments in nonhuman primates, control animals are from
the NCI colony, which was started in 1961; some animals have
been used as breeders. Tumor data forcontrol animals are derived
from 132 cynomolgus and 122 rhesus monkeys, and 9 bush
babies. Fourteen ofthese rehsus and 33cynomolgus are still
alive. The denominators in the tumor incidence column ofthe plot
are the numbers alive atthe age ofthefirst death in any group
with a tumor ofthattype.TD5,values for nonhuman primates are
calculated using lifetable data. Methods are given in the text.
W Tumors found atdeath in control monkeysthat lived to an older
age than the last dosed animal are not reported in the tumor
incidence column ofthe plot.




/ signficant departure from linearity, upward curvature
significant departure from lineaarity, downward curvature
Z significant departure from linearity, more than three dose groups
including controls
blank either no dose-related effect, or no curve shape could be deter-
mined because experiment had onlytwo dose groups including
controls












































Fundamental and Applied Toxicology
Food and Chemical Toxicology
(formerly Food and CosmeticsToxicology, until 1982)
Japanese Journal of Cancer Research
(formerly Gann until 1984)
Hiroshima Journal of Medical Sciences
International Journal ofCancer
(formerly International Union Against Cancer until 1964)
International Research and Development Corporation Final Report,
Mattawan, Ml. Contracted by Uniroyal Chemical Company, Inc.,
Bethany, Connecticut
Israel Journal of Medicine and Science
Journal ofthe American College ofToxicology
Journal ofAppliedToxicology
Japanese Journal of Hygene
Japanese Journal ofVeterinary Science
Journal ofToxicology and Environmental Health
Neoplasma
Organ and Species Specificity in Chemical Carcinogenesis
(Langenbach R, Nesnow S, Rice JM, eds). NewYork:Plenum
Press, 1982
Pharmacometrics
Regulatory Toxicology and Pharmacology
Tumori
Toxicology and Applied Pharmacology
Toxicology
Toxicological and Environmental Chemistry
Toxicology and Industrial Health
Toxicologic Pathology
InVivo
Journal of Cancer Research and Clinical Oncology
(formerly Zeitschriftfur Krebsforschung und Klinische Onkologie
until 1979)
Environmental Health Perspectives 92APPENDIX







Appendix 11. Author's Opinion Codes and
Definitions
Code Author's opinion for each site
c NTP evaluation is clearevidenceofcarcinogenic activity: studies
that are interpreted as showing a dose-related (a) increase of
malignant neoplasms, (b) increase of a combination of malignant
and benign neoplasms, or(c) marked increase of benign neoplasms
ifthere is an indication from this or other studies ofthe ability of
such tumors to progress to malignancy.
e NTP evaluation is equivocal evidenceofcarcinogenic activity:
studies that are interpreted as showing a marginal increase of
neoplasms that may be chemically related.
p NTP evaluation is some evidenceof carcinogenic activity: studies
that are interpreted as showing a chemically related increased
incidence of neoplasms (malignant, benign, or combined) in which
the strength ofthe response is less than that required forclear
evidence.
+ Author in general literature evaluated site as positive.
- NTP evaluation is no evidenceof carcinogenic activity: studies
that are interpreted as showing no chemically related increases in
malignant or benign neoplasms; or author in general literature
evaluated site as negative.
blank For NTP and general literature: all sites forwhich no opinion is
stated.
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aL-EPINEPHRINE.HC/was evaluated as inadequate in mice and rats.
Appendix 14. Index to All Chemicals in the Six
Plots ofthe Carcinogenic Potency Database
and Resultsfor Potency (TD50) and Positivity
Appendix 14 is both an index to chemicals in the CPDB and a tabular
compilation of results on positivity and potency in rats and mice.
Chemical names and common synonyms are listed alphabetically for
the 1229 chemicals in the database, Chemical Abstracts Service reg-
istry (CAS) number is reported, and the plots that include experimental
results on the chemical are listed by plot number.
Positivity
For each chemical a result is reported in male rats (MR), female rats
(FR), male mice (MM), and female mice (FM). If there is no experiment
in the CPDB forthat sex-species group, this is indicated by NT. When all
four sex-species groups are NT, the chemical was tested only in a
species other than rats or mice (see footnotes g and h below). The
classification of positivity is based on a positive result in at least one
experiment, and we classify an experiment as either positive or nega-
tive on the basis of the author's opinion in the published paper. We use
the author's opinion to determine positivity because it often takes into
account more information than statistical significance alone, such as
historical control rates for particular sites, survival and latency, and/or
dose response. Generally, this designation by author's opinion corre-
sponds well with the results of statistical tests for the significance of
the dose-response effect. The strongest level of evidence of carcino-
genicity in any experiment in the sex-species group is reported in
Appendix 14 for each chemical. We indicate whether the compound
was tested in each group and list the strongest level of evidence for
carcinogenicity based upon any author's evaluation in either the gen-
eral literature or the NCI/NTP. In the general literature, a (+) indicates a
positive author's opinion, and a (-) indicates either that "no opinion"
was reported for this experiment or that the opinion was negative. In
the NCI/NTP the strongest evaluation is "clear evidence of carcino-
genicity" (+). When there was no such evaluation in one of the sex-
species groups, but the compound was tested by NCI/NTP and their
evaluation was stronger than "no evidence of carcinogenicity" (-), we
indicate whether that NCI/NTP evaluation was "some evidence of car-
cinogenicity" (P), "equivocal" (E) or "inadequate bioassay" (1). For older
NCI/NTP tests the evaluation (A) indicates "associated with carcino-
genicity," and we do not interpret this as positive. These evaluations
correspond to the opinions reported in our published plots. The abbrevi-
ations for positivity in Appendix 14 are as follows:
NT No test in the CPDB in this group
+ The CPDB contains at least one experiment in which the compound was
evaluated as a carcinogen by the published author. For NCI/NTP tests,
the evaluation was "clear evidence of carcinogenicity."
P The strongest level of evidence in the CPDB was an NTP evaluation of
"some evidence" of carcinogenicity.
No tests in the CPDB in this sex-species group were evaluated as
positive; however, the NCI/NTP test was evaluated as inadequate.
A The strongest level of evidence in the CPDB was an NCI/NTP evaluation
of "associated with carcinogenicity."
E The strongest level of evidence in the CPDB was an NTP evaluation of
"equivocal."
- All tests in this group were negative.
B+ In the only positive test in the sex-species, results were reported only
for males and females combined.
B- In the only test in the sex-species, results were reported only for males
and females combined, and the test was negative.
Carcinogenic Potency
For the purposes of Appendix 14, TD50 values for a chemical are
reported only for a species with a positive evaluation of carcinogenicity
in at least one test. In any given positive experiment we select the low-
est TD50 value from among positively evaluated target sites with a sta-
tistically significant dose response (two-tailed p<0.1). If no positive
sites have a significant dose response, then we select the most potent
(lowest TD50) from among positively evaluated sites with p20.1. This
method provides a single TD50 to represent an experiment. For chemi-
cals with more than one positive experiment, we summarize potency in
a species by selecting the lowest significant TD50 value from among
those representing each experiment. If none is significant, the lowest
TD50 is chosen from among the nonsignificant values with a positive
author's opinion (see footnote b below). In some experiments, no TD50
could be estimated because all dosed animals had the tumor of inter-
est, and the only data available were for crude percentages of animals
with a tumor. For these cases we use the 99% upper confidence limit
ofTD50 as a replacement for the TD50.
In a series of footnotes, we provide additional information about
TD50 values and test results in the CPDB. These are as follows:
a The CPDB contains more than one positive test in the species.
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b The reported TD50 is not statistically significant (i.e., p20.1), and all
results evaluated as positive in the species are not significant.
c Only an upper bound and no TD50 could be estimated because all dosed
animals had the tumor of interest and only summary data were available.
The reported value is the 99% upper confidence limit.
d All positive results forthis species in the CPDB are from tests in which
the compound was administered by either intraperitoneal or intravenous
injection.
e The reported TD50 is from a test in which the compound was adminis-
tered by intraperitoneal or intravenous injection; however, the CPDB
also contains a positive test in this species with a less potentTD50
value from a test where the route was oral or inhalation.
f TD50 values from different significant, positive experiments in this
species vary by more than tenfold from one another. The most potent
TD50 value is reported here.
g The CPDB includes tests in a species other than rats or mice, and at
least one test is positive.
h The CPDB includes tests in a species otherthan rats or mice, and all
tests are negative.
i Data on four NCI bioassays are included in Appendix 14 but are excluded
from the analyses and tables in this and previous papers: C.l. Direct
Black 38, C.l. Direct Blue 6, and C.l. Direct Brown 95, which were only
tested subchronically; 3-amino-9-ethylcarbazole. HCland 3-amino-9-
ethylcarbazole mixture were tested by NCI in one bioassay butwe
separated them in the CPDB because slightly different chemicals were
used for different dose groups; we combined them for ouranalyses, as
NCI had done.
The experimental results used in Appendix 14 appear in the six plots of
the CPDB:
1 Gold LS, Sawyer CB, Magaw R, Backman GM, de Veciana M, Levinson
R, Hooper NK, Havender WR, Bernstein L, Peto R, Pike MC, Ames BN. A
carcinogenic potency database of the standardized results of animal
bioassays. Environ Health Perspect 58:9-319 11984).
2 Gold LS, de Veciana M, Backman GM, Magaw R, Lopipero P, Smith M,
Blumenthal M, Levinson R, Bernstein L, Ames BN. Chronological supple-
ment to the carcinogenic potency database: standardized results of ani-
mal bioassays published through December 1982. Environ Health
Perspect 67:161-200 (1986).
3 Gold LS, Slone TH, Backman GM, Magaw R, Da Costa M, Lopipero P,
Blumenthal M, Ames BN. Second chronological supplement to the car-
cinogenic potency database: standardized results of animal bioassays
published through December 1984 and by the National Toxicology
Program through May 1986. Environ Health Perspect 74:237-329 (1987).
4 Gold LS, Slone TH, Backman GM, Eisenberg S, Da Costa M, Wong M,
Manley NB, Rohrbach L, Ames BN. Third chronological supplement to
the carcinogenic potency database: standardized results of animal
bioassays published through December 1986 and by the National
Toxicology Program through June 1987. Environ Health Perspect
84:215-285 (1990).
5 Gold LS, Manley NB, Slone TH, Garfinkel GB, Rohrbach L, Ames BN. The
fifth plot of the carcinogenic potency database: results of animal bioas-
says published in the general literature through 1988 and by the
National Toxicology Program through 1989. Environ Health Perspect
100:65-135 (1993).
6 Gold LS, Manley NB, Slone TH, Garfinkle GB, Ames BN, Rohrbach L,
Stern BS, Chow K. Sixth Plot of the Carcinogenicity Potency in the
General Literature 1989 to 1990 and bythe National Toxicology Program
1990 to 1993. Environ Health Perspect 103(Suppl 7):1-122 (1995)


























































MR FR MM FM
NT NT + +
+ + NT NT
NT NT + +
- NT NT NT
+ + + -
+ + + +
NT + NT NT
+ - NT NT
+ NT - NT
NT NT + +
NT NT + +
NT NT - -
NT NT + +
NT + NT NT
NT - NT NT
+ + + +
NT - NT NT
- - NT NT
- - NT NT
- - NT NT
- - NT NT
- - NT NT
- - NT NT
- - NT NT
+ +
+ + NT NT
+ + NT NT
- NT NT NT
+ + NT NT
+ + + +
+ NT NT NT
+ + - _
+ NT + NT
_ - + 8+
- - NT NT
- - NT NT
- - NT NT
- - NT NT
A A
E - P E
+ A - -
+ - - +
+ + NT NT
NT NT + +
Plot CAS















































































































AGERITEALBA(see HYDROQUINONE MONOBENZYL ETHER)



























Environmental Health Perspectives 98- - + - 1 17026-81-2
+ + + + 1 6109-97-3
+ + + + 1 mixture
174 + + + 1 82-28-0
3.67 NT NT + NT NT 1 3775-55-1
0.662 NT NT + NT NT 1 712-68-5
5.85 7.87 NT + NT + 1,2 38514-71-5
NT 105a NT NT + + 3 28754-68-9
839 - P - - - 5 99-57-0
111 - P - - 5 121-88-0
309 - + A - - 1 119-34-6
NT 9.95 NT NT NT + 1 2104-09-8
44.6 - A + - - 1 121-66-4
- NT NT - NT NT 1 18968-99-5
101 755a + _ + + 1 117-79-3
3.7a
- + + - NT 1 97-56-3
0.993a NT NT +
32.6a NT + +




+ + + + 1,3 61-82-5
+ - - - 2 2432-99-7
- NT NT NT -
NT - NT NT NT
- NT NT - -
NT - NT NT NT
NT + NT NT
NT + + NT NT
NT + NT NT NT
- NT NT NT -
NT - - NT NT
- NT NT - -
NT - NT NT NT
_
935a
+ + + +
- A - _ _
- NT NT - -
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TD50(mg/kg/day) Positivity Plot CAS























99TD50 (mg/kg/day) Positivity Plot CAS





































































- - P P 6 100-52-7
+ + + + 1,3-5 71-43-2
NT NT NT NT
























- P P 4,6 140-11-4
- - - 5 100-51-6
- + + 4 100-44-7
85.3 NT NT - + 1 20570-96-1
- - - - - 1 13510-49-1
- NT NT -
1120 - - A
138a +
8.19a NT NT +
- NT NT NT
4.62d NT NT NT




































































BENZYLVIOLET 4B (see FD & C VIOLET NO. 1)
BENZYLHYDRAZINE.2HCI
BERYLLIUM SULFATE
BHA (see BUTYLATED HYDROXYANISOLE)





































































TD50(mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number Chemical Name
NT NT NT +
+ NT + +
+ NT NT NT
NT - NT NT
NT NT + -
- NT NT NT
- - NT NT
NT NT - -
B- B- NT NT
+ + NT NT
+ + NT NT
+ + NT NT
+ + E -
B- B- - -
B- B- - -
E P + +
NT NT NT +
NT NT - -
_ + + -
- NT NT -
28.9a + + +
535 P E E



























NT - + NT NT 16071-86-6
+ + + 3,5,6 106-99-0
A - _ 85-68-7
109-69-3
NT NT - -
NT NT + +
NT NT - -
+ + NT NT
- - NT NT
- NT NT NT
+ + NT NT
+ + + B-
N +
NT NT + +
NT NT + +
NT NT + +
NT + NT NT
E
- B- B- - -
+ + NT -
NT - - NT NT




































C.I. DIRECT BLUE 15
C.I. DISPERSE BLUE 1
FD & C BLUE NO. 1
FD & C BLUE NO. 2
HC BLUE NO. 1
HC BLUE NO. 2





BRILLIANT BLACK BN (see BLACK PN)
BRILLIANT BLUE FCF(see FD & C BLUE NO. 1)








C.I. DIRECT BROWN 95J
BSH (see BENZENESULPHONOHYDRAZIDE)
BUSULFAN (see MYLERAN)








2,6-DI-tert-BUTYL-p-CRESOL (see BUTYLATED HYDROXYTOLUENE)
2-sec-BUTYL-4,6-DINITROPHENOL
N-n-BUTYL-N-FORMYLHYDRAZINE






















































































MR FR MM FM
+ + NT -
- NT - NT
39.6b NT NT NT +
















89.4a + + + + 3,6 2425-06-1
- - - A A 1 133-06-2
223a NT NT + +
1i55a NT NT + +
NT - - NT NT
- B+ B+ - -
102a NT NT + +
127a + + + +
NT + + NT NT
NT + B+ NT NT
NT - - NT NT
- NT NT - -






















NT NT - -
NT NT B- B-
_ - A +
+ + + +
- E - -
NT - NT NT























+ + 1,2,6 57-74-9
141 + + + - 4
86.8a + + + + 3
6540 - E + E 3
- NT NT - - 4
- - E - - 6
NT B- B- NT NT 1
- NT NT NT - 1
346 + NT - + 1
NT + NT NT NT 1
- - NT - - 1
73.5a + + + + 4
108a - NT + + 1
430a - NT + + 1
1230 + - - + 1
957a + + + + 1
134a _ + + 1
15.4a,, + + 1
NT + + NT NT 3
10.8c + NT + NT 1,3
44.6 + NT NT + 1



























CADMIUM SULPHATE (1:1) HYDRATE (3:8)
CAFFEIC ACID
CAFFEINE
CAFFEINE, ASPIRIN, AND PHENACETIN
(see ASPIRIN, PHENACETIN, AND CAFFEINE)
CALCIFEROL
CALCIUM ACETATE













CARMOISINE (see C.I. FOOD RED 3)





















CHLORFENSON (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)
CHLORINATED PARAFFINS (C12, 60% CHLORINE)

































TD,,(mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number Chemical Name
- - A 1 140-49-8
- A A 1 106-47-8
E P - 5 20265-96-7
- - - 3 108-90-7
_ + + 1 510-15-6
- E P 3 124-48-1
- - - 5 75-45-6
E + 5 75-00-3
NT + - NT NT
NT + + NT NT
48a + + + +
NT + NT NT NT
161a + - + +
- NT NT - -
+ _-
NT + NT NT NT
NT - - NT NT
12.9 NT NT - +
5.05 NT NT - +
_ + + _-
NT + + NT
NT NT - -
- NT - NT
B- B- NT NT
B- B- - -
+ NT + NT
NT NT NT -
+ - + +
+ + + NT
+ NT NT NT
B+ B+ NT NT
+ NT NT NT
NT NT NT -
+ NT NT NT
- NT NT NT





































- NT NT - - 1 137-29-1
- NT NT - - 1 10380-28-6




































CHLOROWAX 40 (see CHLORINATED PARAFFINS (C23, 43% CHLORINE))























CLOPHEN A 60(see AROCLOR 1260)
CLOROX(see SODIUM HYPOCHLORITE)




































































+ + + +
+ NT NT NT
+
103GOLDETAL.
TD50 (mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number Chemical Name
_ _-_ - - - 1 156-62-7
NT NT NT NT NT 6 mixture























- + + + 1 1596-84-5
+ - - - 1 80-08-0
- NT NT -
24.9a A - +
9.45a - - +





- P P E - 3 1163-19-5
- - - - - 6 52918-63-5
NT B- B- NT
NT - - NT
NT + + NT
NT - - NT
NT - - NT
NT NT + NT
- NT NT -
19.4a NT NT +
- - E A
25.7a NT NT +
33.8a NT NT +
NT + + NT
NT NT + NT
791a + + +
- NT NT -
- NT NT -
143 - - P
1.43a 26.7 + +
4.42 201a + NT +
37.6 NT + NT NT




















































(1-METHYLETHYL)BENZENE ACETATE (see FENVALERATE)
































DEGRANOL (see MANNITOL NITROGEN MUSTARD)









DEXTRAN SULFATE SODIUM (DS-M-1)
DEXTRAN SULFATE SODIUM (DST-H)




















































TD5.(mg/kg/day) Positivity Plot CAS










+ NT NT NT
- - NT NT
+ + + +
+ NT + +
+ + + +
+ + + +
- - NT NT
- - NT NT
NT + NT NT
_ _ _
119 NT NT +
- NT NT NT
- NT NT -








NT + + NT
1.52d NT NT NT
A
A
61.2a + + +
- NT NT -
- NT NT -
- NT NT -
- NT NT -
- NT NT -
- NT NT -
- NT NT -
- NT NT -











































P E P + 1,5 62-73-7





NT + NT NT
NT - - NT
NT + NT NT































DICHLOREN (see NITROGEN MUSTARD)





























2,4-DICHLOROPHENOXYACETIC ACID, N-BUTYL ESTER
2,4-DICHLOROPHENOXYACETIC ACID, ISOOCTYL ESTER






































































MR FR MM FM
+ NT NT NT
- NT NT NT
- NT NT NT
+ - + +
+ + _
NT NT + +
NT NT + +
+ + + +
- NT NT NT
NT NT + NT NT



























90a B+ B+ + + 1 94-58-6
NT + NT NT NT
E
95.9 + NT + -
_ + + _-
_ + + _-
NT - NT NT NT
NT - NT NT NT
NT - NT NT NT
NT + NT NT NT
NT NT + NT NT
NT - NT NT NT
- + E - -
p
p p
NT NT + NT NT
NT NT + NT NT








































NT NT - -
NT NT - -
NT NT NT -
P - - E
NT NT - -
NT NT NT +
+ + + _
NT NT NT +
NT NT - -
- - NT NT
_ _ + +
NT NT + +
NT + NT NT
+ + NT NT
+ + + +
NT NT - -
NT NT B- -
NT NT NT -
NT NT NT NT
NT + NT NT
- NT NT NT
NT NT + +
























































DIGLYCIDYL RESORCINOL ETHER, TECHNICAL GRADE
5,6-DIHYDRO-5-AZACYTIDINE
(2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1 H-PYRAZOL-4-YL)
METHYLAMINO METHANESULFONATE MONOHYDRATE(see DIPYRONE)
1,2-DIHYDRO-2-(5-NITRO-2-THIENYL) QUINAZOLIN-4(3H)-ONE
3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE
1,2-DIHYDRO-3,6-PYRIDAZINEDIONE (see MALEIC HYDRAZIDE)
DIHYDROSAFROLE























































TD5,(mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number Chemical Name
NT - NT NT NT
NT + NT NT NT
NT + NT NT NT
594a + + + +
- NT NT - -
NT + + NT NT
- E E - -
- NT NT - -
- NT NT - -
NT
547a
- NT NT NT 1
- - + + 3,4
NT NT - N















IT NT 1 79-40-3
- 1 2439-10-3
NT - - NT NT 6 40762-15-0
- - - - - 1 9004-59-5
- - - - - 1 9004-32-4
- - - - - 1 150-38-9
NT 1 316-42-7
- - - - - 1 55965-13-4
- - -' - 1 115-29-7
_ _ _ - - 1 72-20-8
- NT NT - - 3 13838-16-9
0.151a,, NT NT - + 1 8015-30-3
- NT NT - - 1 8015-30-3
- - - - - 3 134-72-5
- + + NT - 1,4 106-89-8
NT 6 55-31-2
- + E - - 5 106-88-7
- - - - - 3,6 6381-77-7
- - - - - 5 643-22-1
- - - - - 6 29975-16-4
0.282b NT NT NT + 1 50-28-2
2,4-DINITROTOLUENE (PURIFIED)
2,6-DINITROTOLUENE


















DISODIUM SULFATE (see SULFATE, SODIUM)














DODINE (see N-DODECYLGUANIDINE ACETATE)
DOWICIDE 1 (see o-PHENYLPHENOL)
DOWICIDE 2S (see 2,4,6-TRICHLOROPHENOL)
DOWICIDE 7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
DOWICIDE EC-7 (see 2,3,4,5,6-PENTACHLOROPHENOL (Dowicide EC-7))
DOXEFAZEPAM
DS-M-1 (see DEXTRAN SULFATE SODIUM (DS-M-1))






















1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
ERYTHORBATE, SODIUM
ERYTHROMYCIN STEARATE

























MR FR MM FM
+ +
NT NT NT +
+
+ NT NT NT
+ NT + +
NT NT + -
- NT NT NT
+ + + +
+ - NT -
+ NT NT NT
+ NT NT NT
+ + NT NT






- NT NT NT
_ A
NT NT + +
- - NT NT
NT NT B+ B+
+ + NT NT



























NT NT - -
NT NT NT -
NT NT + +
+ + + +
+ + + +
NT NT - -
NT NT - -
NT - NT NT
_ _ + +
+ + + +
NT NT + +
+ + NT NT
+ + NT NT
+ + NT NT
- NT NT NT
NT NT NT +
NT - NT -

























































- - - - - 1 140-56-7
- - - A - 1 55-38-9
- - - - - 3,6 51630-58-1
NT NT NT - -
_ - - A -



















ETHYL BROMIDE (see BROMOETHANE)
ETHYL BROMOACETATE















ETHYLENE DIBROMIDE (see 1,2-DIBROMOETHANE)
ETHYLENE DICHLORIDE (see 1,2-DICHLOROETHANE)
ETHYLENE GLYCOL

























FERBAM (see FERRIC DIMETHYLDITHIOCARBAMATE)
FERRIC DIMETHYLDITHIOCARBAMATE
FERRIC NITROSODIMETHYLDITHIOCARBAMATE AND
TETRAMETHYLTHIURAM DISULFIDE (seeVANGUARD GF)
FIREMASTER BP-6(see POLYBROMINATED BIPHENYLS)


























TD5,(mg/kg/day) Positivity Plot CAS




NT + NT NT
NT + NT NT












NT NT - NT
36a NT NT +
NT NT - NT
2.19a + + +
135a p - +
732 E - -
NT
NT
- NT NT NT
- - NT NT
57.9a NT NT + +
- E - _ _
- B- B- B- B-
- NT NT - -
5.08a + + + +
12a + + + +





NT NT + -
NT NT - -
- - NT NT
NT - NT NT
+ + + +
- NT NT NT
- NT NT -
_ + + _
- B+ B+ -














































_ + + +
B+ B+ NT NT











FLUOROCARBON 31 (see CHLOROFLUOROMETHANE)
FLUOROCARBON 11 (seeTRICHLOROFLUOROMETHANE)
FLUOROCARBON 113 (see 1,1,2-TRICHLORO-1,2,2-TRIFLUOROETHANE,
TECHNICAL GRADE)
FLUOROCARBON 12 (see DICHLORODIFLUOROMETHANE)
FLUOROCARBON 133a (see2-CHLORO-1,1,1-TRIFLUOROETHANE)
FLUOROCARBON 22 (see CHLORODIFLUOROMETHANE)
2-FLUOROETHYL-NITROSOUREA
5-FLUOROURACIL






FORMULATED FENAMINOSULF(see FENAMINOSULF, FORMULATED)
1-FORMYL-3-THIOSEMICARBAZIDE
FORMYLHYDRAZINE










GENITE-R99 (see 2,4-DICHLOROPHENYLBENZENE SULFONATE)
GENTIAN VIOLET
GERANYL ACETATE, FOOD GRADE














GLYCOL SULFATE(see ETHYLENE GLYCOL, CYCLIC SULFATE)
GLYCOL SULFITE
GLYCYRRHIZINATE, DISODIUM
FD & C GREEN NO. 1
FD & C GREEN NO. 2
FD & C GREEN NO. 3
GUINEA GREEN B (see FD & C GREEN NO. 1)
FAST GREEN FCF(see FD & C GREEN NO. 3)
LIGHT GREEN SF YELLOWISH (see FD & C GREEN NO. 2)
GRISEOFULVINh
GUAR GUM
































109TD,(mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number
- NT - NT NT NT 1 1241-27-6
+ + + +
+ + NT NT
NT NT + NT
+ NT + NT
NT NT + +
_
+ +
NT NT - -
NT + NT NT
+ + NT NT
- E -
NT NT - -
+ + + +
+ + + +
NT + NT +
NT + NT +
NT + NT +
NT - NT NT
NT NT NT -
380a NT NT + +
26 + + - +
NT - NT NT NT
_ - - E -
NT - - NT NT
7540 NT NT - +
122a, + P + P
- NT NT - -
NT NT - NT NT
6.23 + + NT +
NT NT - NT NT
5530 NT NT + -
NT + NT NT NT
57.8 NT NT NT +
NT NT + NT NT
NT + + NT NT
NT + + NT NT
0.603a + + + +
NT NT + NT NT
0.314a NT NT +
NT - - NT NT
NT - - NT NT
NT + + NT NT



















































































































(see MALONALDEHYDE, SODIUM SALT)
1-(2-HYDROXY-3-PROPYL-4-(4-(1 H-TETRAZOL-5-YL)-

















HYPOCHLOROUS ACID, SODIUM SALT(see SODIUM HYPOCHLORITE)
IBOPAMINE.HCI (see N-METHYLDOPAMINE, O,O'-DIISOBUTYROYL ESTER.HCI)
ICRF-159





















































TD50 (mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number Chemical Name
- A A - - 1 3458-22-8
NT - - NT NT 1 32607-00-4
NT NT -
92.4 p _ _







+ + + + 3,6 76180-96-6
NT + NT NT 4 -
- NT NT -
NT - NT NT NT
NT NT -
- af NT NT -
11.2a,f + + +
- NT NT -
- NT NT -
27.4 NT NT B+
p E
5.06 - + -
- NT NT -
- NT NT -
- NT NT -
- NT NT -
NT - - NT
NT NT - NT
NT + + NT
_72a +
_ _
472a + + +
55.8 NT NT +
_+ _-
NT - - NT
14.8a NT NT +



































- - - - 1 1634-78-2
- - - - 1 121-75-5
- - - - 1,2 123-33-1
3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE(ESTER).HCI
IMINODIACETIC ACID, MONOSODIUM






IPC (see ISOPROPYL-N-PHENYL CARBAMATE)
IPD (see 3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE(ESTER).HCI)
la,
ID.HCI
































KMDS-H (see DEXTRAN SULFATE SODIUM (KMDS-H))





LEAD SUBACETATE (see LEAD ACETATE, BASIC)

















































TD50 (mg/kg/day) Positivity Plot CAS































+ + - +
B+ B+ - -
- NT NT NT
NT NT + +
NT NT + +
+ + + +
+ -
+ + + +
NT - NT NT
P P - E
NT NT - -
- NT NT NT
- - NT NT
P E E -
NT NT + -
NT NT - -
+ NT NT NT
NT - - NT NT
NT - - NT NT
NT + + NT NT
NT + + NT NT
- - NT - NT
- NT NT - -
60.2 NT NT - +
NT + + NT NT
NT - NT NT NT
- NT NT - -








































- - - - 6 74-83-9
+ + - - 5 598-55-0
- - NT NT 1 6294-89-9
+ NT NT NT
NT NT B+ B+
3.28a NT + NT NT NT
1.3bd NT + NT NT NT
NT 0.745 f NT NT + +
NT - NT NT - -
- NT - NT NT NT
- NT - NT NT NT
NT 31.8 NT NT + NT
0.403a NT + + NT NT
48.8a 1.34a + + + +
5.34 NT NT + NT NT
0.468a NT + + NT NT
3.23a NT + + NT NT
0633a,d NT + + NT NT
20.4 NT B+ B+ NT NT
13.2 NT B+ B+ NT NT






















MAM ACETATE AND CYCASIN MIXTURE
(see CYCASIN AND METHYLAZOXYMETHANOL ACETATE)



































METHYL ALLYL CHLORIDE (see 3-CHLORO-2-METHYL PROPENE,
































Environmental Health Perspectives 1 12APPENDIX
TDSO (mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number Chemical Name





- P - - - 6 98-85-1
1.99a NT NT + + 6 -
- + NT NT 1,2,6
- - E - 5
- - NT NT 5
+ + NT NT 1
- NT - + 1
+ + NT NT 1
P + + + 3-5
+ + - + 1
+ + + + 3
- NT NT NT 1
B- B- NT NT 1
NT NT + + 1
NT NT + + 1
- NT NT NT 6
+ + NT NT 6
+ NT NT NT 5
+ NT NT NT 5
NT NT + - 1
NT NT + + 1
NT + NT NT 3
_ + + 5
- - NT NT 2
- - NT NT 2
NT NT - - 5
NT NT B- B- 1,3
- - NT NT 1
+ + + + 1
1
+ + + + 1
+ + + + 1,6
+ NT NT NT 1































0.000981a NT + + NT NT 1 50-07-7
NT 4.48a NT NT + + 3 1068-57-1
- - - - - - 1,6 79-11-8
0.79a NT + NT NT NT 3 315-22-0
NT - NT NT - NT 3 32221-81-1
NT - NT NT - NT 3 142-47-2
NT - - NT NT 2922-54-5
NT NT + NT NT 1 58139-48-3
NT NT + NT NT 1 3031-51-4
- NT NT NT
_ + + E
163 NT NT -
- NT NT -











METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE





































MITOMEN (see NITROGEN MUSTARD N-OXIDE)
MITOMYCIN-C


















MUCOCHLORIC ACID (see alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID
MUSK XYLOL(see 2,4,6-TRINITRO-1,3-DIMETHYL-5-TERT-BUTYLBENZENE)
MYLERAN
































































TD50(mg/kg/day) Positivity Plot CAS






















- NT NT - - 2 81-16-3
NT - - NT NT 5 88385-81-3
NT - - NT NT 1
- NT NT - - 1
- NT NT - - 1
- NT NT - - 3
NT - - NT NT 1
- NT NT - - 2
- NT NT - - 2
145a NT NT + + 1
NT - - NT NT 1
- NT NT B- B- 1
758 - + + - 1
NT - - NT NT 1,2
- NT NT NT - 1
1470a + + + + 1,6
_ + + - - 1
_ + + - - 1-3,5,6
2270 - - + - 1
3720 + + - + 1
22.4 E + - + 1,5
NT NT - NT NT 1
NT NT - NT NT 1
20.3as + + + + 1
NT NT + NT NT 1
NT NT + NT NT 1
6.74 NT + NT + 1
NT NT + NT NT 2
NT NT + NT NT 1
7.72alf + + + + 1-4
NT NT + NT NT 1
0.346 B+ B+ B+ B+ 1
- E - - - 1,5
614 - _ _ + 1
242a _ _ + + 1
45.3 + + - + 1
- - - E - 6
354a _ _ + + 1




















































NT - - NT NT 3,5 108-03-2
NT - - NT NT 1 79-46-9
- A - - - 1 504-88-1
NT - - NT NT 2 613-50-3
NT + + NT NT 2 607-35-2
NT + NT NT NT 1 38777-13-8
NT + + NT NT 2 83335-32-4








NAS (see 2-NAPHTHYLAMINO,1-SULFONIC ACID)
NEOSUGAR


































































































TD05 (mg/kg/day) Positivity Plot CAS
































































































































































































































































































































































































































TD5.(mg/kg/day) Positivity Plot CAS










- NT NT - - 1 55557-03-4











- - NT NT 1 4515-18-8
NT + + NT NT
1.3 B+ B+ + NT
























































+ + + + 1,4,5 303-47-9
- - NT NT 4 29082-74-4




















































beta-NITROSTYRENE AND STYRENE MIXTURE




NORETHYNODREL/MESTRANOL [25:11 (see ENOVID-E)











C.I. ACID ORANGE 3
C.I. ACID ORANGE 10
ORTHOXENOL (see o-PHENYLPHENOL)
OTOS (see N-OXYDIETHYLENE THIOCARBAMYL-N-OXYDIETHYLENE
SULFENAMIDE)
OVEX (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)
OVULEN


































































TD,,(mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number
24.8 38.3 P E P - 6 1825-21-4
- 5 132-98-9
39.8a A - + +
71.1 - - + _
- NT NT NT -
17.5a - - + +
10.5a NT NT + P
- E E - -
3.12a NT NT + +
NT - NT NT NT
5.87 NT NT - +
- NT NT - NT












+ + + + 1-3 62-44-2
+ NT NT NT
+ + - +
_ + + +
_ - + +
+ + + +
NT NT - -
+ + + +
B+ B+ NT NT














_ - - - - 1 2198-59-6
- - - - - 1 103-85-5
_ + + -
353 E P P -
- NT NT - -
NT - - NT NT
- - NT -






NT NT - +
+ + NT NT
NT NT NT -
NT NT + +
NT NT - -
NT NT - -
+ + _-
+ NT - -
NT NT - -
+ + + +
NT NT - +
- - NT NT






































- - - - - 1 88-96-0





















PETN, NF (see PENTAERYTHRITOL TETRANITRATEWITH
80% D-LACTOSE MONOHYDRATE)
PHENACETIN












































PHOTODIELDRIN (see DIELDRIN, PHOTO-)
PHOTOMIREX (see MIREX, PHOTO-)
PHTHALAMIDE
PHTHALIC ANHYDRIDE
PHTIVAZID (see ISONICOTINIC ACIDVANILLYLIDENEHYDRAZIDE)









































TD50(mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number Chemical Name
_ _ ~ - A - -
NT - NT NT - -
- NT - - NT NT
- NT - - NT NT
- NT - - NT NT
- NT - - NT NT
NT - NT NT - -
- 62.2 - - + -
154a - + + - -
0.148a 0.381a + + + +











E - _ _
NT - NT -
- NT NT NT
- - NT NT
NT + NT NT
NT - NT NT
- - NT NT
NT NT - -
P
+ NT NT NT
+ + + +
NT NT - -
NT NT - -
+ + NT NT
NT NT - -
1.16a NT + + +
- NT NT - -
8.74a NT NT + +
- NT NT - -
NT + NT NT NT
NT - - NT NT
732a + + + +

















































409 + + B+ B+ 1 51-52-5
- NT NT - - 3 22760-18-5
NT - NT NT NT 1 1508-45-8
NT B+ B+ NT NT 1 2611-82-7


























PIPERONYL BUTOXIDE IN SOLVENT
PIPERONYL SULFOXIDE
PIVALOLACTONE
PLANOFIX (see 1-NAPHTHALENE ACETICACID)
POLYBROMINATED BIPHENYL MIXTURE
POLYBROMINATED BIPHENYLS
POLYCHLORINATED BIPHENYLS (see AROCLOR 1254)
POLYCHLORINATED BIPHENYLS (see AROCLOR 1260)
POLYCHLORINATED BIPHENYLS (see KANECHLOR 400)
POLYSORBATE 80
POLYVINYLPYRIDINE-N-OXIDE
PONCEAU 3R (see FD & C RED NO. 1)
PONCEAU 4R (see SX PURPLE)
PONCEAU MX (see D & C RED NO. 5)
PONCEAU SX (see FD & C RED NO. 4)
POTASSIUM BROMATE (see BROMATE, POTASSIUM)
POTASSIUM CHLORIDE













































C.I. ACID RED 114


























TD50(mg/kg/day) Positivity Plot CAS
Rat Mouse MR FR MM FM Number Number Chemical Name
P P p _
E - _ _
+ + + +
+ A _ _
- - NT NT
+ + NT NT
B+ B+ NT NT
B+ B+ B- B-
- E
- - NT NT
- - NT NT
- NT NT NT
E E - -
- - NT NT
+ + + +
E
- - NT NT
- - NT NT
NT NT - -
+ _-
+ B+ + +
NT + NT NT
NT NT NT -
NT NT + -
NT NT - -
+ + - +
+ NT NT NT
+ + + +




































NT - NT NT NT 6 144-55-8
- NT NT - - 1 6385-58-6
- - NT - - 4 7647-14-5
- - - - - 4 7758-19-2
- - - - - 1 148-18-5
- - - - 4 7681-52-9
NT - - NT NT
- - NT NT
+ B+ NT +
+ + + +








C.I. FOOD RED 3
C.I. PIGMENT RED 3
C.I. PIGMENT RED 23
D&C RED NO. 5
D &C RED NO.9
D & C RED NO. 10
FD & C RED NO. 1
FD &C RED NO. 2
FD & C RED NO. 3
FD &C RED NO.4h


































SODIUM ARSENITE (seeARSENITE, SODIUM)
SODIUM AZIDE(seeAZIDE, SODIUM)





SODIUM CYCLAMATE(see CYCLAMATE, SODIUM)
SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE
SODIUM FLUORIDE(see FLUORIDE, SODIUM)
SODIUM HYPOCHLORITE
SODIUM NIOBATE(see NIOBATE, SODIUM)
SODIUM NITRATE(see NITRATE, SODIUM)
SODIUM NITRITE (see NITRITE, SODIUM)
SODIUM SULFATE (see SULFATE, SODIUM)
SODIUM TETRAFLUOROBORATE(seeTETRAFLUOROBORATE, SODIUM)











































































MR FR MM FM
+ A
+ + + +
NT NT - -
+ + + +
NT NT + +
NT NT NT -
NT NT - -
NT + NT NT

























- - NT NT 1 569-57-3
- - - - 2 39300-88-4
- NT NT - -
36.3 + P +








NT NT + NT NT
NT - NT NT NT







- - NT -
+ + + +
NT NT - -
+ +
+ +
+ p + +
- A + A
86.3 - NT + -
NT NT NT NT NT
NT B+ B+ NT NT
























- - 1,3 137-26-8
NT
0.304a
- NT NT -
1.07a + + +
NT - - NT

















- NT NT 6 540-72-7
Chemical Name
STYRENE
STYRENE AND beta-NITROSTYRENE MIXTURE
STYRENE OXIDE
SUCCINIC ANHYDRIDE
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TD05 (mg/kg/day) Positivity Plot CAS















- NT NT - -
NT E E NT NT
NT - NT NT NT
NT - - NT NT
_ + + - _






















B+ B+ NT NT
- NT + -
+ + + +
- NT + +
_ _ + _
A A + +
+ NT NT NT
P + _ _
NT NT - -
- - NT NT
- NT + _
_ _ + +
+ NT + +
+ -N + +
NT NT - -
+ - + +
NT NT - -
_ - + +
- NT NT NT
NT + NT +
_ - +
+ + - +
+ NT + +
+ NT + +
A - - +
_ + _-
NT NT + +
+ + NT NT
NT NT - -
- d + + E E
3.44d NT NT NT +
80.1a + + + +
2560 E - - P

















































25a + + + + 1,4 75104-43-7







THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)
THPC (see TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM CHLORIDE)
THPS (seeTETRAKIS(HYDROXYMETHYL)PHOSPHONIUM SULFATE)
TIBRIC ACID (see 2-CHLORO-5-(3,5-DIMETHYLPIPERIDINOSULPHONYL)
BENZOIC ACID)
TILIDINE FUMARATE











TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4(80%)- AND 2,6 (20%)-)
2,4-TOLUENEDIAMINE.2HCI (see2,4-DIAMINOTOLUENE.2HCI)
2,6-TOLUENEDIAMINE.2HCI (see 2,6-DIAMINOTOLUENE.2HCI)













































































MR FR MM FM Number Number
- NT NT NT 3 54-12-6
- - - - 1-3 73-22-3
- - NT NT 1 13472-45-2
- - - - - 1 57-13-6
5.91at B+ B+ + + 1,6 51-79-6
NT NT - - 1 27774-13-6









NT - NT NT NT
NT + + NT NT
NT + + NT NT




NT + + NT
12.4 - NT -
552a + NT +
1020 +
- B- B- B-

























- - + - 1 128-66-5
- - - - 1,5 1934-21-0
- - - - 1,2 2783-94-0
E - - - 6 59820-43-8
- - + + 2 17924-92-4
NT NT - - 1 136-23-2
NT NT - - 1 14324-55-1
+ B+ - E 1,3 137-30-4
B+ B+ - - 1 12122-67-7








UNADS (see TETRAMETHYLTHIURAM MONOSULFIDE)
UREA
URETHANE'
VALORON (see TILIDINE FUMARATE)
VANADYL SULFATE
VANCIDE BL(see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
VANCIDE BN (see SODIUM BITHIONOLATE)
VANCIDE PB (see 1,2,3-TRICHLORO-4,6-DINITROBENZENE)
VANGUARD GF






VINYL TOLUENE (65-71% m- and 32-35% p-)
4-VINYLCYCLOHEXENE
VINYLIDENE CHLORIDE
FD & C VIOLET NO. 1
VITAMIN AACID (see RETINOICACID)
VITAMIN A, ACETATE (see RETINOLACETATE)
VITAMIN A, PALMITATE (see RETINOL PALMITATE)
VITAMIN C (see L-ASCORBIC ACID)
VITAMIN C, SODIUM (see L-ASCORBATE, SODIUM)
VITAMIN D2 (see CALCIFEROL)
VITAMIN E ACETATE (see DL-alpha-TOCOPHERYL ACETATE)
XYLENE MIXTURE (60% m-XYLENE, 9% o-XYLENE, 14% p-XYLENE,
17% ETHYLBENZENE)
XYLENE MIXTURE (m-XYLENE, o-XYLENE, p-XYLENE)
2,4-XYLIDINE.HCI
2,5-XYLIDINE.HCI




C.I. SOLVENTYELLOW 14 (see 1-PHENYLAZO-2-NAPHTHOL)
C.I. VATYELLOW 4
DIARYLANILIDE YELLOW (see C.I. PIGMENT YELLOW 12)
FD & C YELLOW NO. 5









ZINEB (see ZINC ETHYLENEBISTHIOCARBAMATE)
ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)
ZIRCONIUM (IV) SULFATE
Environmental Health Perspectives
GOLDETAL.
TD50(mglkglday)
Rat Mouse
- NT
- NT
122